Endogenous tumor-derived circular RNA and proteins thereof for use as vaccine

The present invention relates to an endogenous tumor-derived circular ribonucleic acid (circ RNA) as well as one or more proteins expressed from said tumor-derived circ RNA. The invention further relates said tumor-derived circ RNA and the protein(s) expressed thereof for use vaccines in the prophylaxis and/or treatment of cancer.

1. 11. A pharmaceutical composition comprising endogenous tumor circRNA, and a pharmaceutically acceptable excipient comprising a preservative, an adjuvant, a stabilizer, a buffer, or any combination thereof, formulated as a vaccine effective in the treatment of cancer, wherein the circRNA is the total circRNA content from the tumor cells.
2. 22. A pharmaceutical composition comprising protein derived from endogenous tumor circRNA, and a pharmaceutically acceptable excipient comprising a preservative, an adjuvant, a stabilizer, a buffer, or any combination thereof, formulated as a therapeutic vaccine effective in the treatment of cancer, wherein the circRNA from which the protein is derived is the total circRNA content from the tumor cells.
3. 33. A method of preparing an endogenous tumor circRNA to be formulated as a vaccine in the treatment of cancer, wherein the method comprises the steps of: a. extracting total RNA content from tumor cells; b. enriching circRNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells, and c. mixing the enriched circRNA with at least one pharmaceutically acceptable excipient comprising a preservative, an adjuvant, a stabilizer, a buffer, or any combination thereof.
4. 44. A method of preparing an endogenous tumor circRNA vaccine, comprising the steps of: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells; and c. mixing the enriched circRNA with at least one pharmaceutically acceptable excipient suitable for the vaccine.
5. 55. A method of preparing a protein derived from endogenous tumor circRNA for use as a vaccine, comprising the steps of: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells; c. identifying neoantigen protein expressed by the enriched circRNA; and d. detecting personalized/general potential of the protein as immunogen.
6. 66. A method of preparing an endogenous tumor circRNA, comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells; and c. returning the enriched circRNA to antigen presenting cells ex vivo; wherein the antigen presenting cells generate an immune response.
7. 77. A personalized method of treating a prostate cancer patient comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells; c. mixing the enriched circRNA with at least one pharmaceutically acceptable excipient to form a mixture; and d. administering an effective amount of the mixture to the patient.
8. 88. A method of treating a prostate cancer patient comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA, wherein the enriched circRNA is the total circRNA content from the tumor cells; c. identifying an immunogenic potential of neoantigen protein from the circRNA; and d. administering an effective amount of the neoantigen protein to the patient.
9. 99. The pharmaceutical composition according to claim 1, wherein the cancer is prostate cancer, breast cancer, colon cancer, lung cancer and/or pancreatic cancer.
10. 1010. The pharmaceutical composition according to claim 2, wherein the cancer is prostate cancer, breast cancer, colon cancer, lung cancer and/or pancreatic cancer.
11. 1111. The pharmaceutical composition according to claim 1, wherein the cancer is prostate cancer.
12. 1212. The pharmaceutical composition according to claim 2, wherein the cancer is prostate cancer.
13. 1313. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable comprises an adjuvant comprising an aluminum salt or an oil-based compound, or a stabilizer comprising a sugar, amino acid, human serum albumin or gelatin, or any combination thereof.
14. 1414. The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable comprises an adjuvant comprising an aluminum salt or an oil-based compound, or a stabilizer comprising a sugar, amino acid, human serum albumin or gelatin, or any combination thereof.
15. 1515. The pharmaceutical composition according to claim 1, wherein the endogenous tumor circRNA is prepared by a method comprising: a. extracting total RNA content from tumor cells of a patient; and b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA.

SEQUENCE LISTING
The Sequence Listing submitted herewith, entitled “20181227_sequence-listing.txt”, created Jul. 2, 2020, and having a size of 218,587 bytes, is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a tumor-derived circular ribonucleic acid (circRNA) as well as one or more proteins expressed from said tumor-derived circRNA for use as vaccine. The invention further relates said tumor-derived circRNA and the protein(s) expressed thereof for use as vaccine in the prophylaxis and/or treatment of cancer.
BACKGROUND OF THE INVENTION
Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells beyond their usual boundaries that can then invade adjoining parts of the body and/or spread to other organs [1]. Other common terms used are malignant tumors and neoplasms. Cancer can affect almost any part of the body and has many anatomic and molecular subtypes that each require specific management strategies.
Cancer is the second leading cause of death globally and accounted for 8.8 million deaths in 2015. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervix and stomach cancer are the most common among women. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality. US$1.16 trillion is the estimated total annual economic cost of cancer in 2010. Hence, there is a need for more effective and cost-efficient pharmaceuticals for use in the prophylaxis and treatment of cancer.
The adaptive immune response, mediated by antibody-producing B cells and cytotoxic T cells, protects us from disease by the killing of invading pathogens and performs immune surveillance to eliminate tumors prior to metastasis. Antibody-based and T-cell based therapy has been used with success to treat a number of malignancies. However, it would be advantageous, both for patients and for public health, to develop prophylaxis, such as vaccines, against different cancers, and to activate the immune system against the cancer.
To avoid killing of “self” and induction of severe autoimmunity, cells of the adaptive immune system undergo a stringent selection process during their development, where self-reactive cells are eliminated. With few exceptions (mutations changing the structure or gene fusions), cancer cells express proteins that will be considered “self” to the immune system. Effectively, this means that the frequency of circulating B cells and T cells that have a potential to recognize cancer cells are exceedingly low. This is true even in the form of fusion proteins, and mutations, where both proteins retain much of their original structure. However, even though small changes induced by mutations they have been used to elicit an immune response against the tumor [2,3].
Messenger RNA (mRNA) based vaccines for the treatment of tumors are described in US2008171711. The use of mRNA and peptides as vaccines is safer than using DNA-based vaccines and gene therapeutics since there is no risk of RNA and peptides being integrated into the genome. However, the instability of mRNA or of RNA for example due to RNA-degrading enzymes is a problem in using RNA in pharmaceutical compositions.
Hence, there is a need for vaccine which are not degraded by RNA-degrading enzymes.
Personalized RNA and peptide vaccines for the prophylaxis of cancer have been reported in the art [2,3]. However, the reported personalized peptide vaccines were not fully effective, the time to develop treatment is time consuming, and the treatment had to be combined with other immunotherapies [2]. Moreover, one of the patients had a late relapse when a personalized RNA vaccine was used [3]. Hence, there is a need for more effective and rapid vaccine development for the treatment of cancer. The use of circular RNAs (circRNA or cRNA) could potentially overcome these obstacles.
Recently, it was shown that circular RNAs (circRNA or cRNA) can form during RNA processing (e.g. back splicing) within cancer cells as well as normal cells [4-6]. During the formation of the circular RNA, the back-splicing process will introduce a unique fusion of two RNA nucleotides stretches. The function of circRNA is not well understood, but it has been shown that protein peptides can be generated from (open reading frames) ORFs [7,8].
Depending on the circRNA, proteins can be expressed from the RNA template, and the ORFs may overlap with the ‘true mRNA’ sequence and produce parts of the ‘true protein’, there is also a chance that the circRNA allow new ORFs to be expressed that is ‘out of frame’ and therefore contain a new composition of amino acids that will be recognized as “non-self”, and potentially reactive to the immune system. Another possible outcome of the circulation is that the ORF will cover the back-splicing site (BSS) and translate a protein that is ‘in-frame’ until the fusion site and then becomes ‘out of frame’ when it passes the BSS.
US2017298347 relates to fusion-circular RNAs (f-circRNAs) for diagnosis of cancer. Additionally, US2017298347 discloses a f-circRNA inhibiting agent which binds to f-circRNAs and said inhibiting agent is used for treating cancer. However, said inhibiting agent is neither a circRNA nor a protein derived from circRNA (paragraph 145; claims 15 and 26). Consequently, US2017298347 is silent about circRNAs and peptide products thereof being used for the treatment of cancer.
CN107384909 relates to the use of circRNA in a screening of gastric cancer. However, CN107384909 is altogether silent about using circRNA as a vaccine.
CN106480033 relates to a kit for detecting the circRNA-005365 gene. However, CN106480033 is altogether silent about using circRNA as a vaccine.
US20160194368 relates to synthetically produced circRNA. However, the circRNA are neither tumor-derived nor endogenous. More importantly, circRNA of US20160194368 does not comprise at least one open reading frame (ORF) not expressed in non-tumorous healthy cells.
OBJECT OF THE INVENTION
The object of the invention is to provide a vaccine for the prophylaxis and treatment of cancer.
The object of the invention is to provide an RNA-based vaccine for the prophylaxis and treatment of cancer.
The object of the invention is to provide an RNA-based vaccine for the prophylaxis and treatment of cancer wherein the RNA is not degraded by RNA-degrading enzymes and nucleases.
The object of the invention is to provide a peptide-based vaccine for the prophylaxis and treatment of cancer.
The object of the invention is to overcome the disadvantages of DNA-based vaccines and immunotherapies.
The object of the invention is to overcome the disadvantages of mRNA-based vaccines and immunotherapies.
SUMMARY OF THE INVENTION
The objects of the present invention are solved by the subject-matter disclosed in the claims.
The present invention relates to a plurality of interrelated products listed below and therefore discloses a single inventive concept:

    
    
        DNA
        RNA
        protein (RNA product)
        vaccine (DNA, RNA or protein for use in prophylaxis or treatment of cancer),
        methods of preparing said RNA and protein, and
        diagnostics (protein for the use in screening of disease)
    
    


Tumor-derived circRNA
In the preferred embodiment of the invention, the objects of the invention are solved by an endogenous tumor-derived circRNA for use as a vaccine in the prophylaxis and/or treatment of cancer. Preferably said circRNA comprises at least one open reading frame (ORF) not expressed in non-tumorous cells.
In one embodiment of the invention, the tumor-derived circRNA comprises a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.
In a further embodiment of the invention, the tumor-derived circRNA is for use as vaccine in the prophylaxis and/or treatment of prostate cancer, breast cancer, colon cancer, lung cancer and/or pancreatic cancer.
In a further embodiment of the invention, the tumor-derived circRNA is for use as a prophylactic vaccine.
In a further embodiment of the invention, the tumor-derived circRNA is for use as a therapeutic vaccine.
In a further embodiment of the invention, the tumor-derived circRNA is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.
The invention also relates to a method of prophylaxis and/or treatment of cancer by using a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.
The invention also relates to a method of preparing a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology, comprising the steps of:

    
    
        a. Extracting total RNA content from tumor cells, and
        a. Enriching circRNA by enzyme digestion of linear RNA and
        b. Return circRNA to antigen presenting cells in vivo or ex vivo.
    
    


The invention also relates to a vaccine comprising a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.
Proteins from Tumor-Derived circRNA
In the preferred embodiment of the invention, the objects of the invention are solved by a protein derived from a tumor-derived circRNA.
In a further embodiment of the invention, the protein is derived from a tumor-derived circRNA comprising a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology, wherein said protein comprise an amino acid sequence selected from SEQ ID No: 300 to 598 or homologous amino acid sequences thereof having at least 80% homology.
In a further embodiment of the invention, the protein comprise an amino acid sequence selected from SEQ ID No: 301 to 598 or homologous amino acid sequences thereof having at least 80% homology.
In a further embodiment of the invention, the protein comprises an amino acid selected from SEQ ID No: 301 to 598.
In a further embodiment of the invention, the protein is for use in the prophylaxis and/or treatment of cancer.
In a further embodiment of the invention, the protein is for use in the prophylaxis and/or treatment of prostate cancer, breast cancer, colon cancer, lung cancer and pancreatic cancer.
In a further embodiment of the invention, the protein is for use as a prophylactic vaccine.
In a further embodiment of the invention, the protein is for use as a therapeutic vaccine.
In a further embodiment of the invention, the protein is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.
The invention also relates to a method of prophylaxis and/or treatment of cancer by using a protein derived from tumor-derived circRNA. The protein may comprise a protein sequence selected from SEQ ID No: 300 to 598 or homologous nucleotide sequences thereof having at least 80% homology.
The invention also relates to a method of preparing the protein, comprising the steps of:

    
    
        c. Extracting total RNA content from tumor cells,
        d. Enriching circRNA by enzyme digestion of linear RNA,
        e. Identifying proteins:
        
            i. RNA sequencing,
            ii. protein mass-spectrometry,
            iii. In vitro translation, and/or
            iv. Prediction of MHC class I/II-binding
        
        
        f. identification of personalized/general potential of the protein as immunogen by:
        
            v. In vitro stimulation of T-cells from patients with neoantigens, and/or
            vi. Determination of B cell-responses to neoantigen
        
        
    
    


The invention also relates to vaccine comprising the protein derived from a tumor-derived circRNA.
The invention also relates to a pharmaceutical composition comprising the protein derived from a tumor-derived circRNA.
DNA Expressing (or Encoding) RNA and/or Proteins
The invention also relates to DNA which encodes for a circRNA discussed above.
The invention is also related to DNA which encodes for a protein discussed above.
The DNA may have a DNA sequence disclosed in Table 1.
In a further embodiment, said DNA is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.
The invention also relates to a vaccine vector or genetic vector which comprises DNA as discussed above.
The invention also relates to a vaccine vector or genetic vector which comprises DNA or RNA that express a protein (described above) corresponding to a protein encoded by a tumor-derived circRNA



BRIEF DESCRIPTION OF FIGURES
FIG. 1A illustrates RNA splicing and FIG. 1B illustrates circRNA splicing.
FIG. 2 illustrates the translation of circRNA into proteins.
FIG. 3 illustrates the process for manufacturing circRNA-based vaccines.
FIG. 4 illustrates the process for manufacturing vaccines comprising proteins derived from circRNA.
FIGS. 5 and 6 show experimental results from circRNA vaccination of rats. There is increased proliferation of CD8+ T cells in vaccinated rats compared to a control rat group.
FIG. 7 show experimental results from circRNA vaccination of rats. There is no difference in proliferation of CD4+ T cells between vaccinated rats and a control rat group.
FIG. 8 show experimental results from circRNA vaccination of rats. In vaccinated rats there is an increased tumor necrosis.
FIGS. 9a-9c show experimental results from circRNA vaccination of mice. There is increased proliferation of CD4+ T cells and B cells in vaccinated mice compared to a control mice group, FIG. 9a and FIG. 9c, respectively. There is a minimal effect on proliferation of CD8+ T-cells, FIG. 9b. 



DETAILED DESCRIPTION
Splicing is the editing of the nascent precursor messenger RNA (pre-mRNA) transcript into a mature mRNA. As illustrated in FIG. 1A, after splicing (i.e. normal RNA splicing), introns are removed and exons are joined together (ligated). The splicing of the tumor-derived circRNA of the present invention differs from normal RNA splicing in that, during the formation of the circular RNA, the back-splicing process will introduce a unique fusion of two RNA nucleotides stretches as illustrated in FIG. 1B.
The tumor-derived circRNA of the present invention can be translated into proteins by at least the three types of processes as illustrated in FIG. 2. Both the circRNA and the resulting proteins can be used for use in the prophylaxis and treatment of cancer.
In the Type-I process illustrated in FIG. 2A, the ORF is out of frame and the RNA is translated into a (neo-antigen) protein from an alternative read frame compared to the normal gene product.
The type-II process which is illustrated in FIG. 2B differs from the Type-I process in that, the Type-II process the translation of the (neo-antigen) protein cross a back-splicing site (BSS), and therefore, in the type-II process novel (neo-antigen) proteins can be produced by out-of-frame (from the normal gene product) translation of the ORF both before and/or after the BSS. In the type-II process the fusion site at the BSS can as well generate neo-antigen peptides.
The type III process which is illustrated in FIG. 2C involves a rolling circle amplified protein. The circRNA has an ORF that only contains a start codon (AUG) and produce a peptide that is in-frame with itself after passing the start codon and protein can continue to be translated in a rolling circle amplification manner. This leads to a rolling circle amplification of the generated peptide and potentiate the neo-antigen production, which leads to an enhanced immune response to the antigen.
Delivering RNA to subjects and induction of an adaptive immune response against said RNA is known in the art. This approach has previously been used in eliciting an immune response to RNA. Hence, full-length mRNAs or short oligonucleotide repeats against mutated regions have been selected and amplified in prior art techniques.
The present invention differs from prior art techniques in that tumor tissue is used and total RNA is extracted from the tumor cells. Within the total pool of tumor derived RNA molecules there is a fraction that consist of circularized RNA molecules (due to back-splicing events). The tumor-derived circRNA pool contains tumor specific circRNA with unique open-reading frames (ORFs) not normally expressed. ORFs that can be translated into peptides as novel proteins and hence be presented as novel neo-antigens that can stimulate immune responses toward the neo-antigens.
The strength of the present invention is that it is totally new protein sequence that compose the epitopes that are inducing the immune response, compared to mutations that only change a single or a few amino acids or full proteins over expressed in cancer that already have had a negative selection against their epitopes. Another aspect is that circRNAs are very diverse in their composition and that cancer induced changes have big impact on the repertoire of expressed circRNAs, thus a wide range of neo-antigens can be present at the same time within a tumor. Moreover, circRNAs are nuclease resistant by their circular structure and much more resistant against degradation than linear RNA molecules once injected in the patient enhancing the delivering potential.
The circRNA extracted from the patient will contain the multiplicity of unique tumor-derived circRNAs that have the potential to via antigen presenting cells present novel neo-antigens for the immune system.
In the present invention, tumor-derived circRNA from the patient will be prepared and divided into vaccination batches and booster batches, and administered either by injection in-vivo at sites of immune presentation (like adjacent to lymph nodes, within lymph nodes) or ex-vivo for immune cell stimulation and cell based therapy.
In the present invention, tumor-derived circRNA are isolated and sequenced from subjects (i.e. patients) with well-defined tumor types. The invention is not limited to a certain cancer type and is therefore applicable for all types of cancer. Subsequently, a database with identified and potential unique open reading frames within circRNA are built that are not present within normal cell transcription within the patients. This will:

    
    
        1. Allow for the identification of potential neo-antigens within (back-spliced) circRNA that are common for a certain tumor type, and
        2. Allow for the identification of potential neo-antigens within (back-spliced) circRNA that are unique for a single patient
    
    


Importantly, results from (1) will identify circRNA neo-antigens that are suitable for prophylactic vaccination (i.e. to vaccinate healthy individuals against a particular cancer) and therapeutic vaccination (i.e. patients with corresponding cancer). Results from (2) will identify circRNA neo-antigens that can be rapidly introduced into a delivery vector for personalized therapeutic vaccination against pre-existing tumors in a cancer patient.
The pharmaceutical compositions and vaccines of the present invention may comprise pharmaceutically acceptable excipients used in the art. Preservatives, adjuvants, stabilizers and buffers are examples excipients which may be used but the present invention is not restricted to these examples.
Preservatives are used to prevent growth of bacteria or fungi that may be introduced into the vaccine during its use, for example by repeated puncture of a multi-dose vaccine vial with a needle.
Adjuvants helping stimulate a stronger immune response of vaccinated individuals.
Aluminum salts may be incorporated into a vaccine formulation as an adjuvant. Examples of aluminum salts are aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or mixed aluminum salts. Organic compounds such as squalene or oil-based compounds may also be used as adjuvant.
Stabilizers keep vaccines potent during transportation and storage. They help protect the vaccine from adverse conditions such as the freeze-drying process, for those vaccines that are freeze dried. Some examples of stabilizers which may be added to vaccines include: sugars such as sucrose and lactose, amino acids such as glycine or the monosodium salt of glutamic acid and proteins such as human serum albumin or gelatin.
In the present invention, the term “protein” is defined as a molecule which comprises one or more chains of amino acid residues. The terms peptide, oligopeptide and polypeptide are in the present invention also included in the definition of protein.
In the present invention, the expression “tumor-derived circRNA” is defined as “tumor-isolated circRNA” (or alternatively “circRNA isolated from tumor”).
In the present invention, the expression “protein derived from a tumor-derived circRNA” is defined as “protein encoded by tumor-derived circRNA” (or alternatively “protein expressed from tumor-derived circRNA”.
EXAMPLES
Example 1—Tumor-derived circRNA
The method described in Example 1 is briefly illustrated in FIG. 3.
Tumor tissue is harvested from the patient and the total RNA content in the tumor cells are extracted with RNA isolation methodology used in the art. The circular RNA fraction is further enriched by for example enzyme digestion of linear RNA (by for example using RNAse R).
RNA quality control and content may be monitored by a combination of Bioanalyser (Agilent) and Qubit (Thermofisher) measurements or by similar instruments. circRNA is aliquoted and may be stored at −80° C. (or at other suitable temperatures) in different batches (e.g. vaccination and booster) ready to be administered to the patient after reconstituting the frozen batches with physiological buffer (such as Hanks Buffers Saline Solution/NaCl).
The endogenous tumor-derived circRNA prepared according to Example 1 comprises a nucleotide sequence selected from SEQ ID No: 1 to 299 (which are disclosed in Table 1 and the sequence listing) or homologous nucleotide sequences thereof having at least 80% homology. However, the present invention is not restricted to these specific sequences, and therefore, tumor-derived circRNA having other RNA sequences may be used for prophylaxis and/or treatment of disease.
The resulting vaccine is a therapeutic vaccine which is personalized for the patient from whom the tumor tissue has been harvested.
The personalized vaccine described in Example 1 is advantageous since it can be produced in 1-2 days. As a contrast, it takes several months, if not longer, to produce the vaccines described in the prior art.
The usability of the method described has been demonstrated in a pilot experiment where personalized therapeutic vaccination led to an increased immune activation against prostate cancer cells in two animal models (the Dunning Rat prostate cancer model and the TRAMP-C1 prostate cancer mouse model).
Example 2—Proteins from Tumor-Derived Circular RNA
The method described in Example 2 is briefly illustrated in FIG. 4.
Tumor tissue is harvested from the patient and the total RNA content in the tumor cells are extracted with RNA isolation methodology used in the art. The circular RNA fraction is further enriched by for example enzyme digestion of linear RNA (by for example using RNAse R).
RNA quality control and content may be monitored by a combination of Bioanalyser (Agilent) and Qubit (Thermofisher) measurements or by similar instruments. circRNA is aliquoted and may be stored at −80° C. (or at other suitable temperatures) in different batches.
The neoantigen proteins which can be expressed by circRNA are identified by using one or more of the following methods:

    
    
        RNA sequencing
        protein mass-spectrometry
        In vitro translation
        Prediction of MHC class I/II-binding
    
    


The next step in the method involves the identification of personalized/general potential of the neoantigen protein as immunogen by using one or more of the following methods:

    
    
        In vitro stimulation of T-cells from patients with neo-antigens and detection of specific T cell responses by standard immunological assays, such as immune cell proliferation of cytokine production by Flow cytometry or ELISpot Determination of B cell-responses to neoantigen by standard immunological assays (such as ELISA/ELISpot)
    
    


The proteins derived from the tumor-derived circRNA isolated according to the method described in Example 2 comprise a protein sequence selected from SEQ ID No: 300 to 598 (which are disclosed in Table 1 and the sequence listing). However, the present invention is not restricted to these specific sequences, and therefore, proteins derived from tumor-derived circRNA having other protein sequences may be used for prophylaxis and/or treatment of disease.
The proteins can be extracted from tumor cells. Moreover, the proteins can also be prepared by liquid-phase synthesis [11,13], solid-phase synthesis [11,13] or by an expression vector [12,13], or by any other method known in the art.
The proteins can also be synthesized by the patient's cell by genetic vaccination or gene therapy with DNA or RNA vectors coding for neoantigen sequences corresponding to a tumor-derived circRNA sequence.
EXPERIMENTS
Rat Experiment:

    1. Total RNA was isolated from MAT-Ly-Lu (Dunning R-3327 prostate cancer animal model) cells.
    2. Linear RNA was digested with RNAse R (Epicenter) to enrich for circRNA (1U RNAse R/ug total RNA). The digest total RNA was cleaned-up (Agencourt RNAClean XP), and yielded 12 vaccine doses of 30 ug circRNA per dose.
    3. Vaccine was prepared for the four Copenhagen rats: One dose (30 ug) circRNA was mixed with physiological NaCl solution to a volume of 100 ul, and the prepared “vaccine” was injected intradermal, close to the inguinal lymph nodes in four Copenhagen rats. Resulting in a dose of 80 ug circRNA/kg animal.
    4. To four rats in a control group, 100 ul physiological NaCl solution was injected in the same way as in the vaccination group.
    5. Time plan: Vaccination took place during three weeks before injecting 10.000 MAT-Ly-Lu cells within prostate. In brief, at day 0 the first dose was administered, and the second and third was injected at day 7 and day 14. At day 21, ten thousand MAT-Ly-Lu cells was injected into the prostate, and at day 35 the animal was sacrificed.
    6. Sample collected: Spleen and lymph nodes where collected, as well as prostate tumor and lung.
    7. Analysis: Immune activation was measured by labelling splenocytes/lymphocytes with CFSE and exposing them to mitomycin C-treated MAT-Ly-Lu cells for 5 days. Cells were then labelled with anti-CD8 and anti-CD4 and subjected to flow cytometry. Activation and subsequent proliferation of CD4+ and CD8+ T cells were measured as a decrease in CFSE-intensity (the CFSE is diluted in cells upon cell division). The necrotic tumor areas within the tumor was also investigated and measured between the control group and the vaccinated group.
    8. Results: The main mediators of tumor induced immune response are the CD8+ T-cells, the so called cytotoxic T-cells. These cells are well-known to mediate tumor cell elimination of cells expressing neoantigen epitopes on their MHC-I complexes. Interestingly there was a more than threefold induction of proliferation in 50% of the animals (2/4) of the CD8+ T-cells after in vitro exposure to MAT-Ly-Lu cells (2:1 spleenocyte/tumor cell ratio), indicative that two rats have acquired an adaptive immune response against the tumor (see FIGS. 5 and 6). In line with an increased CD8+ T-cell activity there was also a trend toward an increased tumor cell death and necrotic area in vaccinated animals (see FIG. 8). There was no difference in induced CD4 activity between vaccinated rats and a control rat group (see FIG. 7).
    9. Summary: We could see an increased mobilization of the adaptive immune system toward the tumor cells after administration of a circRNA vaccination program.

Mouse Experiment:

    1. Total RNA was isolated from TRAMP-C1 (prostate cancer mouse cell line with C57BL/6 background) cells.
    2. Linear RNA was digested with RNAse R (Epicenter) to enrich for circRNA (1U RNAse R/ug total RNA). The digest total RNA was cleaned-up (Agencourt RNAClean XP), and yielded RNA for eight vaccine doses of 10 ug circRNA per dose.
    3. Vaccine was prepared for the four C57BL/6 mice: One dose (10 ug) circRNA was prepared as following, 5 ug circRNA was prepared with 5 ug protamine, incubated 30 min RT for complex binding and then another 5 ug of circRNA was added to the tube in a volume of 100 ul in ringers salt solution. The prepared “vaccine” was injected intradermal, on the flanks close to the groins. Resulting in a dose of ˜300 ug circRNA/kg animal.
    4. To four mice in a control group, 100 ul ringers salt solution containing 5 ug of protamine was injected in the same way as in the vaccination group.
    5. Time plan: Animals were vaccinated day 0 and day 14, and then sacrificed on day 21.
    6. Sample collected: Spleens where collected.
    7. Analysis: Single cell suspension of CFSE-labelled splenocytes were co-incubated with lysate from TRAMP-C1 cells for 4-5 days. Proliferation/activation of B and T cells was measured as reduced CFSE-intensity on B220+ B cells, CD8+ T cells or CD4+ T cells by flow cytometry.
    8. Results: The tumor induced immune response were a pronounced effect seen among the CD4+ T-cell (FIG. 9a) and the B-cells (FIG. 9b), with minimal effect on the CD8+ T-cells (FIG. 9c). In this experiment the mice had not been exposed to the tumor cells in question before analysis, contrary to in the rat experiment (discussed above) where the rats had known the tumor cells for two weeks and thereby triggering a potential immune response.
    9. Summary: We could see an increased mobilization of the adaptive immune system toward the tumor cells after administration of a circRNA vaccination program.













TABLE 1








SEQ





KLK3 neo-
ID NO





antigen
cRNA/protein
DNA sequence
RNA sequence
Protein sequence





  1
  1/300
TTGCTAGGAAAAGAAATCAGCAGACACAGGTGTA
UUGCUAGGAAAAGAAAUCAGCAGACACAG
LLGKEISRHRCRPECFLNGVILSSLCPGEY




GACCAGAGTGTTTCTTAAATGGTGTAATTTTGTCC
GUGUAGACCAGAGUGUUUCUUAAAUGGU
WPCLETYHSISLRTQIGWGVCVICGVQR




TCTCTGTGTCCTGGGGAATACTGGCCATGCCTGGA
GUAAUUUUGUCCUCUCUGUGUCCUGGGG





GACATATCACTCAATTTCTCTGAGGACACAGATAG
AAUACUGGCCAUGCCUGGAGACAUAUCAC





GATGGGGTGTCTGTGTTATTTGTGGGGTACAGAG
UCAAUUUCUCUGAGGACACAGAUAGGAUG





ATGA
GGGUGUCUGUGUUAUUUGUGGGGUACAG






AGAUGA



 


  2
  2/301
ATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCA
AUGUGCCCUGCCCGAAAGGCCUUCCCUGU
MCPARKAFPVHQGGALPEVDQGHHRG




AGGTGGTGCATTACCGGAAGTGGATCAAGGACAC
ACACCAAGGUGGUGCAUUACCGGAAGUGG
QPLSTPINPLL




CATCGTGGCCAACCCCTGAGCACCCCTATCAACCC
AUCAAGGACACCAUCGUGGCCAACCCCUGA





CCTATTGTAG
GCACCCCUAUCAACCCCCUAUUGUAG



 


  3
  3/302
GTGTCTGTGTTATTTGTGGGGTACAGAGATGAAA
GUGUCUGUGUUAUUUGUGGGGUACAGAG
VSVLFVGYRDERGVGSTLREWRVTCAGH




GAGGGGTGGGATCCACACTGAGAGAGTGGAGAG
AUGAAAGAGGGGUGGGAUCCACACUGAGA
CP




TGACATGTGCTGGACACTGTCCATGA
GAGUGGAGAGUGACAUGUGCUGGACACU






GUCCAUGA



 


  4
  4/303
TTGTCCTTAGGTGTGAGGTCCAGGGTTGCTAGGA
UUGUCCUUAGGUGUGAGGUCCAGGGUUG
LSLGVRSRVARKRNQQTQV




AAAGAAATCAGCAGACACAGGTGTAG
CUAGGAAAAGAAAUCAGCAGACACAGGUG






UAG



 


  5
  5/304
GTGTTTCTTAAATGGTGTAATTTTGTCCTCTCTGTG
GUGUUUCUUAAAUGGUGUAAUUUUGUCC
VFLKWCNFVLSVSWGILAMPGDISLNFS




TCCTGGGGAATACTGGCCATGCCTGGAGACATAT
UCUCUGUGUCCUGGGGAAUACUGGCCAUG
EDTDRMGCLCYLWGTEMKEGWDPH




CACTCAATTTCTCTGAGGACACAGATAGGATGGG
CCUGGAGACAUAUCACUCAAUUUCUCUGA





GTGTCTGTGTTATTTGTGGGGTACAGAGATGAAA
GGACACAGAUAGGAUGGGGUGUCUGUGU





GAGGGGTGGGATCCACACTGA
UAUUUGUGGGGUACAGAGAUGAAAGAGG






GGUGGGAUCCACACUGA



 


  6
  6/305
GTGCTGGACACTGTCCATGAAGCACTGAGCAGAA
GUGCUGGACACUGUCCAUGAAGCACUGAG
VLDTVHEALSRSWRHNAPDTHSKDGAE




GCTGGAGGCACAACGCACCAGACACTCACAGCAA
CAGAAGCUGGAGGCACAACGCACCAGACAC
NITHSVLEALGSLEKAVSQGGRVFLWHG




GGATGGAGCTGAAAACATAACCCACTCTGTCCTG
UCACAGCAAGGAUGGAGCUGAAAACAUAA
MGMK




GAGGCACTGGGAAGCCTAGAGAAGGCTGTGAGC
CCCACUCUGUCCUGGAGGCACUGGGAAGC





CAAGGAGGGAGGGTCTTCCTTTGGCATGGGATGG
CUAGAGAAGGCUGUGAGCCAAGGAGGGAG





GGATGAAGTAA
GGUCUUCCUUUGGCAUGGGAUGGGGAUG






AAGUAA



 


  7 (BSS)
  7/306
TTGAGCCCCAAGCTTACCACCTGCACCCGGAGAGC
UUGAGCCCCAAGCUUACCACCUGCACCCGG
LSPKLTTCTRRAVSPCGSRLSSSPCP




TGTGTCACCATGTGGGTCCCGGTTGTCTTCCTCAC
AGAGCUGUGUCACCAUGUGGGUCCCGGUU





CCTGTCCGTGA
GUCUUCCUCACCCUGUCCGUGA



 


  8 (BSS)
  8/307
GTGCTGCACCCCTCATCCTGTCTCGGATTGTGGGA
GUGCUGCACCCCUCAUCCUGUCUCGGAUU
VLHPSSCLGLWEAGSARSIPNPGRCLWP




GGCTGGGAGTGCGAGAAGCATTCCCAACCCTGGC
GUGGGAGGCUGGGAGUGCGAGAAGCAUU
LVAGQSAAVFWCTPSGSSQLPTASGSAA




AGGTGCTTGTGGCCTCTCGTGGCAGGGCAGTCTG
CCCAACCCUGGCAGGUGCUUGUGGCCUCU
PLILSRIVGGWECEKHSQPWQVLVASRG




CGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTC
CGUGGCAGGGCAGUCUGCGGCGGUGUUC
RAVCGGVLVHPQWVLTAAHCIR




ACAGCTGCCCACTGCATCAGGAAGTGCTGCACCCC
UGGUGCACCCCCAGUGGGUCCUCACAGCU





TCATCCTGTCTCGGATTGTGGGAGGCTGGGAGTG
GCCCACUGCAUCAGGAAGUGCUGCACCCCU





CGAGAAGCATTCCCAACCCTGGCAGGTGCTTGTG
CAUCCUGUCUCGGAUUGUGGGAGGCUGG





GCCTCTCGTGGCAGGGCAGTCTGCGGCGGTGTTC
GAGUGCGAGAAGCAUUCCCAACCCUGGCA





TGGTGCACCCCCAGTGGGTCCTCACAGCTGCCCAC
GGUGCUUGUGGCCUCUCGUGGCAGGGCA





TGCATCAGG
GUCUGCGGCGGUGUUCUGGUGCACCCCCA






GUGGGUCCUCACAGCUGCCCACUGCAUCA






GG



 


  9 (BSS)
  9/308
CTGGGAGTGCGAGAAGCATTCCCAACCCTGGCAG
CUGGGAGUGCGAGAAGCAUUCCCAACCCU
LGVREAFPTLAGACGLSWQGSLRRCSGA




GTGCTTGTGGCCTCTCGTGGCAGGGCAGTCTGCG
GGCAGGUGCUUGUGGCCUCUCGUGGCAG
PPVGPHSCPLHQEVLHPSSCLGLWEAGS




GCGGTGTTCTGGTGCACCCCCAGTGGGTCCTCACA
GGCAGUCUGCGGCGGUGUUCUGGUGCACC
ARSIPNPGRCLWPLVAGQSAAVFWCTPS




GCTGCCCACTGCATCAGGAAGTGCTGCACCCCTCA
CCCAGUGGGUCCUCACAGCUGCCCACUGCA
GSSQLPTASG




TCCTGTCTCGGATTGTGGGAGGCTGGGAGTGCGA
UCAGGAAGUGCUGCACCCCUCAUCCUGUC





GAAGCATTCCCAACCCTGGCAGGTGCTTGTGGCCT
UCGGAUUGUGGGAGGCUGGGAGUGCGAG





CTCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGT
AAGCAUUCCCAACCCUGGCAGGUGCUUGU





GCACCCCCAGTGGGTCCTCACAGCTGCCCACTGCA
GGCCUCUCGUGGCAGGGCAGUCUGCGGCG





TCAGGA
GUGUUCUGGUGCACCCCCAGUGGGUCCUC






ACAGCUGCCCACUGCAUCAGGA



 


 10 (BSS)
 10/309
GTGCTGGACGCTGGACAGGGGGCAAAAGCACCT
GUGCUGGACGCUGGACAGGGGGCAAAAGC
VLDAGQGAKAPARLDPKETSVCGPPCYF




GCTCGTCTTGACCCCAAAGAAACTTCAGTGTGTGGACC
UGCUCGUCUUGACCCCAAAGAAACUUC
Q




ACCTCCATGTTATTTCCAATGA
AGUGUGUGGACCUCCAUGUUAUUUCCAAU






GA



 


 11 (BSS)
 11/310
GTGTGCGCAAGTTCACCCTCAGAAGGTGACCAAG
GUGUGCGCAAGUUCACCCUCAGAAGGUGA
VCASSPSEGDQVHAVCWTLDRGQKHLL




TTCATGCTGTGTGCTGGACGCTGGACAGGGGGCA
CCAAGUUCAUGCUGUGUGCUGGACGCUGG
VLTPKKLQCVDLHVISNDVCAQVHPQKV




AAAGCACCTGCTCGTCTTGACCCCAAAGAAACTTC
ACAGGGGGCAAAAGCACCUGCUCGUCUUG
TKFMLCAGRWTGGKSTCS




AGTGTGTGGACCTCCATGTTATTTCCAATGACGTG
ACCCCAAAGAAACUUCAGUGUGUGGACCU





TGTGCGCAAGTTCACCCTCAGAAGGTGACCAAGT
CCAUGUUAUUUCCAAUGACGUGUGUGCGC





TCATGCTGTGTGCTGGACGCTGGACAGGGGGCAA
AAGUUCACCCUCAGAAGGUGACCAAGUUC





AAGCACCTGCTCG
AUGCUGUGUGCUGGACGCUGGACAGGGG






GCAAAAGCACCUGCUCG



 


 12 (BSS)
 12/311
ATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCA
AUGUGCCCUGCCCGAAAGGCCUUCCCUGU
MCPARKAFPVHQGGALPEVDQGHHRG




AGGTGGTGCATTACCGGAAGTGGATCAAGGACAC
ACACCAAGGUGGUGCAUUACCGGAAGUGG
QPLSTPINPLL




CATCGTGGCCAACCCCTGAGCACCCCTATCAACCC
AUCAAGGACACCAUCGUGGCCAACCCCUGA





CCTATTGTAG
GCACCCCUAUCAACCCCCUAUUGUAG



 


 13 (BSS)
 13/312
CTGATTCACTATGGGGGGAGGTGTATTGAAGTCC
CUGAUUCACUAUGGGGGGAGGUGUAUUG
LIHYGGRCIEVLQTTLRFDDFLVELTEIKSC




TCCAGACAACCCTCAGATTTGATGATTTCCTAGTA
AAGUCCUCCAGACAACCCUCAGAUUUGAU
YTVGDSGGPLVCNGVLQGITSWGSEPCA




GAACTCACAGAAATAAAGAGCTGTTATACTGTGG
GAUUUCCUAGUAGAACUCACAGAAAUAAA
LPERPSLYTKVVHYRKWIKDTIVANP




GTGATTCTGGGGGCCCACTTGTCTGTAATGGTGTG
GAGCUGUUAUACUGUGGGUGAUUCUGGG





CTTCAAGGTATCACGTCATGGGGCAGTGAACCAT
GGCCCACUUGUCUGUAAUGGUGUGCUUCA





GTGCCCTGCCCGAAAGGCCTTCCCTGTACACCAAG
AGGUAUCACGUCAUGGGGCAGUGAACCAU





GTGGTGCATTACCGGAAGTGGATCAAGGACACCA
GUGCCCUGCCCGAAAGGCCUUCCCUGUACA





TCGTGGCCAACCCCTGA
CCAAGGUGGUGCAUUACCGGAAGUGGAUC






AAGGACACCAUCGUGGCCAACCCCUGA



 


 14
 14/313
GTGATCTTGCTGGGTCGGCACAGCCTGTTTCATCC
GUGAUCUUGCUGGGUCGGCACAGCCUGUU
VILLGRHSLFHPEDTGQVFQVSHSFPHPL


(BSS + RCA)

TGAAGACACAGGCCAGGTATTTCAGGTCAGCCAC
UCAUCCUGAAGACACAGGCCAGGUAUUUC
YDMSLLKNRFLRPGDDSSHDLMLLRLSEP




AGCTTCCCACACCCGCTCTACGATATGAGCCTCCT
AGGUCAGCCACAGCUUCCCACACCCGCUCU
AELTDAVKVMDLPTQEPALGTTCYASG




GAAGAATCGATTCCTCAGGCCAGGTGATGACTCC
ACGAUAUGAGCCUCCUGAAGAAUCGAUUC
WGSIEPEECAAPLILSRIVGGWECEKHSQ




AGCCACGACCTCATGCTGCTCCGCCTGTCAGAGCC
CUCAGGCCAGGUGAUGACUCCAGCCACGAC
PWQVLVASRGRAVCGGVLVHPQWVLT




TGCCGAGCTCACGGATGCTGTGAAGGTCATGGAC
CUCAUGCUGCUCCGCCUGUCAGAGCCUGC
AAHCIR




CTGCCCACCCAGGAGCCAGCACTGGGGACCACCT
CGAGCUCACGGAUGCUGUGAAGGUCAUGG





GCTACGCCTCAGGCTGGGGCAGCATTGAACCAGA
ACCUGCCCACCCAGGAGCCAGCACUGGGGA





GGAGTGTGCTGCACCCCTCATCCTGTCTCGGATTG
CCACCUGCUACGCCUCAGGCUGGGGCAGCA





TGGGAGGCTGGGAGTGCGAGAAGCATTCCCAACC
UUGAACCAGAGGAGUGUGCUGCACCCCUC





CTGGCAGGTGCTTGTGGCCTCTCGTGGCAGGGCA
AUCCUGUCUCGGAUUGUGGGAGGCUGGG





GTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGG
AGUGCGAGAAGCAUUCCCAACCCUGGCAG





TCCTCACA
GUGCUUGUGGCCUCUCGUGGCAGGGCAG






UCUGCGGCGGUGUUCUGGUGCACCCCCAG






UGGGUCCUCACA





PCA3 neo-






antigen

DNA sequence
RNA sequence
Protein Sequence





  1
 15/314
CTGGCATCAGAAAAACAGAGGGGAGATTTGTGTG
CUGGCAUCAGAAAAACAGAGGGGAGAUUU
LASEKQRGDLCGCSRGRPGRSAWWEGP




GCTGCAGCCGAGGGAGACCAGGAAGATCTGCAT
GUGUGGCUGCAGCCGAGGGAGACCAGGAA
DDTEVRNKKGC




GGTGGGAAGGACCTGATGATACAGAGGTGAGAA
GAUCUGCAUGGUGGGAAGGACCUGAUGA





ATAAGAAAGGCTGCTGA
UACAGAGGUGAGAAAUAAGAAAGGCUGCU






GA



 


  2
 16/315
GTGCCTGGTCCCGCTTGTGAGGGAAGGACATTAG
GUGCCUGGUCCCGCUUGUGAGGGAAGGAC
VPGPACEGRTLENELMCSLKDGQENRSC




AAAATGAATTGATGTGTTCCTTAAAGGATGGGCA
AUUAGAAAAUGAAUUGAUGUGUUCCUUA
CGYLFERDYRFEMKSQSEHYQ




GGAAAACAGATCCTGTTGTGGATATTTATTTGAAC
AAGGAUGGGCAGGAAAACAGAUCCUGUUG





GGGATTACAGATTTGAAATGAAGTCACAAAGTGA
UGGAUAUUUAUUUGAACGGGAUUACAGA





GCATTACCAATGA
UUUGAAAUGAAGUCACAAAGUGAGCAUUA






CCAAUGA



 


  3
 17/316
ATGGAATACTGTGATGACATGAGGCAGCCAAGCT
AUGGAAUACUGUGAUGACAUGAGGCAGCC
MEYCDDMRQPSWGGDNHGAEGQDSG




GGGGAGGAGATAACCACGGGGCAGAGGGTCAGG
AAGCUGGGGAGGAGAUAACCACGGGGCAG
PAA




ATTCTGGCCCTGCTGCCTAA
AGGGUCAGGAUUCUGGCCCUGCUGCCUAA



 


  4
 18/317
CTGATCTCTACGGTTCCTTCTGGGCCCAACATTCTC
CUGAUCUCUACGGUUCCUUCUGGGCCCAA
LISTVPSGPNILHISSHTHF




CATATATCCAGCCACACTCATTTTTAA
CAUUCUCCAUAUAUCCAGCCACACUCAUUU






UUAA



 


  5
 19/318
GTGTTCTGGCCCAGGGGATCTGTGAACAGGCTGG
GUGUUCUGGCCCAGGGGAUCUGUGAACAG
VFWPRGSVNRLGSISRSFQGYTY




GAAGCATCTCAAGATCTTTCCAGGGTTATACTTAC
GCUGGGAAGCAUCUCAAGAUCUUUCCAGG





TAG
GUUAUACUUACUAG



 


  6
 20/319
GTGCCCATTCTCAAGACCTCAAAATGTCATTCCATT
GUGCCCAUUCUCAAGACCUCAAAAUGUCA
VPILKTSKCHSINITGLTFFFNLEEFNVTCS




AATATCACAGGATTAACTTTTTTTTTTAACCTGGAA
UUCCAUUAAUAUCACAGGAUUAACUUUUU
YGNLITYFVFQCKDD




GAATTCAATGTTACATGCAGCTATGGGAATTTAAT
UUUUUAACCUGGAAGAAUUCAAUGUUACA





TACATATTTTGTTTTCCAGTGCAAAGATGACTAA
UGCAGCUAUGGGAAUUUAAUUACAUAUU






UUGUUUUCCAGUGCAAAGAUGACUAA



 


  7
 21/320
TTGAACATGTCAGGCATACATTATTCCTTCTGCCTG
UUGAACAUGUCAGGCAUACAUUAUUCCUU
LNMSGIHYSFCLRSSSLSLKSRMM




AGAAGCTCTTCCTTGTCTCTTAAATCTAGAATGAT
CUGCCUGAGAAGCUCUUCCUUGUCUCUUA





GTAA
AAUCUAGAAUGAUGUAA



 


  8
 22/321
CTGGCAATAAAGAATTTACAAAGAGCTACTCAGG
CUGGCAAUAAAGAAUUUACAAAGAGCUAC
LAIKNLQRATQDQLLRALCVCVCV




ACCAGTTGTTAAGAGCTCTGTGTGTGTGTGTGTGT
UCAGGACCAGUUGUUAAGAGCUCUGUGU





GTGTGA
GUGUGUGUGUGUGUGUGA



 


  9
 23/322
GTGTACATGCCAAAGTGTGCCTCTCTCTCTTTGAC
GUGUACAUGCCAAAGUGUGCCUCUCUCUC
VYMPKCASLSLTHYFRLKNKHVFKWHYE




CCATTATTTCAGACTTAAAAACAAGCATGTTTTCAA
UUUGACCCAUUAUUUCAGACUUAAAAACA
LPMMYHHHISLFSSKCDNNVIC




ATGGCACTATGAGCTGCCAATGATGTATCACCACC
AGCAUGUUUUCAAAUGGCACUAUGAGCUG





ATATCTCATTATTCTCCAGTAAATGTGATAATAATG
CCAAUGAUGUAUCACCACCAUAUCUCAUU





TCATCTGTTAA
AUUCUCCAGUAAAUGUGAUAAUAAUGUCA






UCUGUUAA



 


 10
 24/323
TTGACTTCACAAAAGCAGCTGGAAATGGACAACC
UUGACUUCACAAAAGCAGCUGGAAAUGGA
LTSQKQLEMDNHNMHKSNSYHQLHTA




ACAATATGCATAAATCTAACTCCTACCATCAGCTA
CAACCACAAUAUGCAUAAAUCUAACUCCUA





CACACTGCTTGA
CCAUCAGCUACACACUGCUUGA



 


 11
 25/324
CTGAGCTGTCATCGTCCCCATCTCTGTGAGCCACA
CUGAGCUGUCAUCGUCCCCAUCUCUGUGA
LSCHRPHLCEPQPTAGPNACLRSLNQGN




ACCAACAGCAGGACCCAACGCATGTCTGAGATCC
GCCACAACCAACAGCAGGACCCAACGCAUG
QCHELNSPIMDASFWPSLALLLTHISF




TTAAATCAAGGAAACCAGTGTCATGAGTTGAATTC
UCUGAGAUCCUUAAAUCAAGGAAACCAGU





TCCTATTATGGATGCTAGCTTCTGGCCATCTCTGG
GUCAUGAGUUGAAUUCUCCUAUUAUGGA





CTCTCCTCTTGACACATATTAGCTTCTAG
UGCUAGCUUCUGGCCAUCUCUGGCUCUCC






UCUUGACACAUAUUAGCUUCUAG



 


 12
 26/325
TTGCTTCCACGACTTTTATCTTTTCTCCAACACATC
UUGCUUCCACGACUUUUAUCUUUUCUCCA
LLPRLLSFLQHIAYQSSLCSVALDFPTRIST




GCTTACCAATCCTCTCTCTGCTCTGTTGCTTTGGAC
ACACAUCGCUUACCAAUCCUCUCUCUGCUC
TLKSFLPSPPLT




TTCCCCACAAGAATTTCAACGACTCTCAAGTCTTTT
UGUUGCUUUGGACUUCCCCACAAGAAUUU





CTTCCATCCCCACCACTAACCTGA
CAACGACUCUCAAGUCUUUUCUUCCAUCCC






CACCACUAACCUGA



 


 13
 27/326
ATGCCTAGACCCTTATTTTTATTAATTTCCAATAGA
AUGCCUAGACCCUUAUUUUUAUUAAUUUC
MPRPLFLLISNRCCLWAILL




TGCTGCCTATGGGCTATATTGCTTTAG
CAAUAGAUGCUGCCUAUGGGCUAUAUUGC






UUUAG



 


 14
 28/327
ATGAACATTAGATATTTAAAGCTCAAGAGGTTCAA
AUGAACAUUAGAUAUUUAAAGCUCAAGAG
MNIRYLKLKRFKIQLIIFSFFHLPAPLPILLIA




AATCCAACTCATTATCTTCTCTTTCTTTCACCTCCCT
GUUCAAAAUCCAACUCAUUAUCUUCUCUU
LNSMVPNVAMQMRNPVAPCGTCMQD




GCTCCTCTCCCTATATTACTGATTGCACTGAACAGC
UCUUUCACCUCCCUGCUCCUCUCCCUAUAU
C




ATGGTCCCCAATGTAGCCATGCAAATGAGAAACC
UACUGAUUGCACUGAACAGCAUGGUCCCC





CAGTGGCTCCTTGTGGTACATGCATGCAAGACTGC
AAUGUAGCCAUGCAAAUGAGAAACCCAGU





TGA
GGCUCCUUGUGGUACAUGCAUGCAAGACU






GCUGA



 


 15
 29/328
GTGCCGAGAAGCTGGCATCAGAAAAACAGAGGG
GUGCCGAGAAGCUGGCAUCAGAAAAACAG
VPRSWHQKNRGEICVAAAEGDQEDLHG




GAGATTTGTGTGGCTGCAGCCGAGGGAGACCAG
AGGGGAGAUUUGUGUGGCUGCAGCCGAG
GKDLMIQR




GAAGATCTGCATGGTGGGAAGGACCTGATGATAC
GGAGACCAGGAAGAUCUGCAUGGUGGGAA





AGAGGTGA
GGACCUGAUGAUACAGAGGUGA



 


 16
 30/329
ATGTTTTTGCACATTTCCAGCCCCTTTAAATATCCA
AUGUUUUUGCACAUUUCCAGCCCCUUUAA
MFLHISSPFKYPHTQEAQKEAQRSLGEM




CACACACAGGAAGCACAAAAGGAAGCACAGAGA
AUAUCCACACACACAGGAAGCACAAAAGGA
PGRHLGSSMSLALCLVPLVREGH




TCCCTGGGAGAAATGCCCGGCCGCCATCTTGGGT
AGCACAGAGAUCCCUGGGAGAAAUGCCCG





CATCGATGAGCCTCGCCCTGTGCCTGGTCCCGCTT
GCCGCCAUCUUGGGUCAUCGAUGAGCCUC





GTGAGGGAAGGACATTAG
GCCCUGUGCCUGGUCCCGCUUGUGAGGGA






AGGACAUUAG



 


 17
 31/330
ATGGGCAGGAAAACAGATCCTGTTGTGGATATTT
AUGGGCAGGAAAACAGAUCCUGUUGUGGA
MGRKTDPVVDIYLNGITDLK




ATTTGAACGGGATTACAGATTTGAAATGA
UAUUUAUUUGAACGGGAUUACAGAUUUG






AAAUGA



 


 18
 32/331
GTGAGCATTACCAATGAGAGGAAAACAGACGAG
GUGAGCAUUACCAAUGAGAGGAAAACAGA
VSITNERKTDEKILMASQDMQQTKWNT




AAAATCTTGATGGCTTCACAAGACATGCAACAAAC
CGAGAAAAUCUUGAUGGCUUCACAAGACA
VMT




AAAATGGAATACTGTGATGACATGA
UGCAACAAACAAAAUGGAAUACUGUGAUG






ACAUGA



 


 19
 33/332
GTGAATTATCTAATCAACATCATCCTCAGTGTCTTT
GUGAAUUAUCUAAUCAACAUCAUCCUCAG
VNYLINIILSVFAHTEIHFPLLCPFSRPQNVI




GCCCATACTGAAATTCATTTCCCACTTTTGTGCCCA
UGUCUUUGCCCAUACUGAAAUUCAUUUCC
PLISQD




TTCTCAAGACCTCAAAATGTCATTCCATTAATATCA
CACUUUUGUGCCCAUUCUCAAGACCUCAA





CAGGATTAA
AAUGUCAUUCCAUUAAUAUCACAGGAUUA






A



 


 20
 34/333
TTGTTTTCCAGTGCAAAGATGACTAAGTCCTTTATC
UUGUUUUCCAGUGCAAAGAUGACUAAGUC
LFSSAKMTKSFIPPLCLIFFPV




CCTCCCCTTTGTTTGATTTTTTTTCCAGTATA
CUUUAUCCCUCCCCUUUGUUUGAUUUUU






UUUCCAGUAUA



 


 21
 35/334
ATGCAAGAGCCACAGAGGGAATGTTTATGGGGCA
AUGCAAGAGCCACAGAGGGAAUGUUUAUG
MQEPQRECLWGTFVSLGCEAKAGNLIVS




CGTTTGTAAGCCTGGGATGTGAAGCAAAGGCAGG
GGGCACGUUUGUAAGCCUGGGAUGUGAA
YIIYFISLSLSQYPTSFSQNSCSANPQR




GAACCTCATAGTATCTTATATAATATACTTCATTTC
GCAAAGGCAGGGAACCUCAUAGUAUCUUA





TCTATCTCTATCACAATATCCAACAAGCTTTTCACA
UAUAAUAUACUUCAUUUCUCUAUCUCUAU





GAATTCATGCAGTGCAAATCCCCAAAGGTAA
CACAAUAUCCAACAAGCUUUUCACAGAAU






UCAUGCAGUGCAAAUCCCCAAAGGUAA



 


 22
 36/335
GTGGGTTCTCTTAAGCAAAATACTTGCATTAGGTC
GUGGGUUCUCUUAAGCAAAAUACUUGCAU
VGSLKQNTCIRSQLGLCIRRFEKYSILSRSQ




TCAGCTGGGGCTGTGCATCAGGCGGTTTGAGAAA
UAGGUCUCAGCUGGGGCUGUGCAUCAGGC
NLNSLIF




TATTCAATTCTCAGCAGAAGCCAGAATTTGAATTC
GGUUUGAGAAAUAUUCAAUUCUCAGCAGA





CCTCATCTTTTAG
AGCCAGAAUUUGAAUUCCCUCAUCUUUUA






G



 


 23
 37/336
CTGTCCCTCTTTGTGTTCATGGATAGTCCAATAAAT
CUGUCCCUCUUUGUGUUCAUGGAUAGUCC
LSLFVFMDSPINNVIFELMLIGENIRTLSDI




AATGTTATCTTTGAACTGATGCTCATAGGAGAGAA
AAUAAAUAAUGUUAUCUUUGAACUGAUGC
NIRDSKKY




TATAAGAACTCTGAGTGATATCAACATTAGGGATT
UCAUAGGAGAGAAUAUAAGAACUCUGAGU





CAAAGAAATATTAG
GAUAUCAACAUUAGGGAUUCAAAGAAAUA






UUAG



 


 24
 38/337
CTGTTGCTTTGGACTTCCCCACAAGAATTTCAACG
CUGUUGCUUUGGACUUCCCCACAAGAAUU
LLLWTSPQEFQRLSSLFFHPHH




ACTCTCAAGTCTTTTCTTCCATCCCCACCACTAA
UCAACGACUCUCAAGUCUUUUCUUCCAUC






CCCACCACUAA



 


 25
 39/338
GTGGTACATGCATGCAAGACTGCTGAAGCCAGAA
GUGGUACAUGCAUGCAAGACUGCUGAAGC
VVHACKTAEARRMTDYASWVEGTTPGP




GGATGACTGATTACGCCTCATGGGTGGAGGGGAC
CAGAAGGAUGACUGAUUACGCCUCAUGGGS





CACTCCTGGGCCTTCGTGA
UGGAGGGGACCACUCCUGGGCCUUCGUGA



 


 26
 40/339
TTGTCAGGAGCAAGACCTGAGATGCTCCCTGCCTT
UUGUCAGGAGCAAGACCUGAGAUGCUCCC
LSGARPEMLPAFSVLCISPF




CAGTGTCCTCTGCATCTCCCCTTTCTAA
UGCCUUCAGUGUCCUCUGCAUCUCCCCUU






UCUAA



 


 27
 41/340
TTGGCATACTATATCAACTTTGATTCTTTGTTACAA
UUGGCAUACUAUAUCAACUUUGAUUCUU
LAYYINFDSLLQLFLLFYHQSGFYSLYYYYF




CTTTTCTTACTCTTTTATCACCAAAGTGGCTTTTATT
UGUUACAACUUUUCUUACUCUUUUAUCAC
LLLLYYVVIILFSIVSIYLI




CTCTTTATTATTATTATTTTCTTTTACTACTATATTA
CAAAGUGGCUUUUAUUCUCUUUAUUAUU





CGTTGTTATTATTTTGTTCTCTATAGTATCAATTTAT
AUUAUUUUCUUUUACUACUAUAUUACGU





TTGATTTAG
UGUUAUUAUUUUGUUCUCUAUAGUAUCA






AUUUAUUUGAUUUAG



 


 28
 42/341
GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT
GUGACAUGUUUUUGCACAUUUCCAGCCCC
VTCFCTFPAPLNIHTHRKHKRKHRDPWE




ATCCACACACACAGGAAGCACAAAAGGAAGCACA
UUUAAAUAUCCACACACACAGGAAGCACAA
KCPAAILGHR




GAGATCCCTGGGAGAAATGCCCGGCCGCCATCTT
AAGGAAGCACAGAGAUCCCUGGGAGAAAU





GGGTCATCGATGA
GCCCGGCCGCCAUCUUGGGUCAUCGAUGA



 


 29
 43/342
GTGACCTTTCTACACTGTAGAATAACATTACTCATT
GUGACCUUUCUACACUGUAGAAUAACAUU
VTFLHCRITLLILFKDPSCCCLICS




TTGTTCAAAGACCCTTCGTGTTGCTGCCTAATATGT
ACUCAUUUUGUUCAAAGACCCUUCGUGUU





AGCTGA
GCUGCCUAAUAUGUAGCUGA



 


 30
 44/343
CTGTTTTTCCTAAGGAGTGTTCTGGCCCAGGGGAT
CUGUUUUUCCUAAGGAGUGUUCUGGCCCA
LFFLRSVLAQGICEQAGKHLKIFPGLYLLA




CTGTGAACAGGCTGGGAAGCATCTCAAGATCTTTC
GGGGAUCUGUGAACAGGCUGGGAAGCAUC
HSMIITE




CAGGGTTATACTTACTAGCACACAGCATGATCATT
UCAAGAUCUUUCCAGGGUUAUACUUACUA





ACGGAGTGA
GCACACAGCAUGAUCAUUACGGAGUGA



 


 31
 45/344
GTGTCTTTGCCCATACTGAAATTCATTTCCCACTTT
GUGUCUUUGCCCAUACUGAAAUUCAUUUC
VSLPILKFISHFCAHSQDLKMSFH




TGTGCCCATTCTCAAGACCTCAAAATGTCATTCCAT
CCACUUUUGUGCCCAUUCUCAAGACCUCA





TAA
AAAUGUCAUUCCAUUAA



 


 32
 46/345
ATGCTTAGCCTTGTACTGAGGCTGTATACAGCCAC
AUGCUUAGCCUUGUACUGAGGCUGUAUAC
MLSLVLRLYTATASPHPSSLICHHHQPLPC




AGCCTCTCCCCATCCCTCCAGCCTTATCTGTCATCA
AGCCACAGCCUCUCCCCAUCCCUCCAGCCU
T




CCATCAACCCCTCCCATGCACCTAA
UAUCUGUCAUCACCAUCAACCCCUCCCAUG






CACCUAA



 


 33
 47/346
ATGCAAAGAAGGGACACATATGAGATTCATCATC
AUGCAAAGAAGGGACACAUAUGAGAUUCA
MQRRDTYEIHHHMRQQILKV




ACATGAGACAGCAAATACTAAAAGTGTAA
UCAUCACAUGAGACAGCAAAUACUAAAAG






UGUAA



 


 34
 48/347
GTGCAAATCCCCAAAGGTAACCTTTATCCATTTCAT
GUGCAAAUCCCCAAAGGUAACCUUUAUCC
VQIPKGNLYPFHGECALEFWQIILVTYLNF




GGTGAGTGCGCTTTAGAATTTTGGCAAATCATACT
AUUUCAUGGUGAGUGCGCUUUAGAAUUU
EMCLSL




GGTCACTTATCTCAACTTTGAGATGTGTTTGTCCTT
UGGCAAAUCAUACUGGUCACUUAUCUCAA





GTAG
CUUUGAGAUGUGUUUGUCCUUGUAG



 


 35
 49/348
GTGTGTGTGTGTGTGTGTGTGAGTGTACATGCCA
GUGUGUGUGUGUGUGUGUGUGAGUGUA
VCVCVCVSVHAKVCLSLFDPLFQT




AAGTGTGCCTCTCTCTCTTTGACCCATTATTTCAGA
CAUGCCAAAGUGUGCCUCUCUCUCUUUGA





CTTAA
CCCAUUAUUUCAGACUUAA



 


 36
 50/349
TTGACATATATTGTTAGAAGCACCTCGCATTTGTG
UUGACAUAUAUUGUUAGAAGCACCUCGCA
LTYIVRSTSHLWVLLSKILALGLSWGCASG




GGTTCTCTTAAGCAAAATACTTGCATTAGGTCTCA
UUUGUGGGUUCUCUUAAGCAAAAUACUU
GLRNIQFSAEARI




GCTGGGGCTGTGCATCAGGCGGTTTGAGAAATAT
GCAUUAGGUCUCAGCUGGGGCUGUGCAUC





TCAATTCTCAGCAGAAGCCAGAATTTGA
AGGCGGUUUGAGAAAUAUUCAAUUCUCAG






CAGAAGCCAGAAUUUGA



 


 37
 51/350
TTGGAGAGGATTCAGACAGCTCAGGTGCTTTCACT
UUGGAGAGGAUUCAGACAGCUCAGGUGCU
LERIQTAQVLSLMSLNFCPSLCSWIVQ




AATGTCTCTGAACTTCTGTCCCTCTTTGTGTTCATG
UUCACUAAUGUCUCUGAACUUCUGUCCCU





GATAGTCCAATAA
CUUUGUGUUCAUGGAUAGUCCAAUAA



 


 38
 52/351
GTGATATCAACATTAGGGATTCAAAGAAATATTAG
GUGAUAUCAACAUUAGGGAUUCAAAGAAA
VISTLGIQRNIRFKLTLVKRNQDTKNSELS




ATTTAAGCTCACACTGGTCAAAAGGAACCAAGAT
UAUUAGAUUUAAGCUCACACUGGUCAAAA
SSPSL




ACAAAGAACTCTGAGCTGTCATCGTCCCCATCTCT
GGAACCAAGAUACAAAGAACUCUGAGCUG





GTGA
UCAUCGUCCCCAUCUCUGUGA



 


 39
 53/352
CTGCTCTGTTGCTTTGGACTTCCCCACAAGAATTTC
CUGCUCUGUUGCUUUGGACUUCCCCACAA
LLCCFGLPHKNFNDSQVFSSIPTTNLNA




AACGACTCTCAAGTCTTTTCTTCCATCCCCACCACT
GAAUUUCAACGACUCUCAAGUCUUUUCUU





AACCTGAATGCCTAG
CCAUCCCCACCACUAACCUGAAUGCCUAG



 


 40
 54/353
CTGATTACGCCTCATGGGTGGAGGGGACCACTCC
CUGAUUACGCCUCAUGGGUGGAGGGGACC
ITPHGWRGPLLGLRDCQEQDLRCSLPSVS




TGGGCCTTCGTGATTGTCAGGAGCAAGACCTGAG
ACUCCUGGGCCUUCGUGAUUGUCAGGAGC
SASPLSNEDP




ATGCTCCCTGCCTTCAGTGTCCTCTGCATCTCCCCT
AAGACCUGAGAUGCUCCCUGCCUUCAGUG





TTCTAATGAAGATCCATAG
UCCUCUGCAUCUCCCCUUUCUAAUGAAGA






UCCAUAG



 


 41
 55/354
TTGCTACATTTGAGAATTCCAATTAGGAACTCACA
UUGCUACAUUUGAGAAUUCCAAUUAGGAA
LLHLRIPIRNSHVLSALSIF




TGTTTTATCTGCCCTATCAATTTTTTAA
CUCACAUGUUUUAUCUGCCCUAUCAAUUU






UUUAA



 


 42
 56/355
GTGTCTTGGCATACTATATCAACTTTGATTCTTTGT
GUGUCUUGGCAUACUAUAUCAACUUUGA
VSWHTISTLILCYNFSYSFITKVAFILFIIIIFF




TACAACTTTTCTTACTCTTTTATCACCAAAGTGGCT
UUCUUUGUUACAACUUUUCUUACUCUUU
YYYITLLLFCSL




TTTATTCTCTTTATTATTATTATTTTCTTTTACTACTA
UAUCACCAAAGUGGCUUUUAUUCUCUUUA





TATTACGTTGTTATTATTTTGTTCTCTATAG
UUAUUAUUAUUUUCUUUUACUACUAUAU






UACGUUGUUAUUAUUUUGUUCUCUAUAG



 


 43
 57/356
TTGCTGACTTTTAAAATAAGTGATTCGGGGGGTG
UUGCUGACUUUUAAAAUAAGUGAUUCGG
LLTFKISDSGGGRTGEGEH




GGAGAACAGGGGAGGGAGAGCATTAG
GGGGUGGGAGAACAGGGGAGGGAGAGCA






UUAG



 


 44
 58/357
GTGCAGCAAACCACTATGGCACACGTATACCTGTG
GUGCAGCAAACCACUAUGGCACACGUAUA
VQQTTMAHVYLCNKPTHSAHVSQNVK




TAACAAACCTACACATTCTGCACATGTATCCCAGA
CCUGUGUAACAAACCUACACAUUCUGCACA





ACGTAAAGTAA
UGUAUCCCAGAACGUAAAGUAA



 


 45 (BSS)
 59/358
GTGCAGCAAAGAAAGACTACAGACATCTCAATGG
GUGCAGCAAAGAAAGACUACAGACAUCUC
VQQRKTTDISMAGELQHIYLVFQ




CAGGGGAATTACAACACATATACTTAGTGTTTCAA
AAUGGCAGGGGAAUUACAACACAUAUACU





TGA
UAGUGUUUCAAUGA



 


 46 (BSS)
 60/359
GTGAGTCTCCTCAGTGACACAGGGCTGGATCACC
GUGAGUCUCCUCAGUGACACAGGGCUGGA
VSLLSDTGLDHHRRHFLSTQCSKERLQTS




ATCGACGGCACTTTCTGAGTACTCAGTGCAGCAAA
UCACCAUCGACGGCACUUUCUGAGUACUC
QWQGNYNTYT




GAAAGACTACAGACATCTCAATGGCAGGGGAATT
AGUGCAGCAAAGAAAGACUACAGACAUCU





ACAACACATATACTTAG
CAAUGGCAGGGGAAUUACAACACAUAUAC






UUAG



 


 47 (BSS)
 61/360
GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT
GUGACAUGUUUUUGCACAUUUCCAGCCCC
VTCFCTFPAPLNIHTHRKHKRKHRGEK




ATCCACACACACAGGAAGCACAAAAGGAAGCACA
UUUAAAUAUCCACACACACAGGAAGCACAA





GAGGTGAGAAATAA
AAGGAAGCACAGAGGUGAGAAAUAA



 


 48 (BSS)
 62/361
GTGCAGCAAAGAAAGACTACAGACATCTCAATGG
GUGCAGCAAAGAAAGACUACAGACAUCUC
VQQRKTTDISMAGELQHIYLVFQ




CAGGGGAATTACAACACATATACTTAGTGTTTCAA
AAUGGCAGGGGAAUUACAACACAUAUACU





TGA
UAGUGUUUCAAUGA



 


 49 (BSS)
 63/362
ATGTTTTTGCACATTTCCAGCCCCTTTAAATATCCA
AUGUUUUUGCACAUUUCCAGCCCCUUUAA
MFLHISSPFKYPHTQEAQKEAQRNYNTY




CACACACAGGAAGCACAAAAGGAAGCACAGAGG
AUAUCCACACACACAGGAAGCACAAAAGGA
T




AATTACAACACATATACTTAG
AGCACAGAGGAAUUACAACACAUAUACUU






AG



 


 50 (BSS)
 64/363
GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT
GUGACAUGUUUUUGCACAUUUCCAGCCCC
VTCFCTFPAPLNIHTHRKHKRKHRGITTHI




ATCCACACACACAGGAAGCACAAAAGGAAGCACA
UUUAAAUAUCCACACACACAGGAAGCACAA
LSVSMNTKINK




GAGGAATTACAACACATATACTTAGTGTTTCAATG
AAGGAAGCACAGAGGAAUUACAACACAUA





AACACCAAGATAAATAAGTGA
UACUUAGUGUUUCAAUGAACACCAAGAUA






AAUAAGUGA





AR neo-






antigen

DNA sequence
RNA sequence
Protein sequence





  1
 65/364
CTGCCTTCCCCACCCCGAGTGCGGAGCCAGAGAT
CUGCCUUCCCCACCCCGAGUGCGGAGCCAG
LPSPPRVRSQRSKDEKAVRSSVAKKQNK




CAAAAGATGAAAAGGCAGTCAGGTCTTCAGTAGC
AGAUCAAAAGAUGAAAAGGCAGUCAGGUC
QKQKSRNKRKR




CAAAAAACAAAACAAACAAAAACAAAAAAGCCGA
UUCAGUAGCCAAAAAACAAAACAAACAAAA





AATAAAAGAAAAAGATAA
ACAAAAAAGCCGAAAUAAAAGAAAAAGAUA






A



 


  2
 66/365
TTGCACCTACTTCAGTGGACACTGAATTTGGAAGG
UUGCACCUACUUCAGUGGACACUGAAUUU
LHLLQWTLNLEGGGFCFFLLRSGHLLNLP




TGGAGGATTTTGTTTTTTTCTTTTAAGATCTGGGCA
GGAAGGUGGAGGAUUUUGUUUUUUUCUU
FKY




TCTTTTGAATCTACCCTTCAAGTATTAA
UUAAGAUCUGGGCAUCUUUUGAAUCUACC






CUUCAAGUAUUAA



 


  3
 67/366
GTGTCTTCTTCTGCACGAGACTTTGAGGCTGTCAG
GUGUCUUCUUCUGCACGAGACUUUGAGGC
VSSSARDFEAVRALFAWLLPQVSFSGASR




AGCGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCTT
UGUCAGAGCGCUUUUUGCGUGGUUGCUC
RWAASCSDYRIITAC




CTCTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGC
CCGCAAGUUUCCUUCUCUGGAGCUUCCCG





AGCGACTACCGCATCATCACAGCCTGTTGA
CAGGUGGGCAGCUAGCUGCAGCGACUACC






GCAUCAUCACAGCCUGUUGA



 


  4
 68/367
CTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGA
CUGAGCAAGAGAAGGGGAGGCGGGGUAAG
LSKRRGGGVREVGGRFSQAQGWKCS




AGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGG
GGAAGUAGGUGGAAGAUUCAGCCAAGCUC





AAGTGCAGTTAG
AAGGAUGGAAGUGCAGUUAG



 


  5
 69/368
GTGAGGATGGTTCTCCCCAAGCCCATCGTAGAGG
GUGAGGAUGGUUCUCCCCAAGCCCAUCGU
VRMVLPKPIVEAPQATWSWMRNSNLH




CCCCACAGGCTACCTGGTCCTGGATGAGGAACAG
AGAGGCCCCACAGGCUACCUGGUCCUGGA
SRSRPWSATPREVASQSLEPPWPPARGC




CAACCTTCACAGCCGCAGTCGGCCCTGGAGTGCC
UGAGGAACAGCAACCUUCACAGCCGCAGUC
RSSCQHLRTRMTQLPHPRCPCWAPLSPA




ACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGC
GGCCCUGGAGUGCCACCCCGAGAGAGGUU





CGCCGTGGCCGCCAGCAAGGGGCTGCCGCAGCA
GCGUCCCAGAGCCUGGAGCCGCCGUGGCC





GCTGCCAGCACCTCCGGACGAGGATGACTCAGCT
GCCAGCAAGGGGCUGCCGCAGCAGCUGCCA





GCCCCATCCACGTTGTCCCTGCTGGGCCCCACTTT
GCACCUCCGGACGAGGAUGACUCAGCUGC





CCCCGGCTTAA
CCCAUCCACGUUGUCCCUGCUGGGCCCCAC






UUUCCCCGGCUUAA



 


  6
 70/369
CTGACAACGCCAAGGAGTTGTGTAAGGCAGTGTC
CUGACAACGCCAAGGAGUUGUGUAAGGCA
LTTPRSCVRQCRCPWAWVWRRWSI




GGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGA
GUGUCGGUGUCCAUGGGCCUGGGUGUGG





GCATCTGA
AGGCGUUGGAGCAUCUGA



 


  7
 71/370
GTGTCAAAAGCGAAATGGGCCCCTGGATGGATAG
GUGUCAAAAGCGAAAUGGGCCCCUGGAUG
VSKAKWAPGWIATPDLTGTCVWRLPGT




CTACTCCGGACCTTACGGGGACATGCGTTTGGAG
GAUAGCUACUCCGGACCUUACGGGGACAU
MFCPLTITFHPRRPA




ACTGCCAGGGACCATGTTTTGCCCATTGACTATTA
GCGUUUGGAGACUGCCAGGGACCAUGUUU





CTTTCCACCCCAGAAGACCTGCCTGA
UGCCCAUUGACUAUUACUUUCCACCCCAG






AAGACCUGCCUGA



 


  8
 72/371
GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC
GUGGAGAUGAAGCUUCUGGGUGUCACUA
VEMKLLGVTMELSHVEAARSSSKEPLKG




TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA
UGGAGCUCUCACAUGUGGAAGCUGCAAGG
NRSTCAPAEMIALLINSEGKIVHLVVFGN




GAGCCGCTGAAGGGAAACAGAAGTACCTGTGCGC
UCUUCUUCAAAAGAGCCGCUGAAGGGAAA
VMKQG




CAGCAGAAATGATTGCACTATTGATAAATTCCGAA
CAGAAGUACCUGUGCGCCAGCAGAAAUGA





GGAAAAATTGTCCATCTTGTCGTCTTCGGAAATGT
UUGCACUAUUGAUAAAUUCCGAAGGAAAA





TATGAAGCAGGGATGA
AUUGUCCAUCUUGUCGUCUUCGGAAAUG






UUAUGAAGCAGGGAUGA



 


  9
 73/372
TTGCATGCAAAAGAAAAAATCCCACATCCTGCTCA
UUGCAUGCAAAAGAAAAAAUCCCACAUCCU
LHAKEKIPHPAQDASTSSPSSWTPCSLLR




AGACGCTTCTACCAGCTCACCAAGCTCCTGGACTC
GCUCAAGACGCUUCUACCAGCUCACCAAGC
ESCISSLLTC




CGTGCAGCCTATTGCGAGAGAGCTGCATCAGTTC
UCCUGGACUCCGUGCAGCCUAUUGCGAGA





ACTTTTGACCTGCTAA
GAGCUGCAUCAGUUCACUUUUGACCUGCU






AA



 


 10
 74/373
CTGTGCAAGTGCCCAAGATCCTTTCTGGGAAAGTC
CUGUGCAAGUGCCCAAGAUCCUUUCUGGGLC
KCPRSFLGKSSPSISTPSEALETLFPHPS




AAGCCCATCTATTTCCACACCCAGTGAAGCATTGG
AAAGUCAAGCCCAUCUAUUUCCACACCCAG
SCPLSDVFCLL




AAACCCTATTTCCCCACCCCAGCTCATGCCCCCTTT
UGAAGCAUUGGAAACCCUAUUUCCCCACCC





CAGATGTCTTCTGCCTGTTATAA
CAGCUCAUGCCCCCUUUCAGAUGUCUUCU






GCCUGUUAUAA



 


 11
 75/374
ATGGTGTTGTATGCCTTTAAATCTGTGATGATCCT
AUGGUGUUGUAUGCCUUUAAAUCUGUGA
MVLYAFKSVMILIWPSVKLCLFTALLCAS




CATATGGCCCAGTGTCAAGTTGTGCTTGTTTACAG
UGAUCCUCAUAUGGCCCAGUGUCAAGUUG
HTNVYLSYATGSLES




CACTACTCTGTGCCAGCCACACAAACGTTTACTTA
UGCUUGUUUACAGCACUACUCUGUGCCAG





TCTTATGCCACGGGAAGTTTAGAGAGCTAA
CCACACAAACGUUUACUUAUCUUAUGCCA






CGGGAAGUUUAGAGAGCUAA



 


 12
 76/375
CTGGGGAAATCAAAACAAAAACAAGCAAACAAAA
CUGGGGAAAUCAAAACAAAAACAAGCAAAC
LGKSKQKQANKKKKQKQNKK




AAAAAAAGCAAAAACAAAACAAAAAATAA
AAAAAAAAAAAGCAAAAACAAAACAAAAAA






UAA



 


 13
 77/376
GTGGAGCAATTCATTATACTGAAAATGTGCTTGTT
GUGGAGCAAUUCAUUAUACUGAAAAUGU
VEQFIILKMCLLLKICLHVNASPPNPFLSHS




GTTGAAAATTTGTCTGCATGTTAATGCCTCACCCC
GCUUGUUGUUGAAAAUUUGUCUGCAUGU
LPPTSD




CAAACCCTTTTCTCTCTCACTCTCTGCCTCCAACTTC
UAAUGCCUCACCCCCAAACCCUUUUCUCUC





AGATTGA
UCACUCUCUGCCUCCAACUUCAGAUUGA



 


 14
 78/377
ATGTTCTCTTCAGCCAAAACTTGGCGACTTCCACA
AUGUUCUCUUCAGCCAAAACUUGGCGACU
MFSSAKTWRLPQKSLTTEKKESRDLTLCK




GAAAAGTCTGACCACTGAGAAGAAGGAGAGCAG
UCCACAGAAAAGUCUGACCACUGAGAAGA
APFGSRSAFSCVSQGGAGARGEENDSLA




AGATTTAACCCTTTGTAAGGCCCCATTTGGATCCA
AGGAGAGCAGAGAUUUAACCCUUUGUAAG
VLLLRTLTE




GGTCTGCTTTCTCATGTGTGAGTCAGGGAGGAGC
GCCCCAUUUGGAUCCAGGUCUGCUUUCUC





TGGAGCCAGAGGAGAAGAAAATGATAGCTTGGCT
AUGUGUGAGUCAGGGAGGAGCUGGAGCC





GTTCTCCTGCTTAGGACACTGACTGAATAG
AGAGGAGAAGAAAAUGAUAGCUUGGCUG






UUCUCCUGCUUAGGACACUGACUGAAUAG



 


 15
 79/378
CTGCCAAACTCCGTGAAGCCACAAGCACCTTATGT
CUGCCAAACUCCGUGAAGCCACAAGCACCU
LPNSVKPQAPYVLPSVFCGPEFHHTAFQP




CCTCCCTTCAGTGTTTTGTGGGCCTGAATTTCATCA
UAUGUCCUCCCUUCAGUGUUUUGUGGGCC
WSSSLFASFGHVHRFSVKSPHHQEG




CACTGCATTTCAGCCATGGTCATCAAGCCTGTTTG
UGAAUUUCAUCACACUGCAUUUCAGCCAU





CTTCTTTTGGGCATGTTCACAGATTCTCTGTTAAGA
GGUCAUCAAGCCUGUUUGCUUCUUUUGG





GCCCCCACCACCAAGAAGGTTAG
GCAUGUUCACAGAUUCUCUGUUAAGAGCC






CCCACCACCAAGAAGGUUAG



 


 16
 80/379
GTGGGAAGAATGAAGGCACTAGAACCAGAAACC
GUGGGAAGAAUGAAGGCACUAGAACCAGA
VGRMKALEPETLQMLFLSPSISTCRSHEK




CTGCAAATGCTCTTCTTGTCACCCAGCATATCCACC
AACCCUGCAAAUGCUCUUCUUGUCACCCA
REGTKRRL




TGCAGAAGTCATGAGAAGAGAGAAGGAACAAAG
GCAUAUCCACCUGCAGAAGUCAUGAGAAG





AGGAGACTCTGA
AGAGAAGGAACAAAGAGGAGACUCUGA



 


 17
 81/380
CTGACATTGCCCATACTCACTCAGATTCCCCACCTT
CUGACAUUGCCCAUACUCACUCAGAUUCCC
LTLPILTQIPHLCCCLLVRGRPNH




TGTTGCTGCCTCTTAGTCAGAGGGAGGCCAAACC
CACCUUUGUUGCUGCCUCUUAGUCAGAGG





ATTGA
GAGGCCAAACCAUUGA



 


 18
 82/381
ATGAGTAATATGCCAATCCAAGACTGCTGGAGAA
AUGAGUAAUAUGCCAAUCCAAGACUGCUG
MSNMPIQDCWRKLKLTGSLFGVG




AACTAAAGCTGACAGGTTCCCTTTTTGGGGTGGG
GAGAAAACUAAAGCUGACAGGUUCCCUUU





ATAG
UUGGGGUGGGAUAG



 


 19
 83/382
ATGTACAGGATCACTTTTAGCTGTTTTAAACAGAA
AUGUACAGGAUCACUUUUAGCUGUUUUA
MYRITFSCFKQKKISTTLFSYTRLHFNRSFT




AAAAATATCCACCACTCTTTTCAGTTACACTAGGTT
AACAGAAAAAAAUAUCCACCACUCUUUUCA
SVLE




ACATTTTAATAGGTCCTTTACATCTGTTTTGGAATG
GUUACACUAGGUUACAUUUUAAUAGGUCC





A
UUUACAUCUGUUUUGGAAUGA



 


 20
 84/383
GTGATACACAGATTGAATTATATCATTTTCATATCT
GUGAUACACAGAUUGAAUUAUAUCAUUU
VIHRLNYIIFISLLVNTRSSPLHFSIKFFIFM




CTCCTTGTAAATACTAGAAGCTCTCCTTTACATTTC
UCAUAUCUCUCCUUGUAAAUACUAGAAGC
GFPIVTLVFMNICFSFAKAKNQ




TCTATCAAATTTTTCATCTTTATGGGTTTCCCAATT
UCUCCUUUACAUUUCUCUAUCAAAUUUUU





GTGACTCTTGTCTTCATGAATATATGTTTTTCATTT
CAUCUUUAUGGGUUUCCCAAUUGUGACUC





GCAAAAGCCAAAAATCAGTGA
UUGUCUUCAUGAAUAUAUGUUUUUCAUU






UGCAAAAGCCAAAAAUCAGUGA



 


 21
 85/384
ATGACAAAACTAGGGAAAAATAGCCTACACAAGC
AUGACAAAACUAGGGAAAAAUAGCCUACA
MTKLGKNSLHKPLGLLFLCLGLSEQRRF




CTTTAGGCCTACTCTTTCTGTGCTTGGGTTTGAGTG
CAAGCCUUUAGGCCUACUCUUUCUGUGCU





AACAAAGGAGATTTTAG
UGGGUUUGAGUGAACAAAGGAGAUUUUA






G



 


 22
 86/385
CTGCTCTACAAACAGAGTTGGTATGGTTGGTATAC
CUGCUCUACAAACAGAGUUGGUAUGGUUG
LLYKQSWYGWYTVLTCEGLATQTHLAGE




TGTACTCACCTGTGAGGGACTGGCCACTCAGACCC
GUAUACUGUACUCACCUGUGAGGGACUGG
LEDEDHSLEKSQGPSPNKLAVLDVDEE




ACTTAGCTGGTGAGCTAGAAGATGAGGATCACTC
CCACUCAGACCCACUUAGCUGGUGAGCUA





ACTGGAAAAGTCACAAGGACCATCTCCAAACAAG
GAAGAUGAGGAUCACUCACUGGAAAAGUC





TTGGCAGTGCTCGATGTGGACGAAGAGTGA
ACAAGGACCAUCUCCAAACAAGUUGGCAG






UGCUCGAUGUGGACGAAGAGUGA



 


 23
 87/386
CTGTGCTGGGCAGCAGACAGCTGCCAGGATCACG
CUGUGCUGGGCAGCAGACAGCUGCCAGGA
LCWAADSCQDHELCSQRKESCGSFSSRSL




AACTCTGTAGTCAAAGAAAAGAGTCGTGTGGCAG
UCACGAACUCUGUAGUCAAAGAAAAGAGU
GSSPRPSL




TTTCAGCTCTCGTTCATTGGGCAGCTCGCCTAGGC
CGUGUGGCAGUUUCAGCUCUCGUUCAUU





CCAGCCTCTGA
GGGCAGCUCGCCUAGGCCCAGCCUCUGA



 


 24
 88/387
CTGAGAAAGGGATATTTTGAAGGACTGTCATATA
CUGAGAAAGGGAUAUUUUGAAGGACUGU
LRKGYFEGLSYIFEKRKSVIHIFLCMFTGTK




TCTTTGAAAAAAGAAAATCTGTAATACATATATTTT
CAUAUAUCUUUGAAAAAAGAAAAUCUGUA
KYRELHSVLWVVAEVIVQVEK




TATGTATGTTCACTGGCACTAAAAAATATAGAGAG
AUACAUAUAUUUUUAUGUAUGUUCACUG





CTTCATTCTGTCCTTTGGGTAGTTGCTGAGGTAATT
GCACUAAAAAAUAUAGAGAGCUUCAUUCU





GTCCAGGTTGAAAAATAA
GUCCUUUGGGUAGUUGCUGAGGUAAUUG






UCCAGGUUGAAAAAUAA



 


 25
 89/388
CTGCCCCTTCCCAGCCCTGCACCAAAGCTGCATTT
CUGCCCCUUCCCAGCCCUGCACCAAAGCUG
LPLPSPAPKLHFRRLSPDSPVTTRAWPLH




CAGGAGACTCTCTCCAGACAGCCCAGTAACTACCC
CAUUUCAGGAGACUCUCUCCAGACAGCCCA
SPGKIRG




GAGCATGGCCCCTGCATAGCCCTGGAAAAATAAG
GUAACUACCCGAGCAUGGCCCCUGCAUAGC





AGGCTGA
CCUGGAAAAAUAAGAGGCUGA



 


 26
 90/389
CTGTCTACGAATTATCTTGTGCCAGTTGCCCAGGT
CUGUCUACGAAUUAUCUUGUGCCAGUUGC
LSTNYLVPVAQVRGHWAKGVVFMFDPL




GAGAGGGCACTGGGCCAAGGGAGTGGTTTTCAT
CCAGGUGAGAGGGCACUGGGCCAAGGGAG
QGVMGIRNAKAPDQIQNLKSK




GTTTGACCCACTACAAGGGGTCATGGGAATCAGG
UGGUUUUCAUGUUUGACCCACUACAAGGG





AATGCCAAAGCACCAGATCAAATCCAAAACTTAAA
GUCAUGGGAAUCAGGAAUGCCAAAGCACC





GTCAAAATAA
AGAUCAAAUCCAAAACUUAAAGUCAAAAU






AA



 


 27
 91/390
GTGTGTGTGTGTGTTCTGATAGCTTTAACTTTCTCT
GUGUGUGUGUGUGUUCUGAUAGCUUUAA
VCVCVLIALTFSASLYLVPDHT




GCATCTTTATATTTGGTTCCAGATCACACCTGA
CUUUCUCUGCAUCUUUAUAUUUGGUUCC






AGAUCACACCUGA



 


 28
 92/391
GTGAGAGAGGATGCAGTTTTGTTTTGGAAGCTCT
GUGAGAGAGGAUGCAGUUUUGUUUUGGA
VREDAVLFWKLSQNKQDTWIDQLTKSFL




CTCAGAACAAACAAGACACCTGGATTGATCAGTTA
AGCUCUCUCAGAACAAACAAGACACCUGGA
PYWV




ACTAAAAGTTTTCTCCCCTATTGGGTTTGA
UUGAUCAGUUAACUAAAAGUUUUCUCCCC






UAUUGGGUUUGA



 


 29
 93/392
GTGAAGGAGCAGAGGGATAAAAAGAGTAGAGGA
GUGAAGGAGCAGAGGGAUAAAAAGAGUAG
VKEQRDKKSRGHDTLYFTSSRQMNVESI




CATGATACATTGTACTTTACTAGTTCAAGACAGAT
AGGACAUGAUACAUUGUACUUUACUAGUU
KTQWN




GAATGTGGAAAGCATAAAAACTCAATGGAACTGA
CAAGACAGAUGAAUGUGGAAAGCAUAAAA






ACUCAAUGGAACUGA



 


 30
 94/393
CTGAGATTTACCACAGGGAAGGCCCAAACTTGGG
CUGAGAUUUACCACAGGGAAGGCCCAAAC
LRFTTGKAQTWGQKPTQVIDQWPPNGT




GCCAAAAGCCTACCCAAGTGATTGACCAGTGGCC
UUGGGGCCAAAAGCCUACCCAAGUGAUUG





CCCTAATGGGACCTGA
ACCAGUGGCCCCCUAAUGGGACCUGA



 


 31
 95/394
CTGTTCCTTGGTCTTCACCATCCTTGTGAGAGAAG
CUGUUCCUUGGUCUUCACCAUCCUUGUGA
LFLGLHHPCERRAVSCIGTWSKRSIFHTNS




GGCAGTTTCCTGCATTGGAACCTGGAGCAAGCGC
GAGAAGGGCAGUUUCCUGCAUUGGAACCULT





TCTATCTTTCACACAAATTCCCTCACCTGA
GGAGCAAGCGCUCUAUCUUUCACACAAAU






UCCCUCACCUGA



 


 32
 96/395
CTGATTCCAATTCAGTATAGCAAGGTGCTAGGTTT
CUGAUUCCAAUUCAGUAUAGCAAGGUGCU
LIPIQYSKVLGFFLSPPVS




TTTCCTTTCCCCACCTGTCTCTTAG
AGGUUUUUUCCUUUCCCCACCUGUCUCUU






AG



 


 33
 97/396
CTGGTGGTTCCCTCTCTGGCTGCTGCCTCACAGTA
CUGGUGGUUCCCUCUCUGGCUGCUGCCUC
LVVPSLAAASQYGNLYSAEVTGQICIISQP




TGGGAACCTGTACTCTGCAGAGGTGACAGGCCAG
ACAGUAUGGGAACCUGUACUCUGCAGAGG





ATTTGCATTATCTCACAACCTTAG
UGACAGGCCAGAUUUGCAUUAUCUCACAA






CCUUAG



 


 34
 98/397
TTGCTTGAAATCTCTTTAGATGGGGCTCATTTCTCA
UUGCUUGAAAUCUCUUUAGAUGGGGCUC
LLEISLDGAHFSRWHLASTGQQDQLQAL




CGGTGGCACTTGGCCTCCACTGGGCAGCAGGACC
AUUUCUCACGGUGGCACUUGGCCUCCACU
VFCSLFVILESFVALNTIKNGRNLFVGLHV




AGCTCCAAGCGCTAGTGTTCTGTTCTCTTTTTGTAA
GGGCAGCAGGACCAGCUCCAAGCGCUAGU





TCTTGGAATCTTTTGTTGCTCTAAATACAATTAAAA
GUUCUGUUCUCUUUUUGUAAUCUUGGAA





ATGGCAGAAACTTGTTTGTTGGACTACATGTGTGA
UCUUUUGUUGCUCUAAAUACAAUUAAAAA






UGGCAGAAACUUGUUUGUUGGACUACAU






GUGUGA



 


 35
 99/398
GTGAGCCTAGCAGGGCAGATCTTGTCCACCGTGT
GUGAGCCUAGCAGGGCAGAUCUUGUCCAC
VSLAGQILSTVCLLLHETLRLSERFLRGCSR




GTCTTCTTCTGCACGAGACTTTGAGGCTGTCAGAG
CGUGUGUCUUCUUCUGCACGAGACUUUGA
KFPSLELPAGGQLAAATTASSQPVELF




CGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCTTCT
GGCUGUCAGAGCGCUUUUUGCGUGGUUG





CTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGCAG
CUCCCGCAAGUUUCCUUCUCUGGAGCUUC





CGACTACCGCATCATCACAGCCTGTTGAACTCTTC
CCGCAGGUGGGCAGCUAGCUGCAGCGACU





TGA
ACCGCAUCAUCACAGCCUGUUGAACUCUU






CUGA



 


 36
100/399
GTGGAAGATTCAGCCAAGCTCAAGGATGGAAGTG
GUGGAAGAUUCAGCCAAGCUCAAGGAUGG
VEDSAKLKDGSAVRAGKGLPSAAVQDLP




CAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGC
AAGUGCAGUUAGGGCUGGGAAGGGUCUA
RSFPESVPERARSDPEPGPQAPRGRERST




CGTCCAAGACCTACCGAGGAGCTTTCCAGAATCTG
CCCUCGGCCGCCGUCCAAGACCUACCGAGG
SRRQFAAAAAAAAAAAAAAAAAAAAAA




TTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGG
AGCUUUCCAGAAUCUGUUCCAGAGCGUGC
AAAARD




GCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACC
GCGAAGUGAUCCAGAACCCGGGCCCCAGGC





TCCCGGCGCCAGTTTGCTGCTGCTGCAGCAGCAG
ACCCAGAGGCCGCGAGCGCAGCACCUCCCG





CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG
GCGCCAGUUUGCUGCUGCUGCAGCAGCAG





CAGCAGCAGCAGCAGCAGCAGCAGCAAGAGACT
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG





AG
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAA






GAGACUAG



 


 37
101/400
GTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCT
GUGCCACCCCGAGAGAGGUUGCGUCCCAG
VPPRERLRPRAWSRRGRQQGAAAAAAS




GGAGCCGCCGTGGCCGCCAGCAAGGGGCTGCCG
AGCCUGGAGCCGCCGUGGCCGCCAGCAAG
TSGRG




CAGCAGCTGCCAGCACCTCCGGACGAGGATGA
GGGCUGCCGCAGCAGCUGCCAGCACCUCCG






GACGAGGAUGA



 


 38
102/401
TTGCATGTACGCCCCACTTTTGGGAGTTCCACCCG
UUGCAUGUACGCCCCACUUUUGGGAGUUC
LHVRPTFGSSTRCASHSLCPIGRMQRFSA




CTGTGCGTCCCACTCCTTGTGCCCCATTGGCCGAA
CACCCGCUGUGCGUCCCACUCCUUGUGCCC
RRQRRQEH




TGCAAAGGTTCTCTGCTAGACGACAGCGCAGGCA
CAUUGGCCGAAUGCAAAGGUUCUCUGCUA





AGAGCACTGA
GACGACAGCGCAGGCAAGAGCACUGA



 


 39
103/402
CTGGGCGGCTGCGGCGGCGCAGTGCCGCTATGG
CUGGGCGGCUGCGGCGGCGCAGUGCCGCU
LGGCGGAVPLWGPGEPAWRGCSGTRF




GGACCTGGCGAGCCTGCATGGCGCGGGTGCAGC
AUGGGGACCUGGCGAGCCUGCAUGGCGCG
WVTLSRRFLILAHSLHSRRRPVVWTVW




GGGACCCGGTTCTGGGTCACCCTCAGCCGCCGCTT
GGUGCAGCGGGACCCGGUUCUGGGUCACC
WWWGWWRRRRRRRRRRRRRRRRRG




CCTCATCCTGGCACACTCTCTTCACAGCCGAAGAA
CUCAGCCGCCGCUUCCUCAUCCUGGCACAC
GSCSPLRLHSAPSGAGGPGKRLHRT




GGCCAGTTGTATGGACCGTGTGGTGGTGGTGGG
UCUCUUCACAGCCGAAGAAGGCCAGUUGU





GGTGGTGGCGGCGGCGGCGGCGGCGGCGGCGG
AUGGACCGUGUGGUGGUGGUGGGGGUGG





CGGCGGCGGCGGCGGCGGCGGCGGCGAGGCGG
UGGCGGCGGCGGCGGCGGCGGCGGCGGCG





GAGCTGTAGCCCCCTACGGCTACACTCGGCCCCCT
GCGGCGGCGGCGGCGGCGGCGGCGAGGCG





CAGGGGCTGGCGGGCCAGGAAAGCGACTTCACC
GGAGCUGUAGCCCCCUACGGCUACACUCG





GCACCTGA
GCCCCCUCAGGGGCUGGCGGGCCAGGAAA






GCGACUUCACCGCACCUGA



 


 40
104/403
GTGGTACCCTGGCGGCATGGTGAGCAGAGTGCCC
GUGGUACCCUGGCGGCAUGGUGAGCAGAG
VVPWRHGEQSALSQSHLCQKRNGPLDG




TATCCCAGTCCCACTTGTGTCAAAAGCGAAATGGG
UGCCCUAUCCCAGUCCCACUUGUGUCAAA





CCCCTGGATGGATAG
AGCGAAAUGGGCCCCUGGAUGGAUAG



 


 41
105/404
GTGTCACTATGGAGCTCTCACATGTGGAAGCTGC
GUGUCACUAUGGAGCUCUCACAUGUGGAA
VSLWSSHMWKLQGLLQKSR




AAGGTCTTCTTCAAAAGAGCCGCTGA
GCUGCAAGGUCUUCUUCAAAAGAGCCGCU






GA



 


 42
106/405
GTGGGCCAAGGCCTTGCCTGGCTTCCGCAACTTAC
GUGGGCCAAGGCCUUGCCUGGCUUCCGCA
VGQGLAWLPQLTRGRPDGCHSVLLDGA




ACGTGGACGACCAGATGGCTGTCATTCAGTACTCC
ACUUACACGUGGACGACCAGAUGGCUGUC
HGVCHGLAILHQCQLQDALLRP




TGGATGGGGCTCATGGTGTTTGCCATGGGCTGGC
AUUCAGUACUCCUGGAUGGGGCUCAUGGU





GATCCTTCACCAATGTCAACTCCAGGATGCTCTAC
GUUUGCCAUGGGCUGGCGAUCCUUCACCA





TTCGCCCCTGA
AUGUCAACUCCAGGAUGCUCUACUUCGCC






CCUGA



 


 43
107/406
GTGTGTCCGAATGAGGCACCTCTCTCAAGAGTTTG
GUGUGUCCGAAUGAGGCACCUCUCUCAAG
VCPNEAPLSRVWMAPNHPPGIPVHEST




GATGGCTCCAAATCACCCCCCAGGAATTCCTGTGC
AGUUUGGAUGGCUCCAAAUCACCCCCCAG
ATLQHYSSGWAEKSKIL




ATGAAAGCACTGCTACTCTTCAGCATTATTCCAGT
GAAUUCCUGUGCAUGAAAGCACUGCUACU





GGATGGGCTGAAAAATCAAAAATTCTTTGA
CUUCAGCAUUAUUCCAGUGGAUGGGCUGA






AAAAUCAAAAAUUCUUUGA



 


 44
108/407
ATGCAAAAGAAAAAATCCCACATCCTGCTCAAGAC
AUGCAAAAGAAAAAAUCCCACAUCCUGCUC
MQKKKSHILLKTLLPAHQAPGLRAAYCER




GCTTCTACCAGCTCACCAAGCTCCTGGACTCCGTG
AAGACGCUUCUACCAGCUCACCAAGCUCCU
AASVHF




CAGCCTATTGCGAGAGAGCTGCATCAGTTCACTTT
GGACUCCGUGCAGCCUAUUGCGAGAGAGC





TGA
UGCAUCAGUUCACUUUUGA



 


 45
109/408
GTGAAGCATTGGAAACCCTATTTCCCCACCCCAGC
GUGAAGCAUUGGAAACCCUAUUUCCCCAC
VKHWKPYFPTPAHAPFQMSSACYNSALL




TCATGCCCCCTTTCAGATGTCTTCTGCCTGTTATAA
CCCAGCUCAUGCCCCCUUUCAGAUGUCUUC
LCSALGNFLY




CTCTGCACTACTCCTCTGCAGTGCCTTGGGGAATT
UGCCUGUUAUAACUCUGCACUACUCCUCU





TCCTCTATTGA
GCAGUGCCUUGGGGAAUUUCCUCUAUUGA



 


 46
110/409
TTGCTGGGCTTTTTTTTTCTCTTTCTCTCCTTTCTTTT
UUGCUGGGCUUUUUUUUUCUCUUUCUCU
LLGFFFLFLSFLFLLPSLSNPPMAPSDFASH




TCTTCTTCCCTCCCTATCTAACCCTCCCATGGCACC
CCUUUCUUUUUCUUCUUCCCUCCCUAUCU
CGSYLCFEWCCMPLNL




TTCAGACTTTGCTTCCCATTGTGGCTCCTATCTGTG
AACCCUCCCAUGGCACCUUCAGACUUUGCU





TTTTGAATGGTGTTGTATGCCTTTAAATCTGTGA
UCCCAUUGUGGCUCCUAUCUGUGUUUUG






AAUGGUGUUGUAUGCCUUUAAAUCUGUG






A



 


 47
111/410
GTGTCAAGTTGTGCTTGTTTACAGCACTACTCTGT
GUGUCAAGUUGUGCUUGUUUACAGCACU
VSSCACLQHYSVPATQTFTYLMPREV




GCCAGCCACACAAACGTTTACTTATCTTATGCCAC
ACUCUGUGCCAGCCACACAAACGUUUACU





GGGAAGTTTAG
UAUCUUAUGCCACGGGAAGUUUAG



 


 48
112/411
GTGAAAATTGCAGGCCCATGGGGAGTTACTGATT
GUGAAAAUUGCAGGCCCAUGGGGAGUUAC
VKIAGPWGVTDFFISSLHGRLYFLPMAIAI




TTTTCATCTCCTCCCTCCACGGGAGACTTTATTTTC
UGAUUUUUUCAUCUCCUCCCUCCACGGGA
RGQSDPRAELGRGVDREERTRRAMEHQ




TGCCAATGGCTATTGCCATTAGAGGGCAGAGTGA
GACUUUAUUUUCUGCCAAUGGCUAUUGCC
YLPTALVPGG




CCCCAGAGCTGAGTTGGGCAGGGGGGTGGACAG
AUUAGAGGGCAGAGUGACCCCAGAGCUGA





AGAGGAGAGGACAAGGAGGGCAATGGAGCATCA
GUUGGGCAGGGGGGUGGACAGAGAGGAG





GTACCTGCCCACAGCCTTGGTCCCTGGGGGCTAG
AGGACAAGGAGGGCAAUGGAGCAUCAGUA






CCUGCCCACAGCCUUGGUCCCUGGGGGCU






AG



 


 49
113/412
ATGTTAATGCCTCACCCCCAAACCCTTTTCTCTCTC
AUGUUAAUGCCUCACCCCCAAACCCUUUUC
MLMPHPQTLFSLTLCLQLQIDFQ




ACTCTCTGCCTCCAACTTCAGATTGACTTTCAATAG
UCUCUCACUCUCUGCCUCCAACUUCAGAU






UGACUUUCAAUAG



 


 50
114/413
ATGTCCTCCCTTCAGTGTTTTGTGGGCCTGAATTTC
AUGUCCUCCCUUCAGUGUUUUGUGGGCCU
MSSLQCFVGLNFITLHFSHGHQACLLLLG




ATCACACTGCATTTCAGCCATGGTCATCAAGCCTG
GAAUUUCAUCACACUGCAUUUCAGCCAUG
MFTDSLLRAPTTKKVSRPTALTSICRCQ




TTTGCTTCTTTTGGGCATGTTCACAGATTCTCTGTT
GUCAUCAAGCCUGUUUGCUUCUUUUGGG





AAGAGCCCCCACCACCAAGAAGGTTAGCAGGCCA
CAUGUUCACAGAUUCUCUGUUAAGAGCCC





ACAGCTCTGACATCTATCTGTAGATGCCAGTAG
CCACCACCAAGAAGGUUAGCAGGCCAACAG






CUCUGACAUCUAUCUGUAGAUGCCAGUAG



 


 51
115/414
CTGGGCGTCTTGCCCTTGTCCCCCAGAGATGATAC
CUGGGCGUCUUGCCCUUGUCCCCCAGAGA
LGVLPLSPRDDTLPASGEVLTSFFRAAKG




CCTCCCAGCAAGTGGAGAAGTTCTCACTTCCTTCT
UGAUACCCUCCCAGCAAGUGGAGAAGUUC
ATQIRVEEKTQLPGWEE




TTAGAGCAGCTAAAGGGGCTACCCAGATCAGGGT
UCACUUCCUUCUUUAGAGCAGCUAAAGGG





TGAAGAGAAAACTCAATTACCAGGGTGGGAAGAA
GCUACCCAGAUCAGGGUUGAAGAGAAAAC





TGA
UCAAUUACCAGGGUGGGAAGAAUGA



 


 52
116/415
ATGGCTTCTTTCGGAAAGGTCTGGTTGGTGTGGCT
AUGGCUUCUUUCGGAAAGGUCUGGUUGG
MASFGKVWLVWLQYFATHELRVCPGTL




CCAATACTTTGCCACCCATGAACTCAGGGTGTGCC
UGUGGCUCCAAUACUUUGCCACCCAUGAA
VLYSLLAHLCSVDFVLQAQVQGKMSTYFL




CTGGGACACTGGTTTTATATAGTCTTTTGGCACAC
CUCAGGGUGUGCCCUGGGACACUGGUUUU
ILASASLLSS




CTGTGTTCTGTTGACTTCGTTCTTCAAGCCCAAGTG
AUAUAGUCUUUUGGCACACCUGUGUUCU





CAAGGGAAAATGTCCACCTACTTTCTCATCTTGGC
GUUGACUUCGUUCUUCAAGCCCAAGUGCA





CTCTGCCTCCTTACTTAGCTCTTAA
AGGGAAAAUGUCCACCUACUUUCUCAUCU






UGGCCUCUGCCUCCUUACUUAGCUCUUAA



 


 53
117/416
CTGTTGAACTCAAGAAATCAAGGGCCAGTCATCA
CUGUUGAACUCAAGAAAUCAAGGGCCAGU
LLNSRNQGPVIKLPILIDSLCLLRG




AGCTGCCCATTTTAATTGATTCACTCTGTTTGTTGA
CAUCAAGCUGCCCAUUUUAAUUGAUUCAC





GAGGATAG
UCUGUUUGUUGAGAGGAUAG



 


 54
118/417
TTGGGGTGGGATAGACATGTTCTGGTTTTCTTTAT
UUGGGGUGGGAUAGACAUGUUCUGGUUU
LGWDRHVLVFFIITQSGSCTGSLLAVLNR




TATTACACAATCTGGCTCATGTACAGGATCACTTTT
UCUUUAUUAUUACACAAUCUGGCUCAUGU
KKYPPLFSVTLGYILIGPLHLFWNDFHLL




AGCTGTTTTAAACAGAAAAAAATATCCACCACTCT
ACAGGAUCACUUUUAGCUGUUUUAAACAG





TTTCAGTTACACTAGGTTACATTTTAATAGGTCCTT
AAAAAAAUAUCCACCACUCUUUUCAGUUA





TACATCTGTTTTGGAATGATTTTCATCTTTTGTGA
CACUAGGUUACAUUUUAAUAGGUCCUUUA






CAUCUGUUUUGGAAUGAUUUUCAUCUUU






UGUGA



 


 55
119/418
TTGGCCATTGATGTTCTAGCCAATGTAATTGACAG
UUGGCCAUUGAUGUUCUAGCCAAUGUAAU
LAIDVLANVIDRSLILHALCSTNRVGMVGI




AAGTCTCATTTTGCATGCGCTCTGCTCTACAAACA
UGACAGAAGUCUCAUUUUGCAUGCGCUCU
LYSPVRDWPLRPT




GAGTTGGTATGGTTGGTATACTGTACTCACCTGTG
GCUCUACAAACAGAGUUGGUAUGGUUGG





AGGGACTGGCCACTCAGACCCACTTAG
UAUACUGUACUCACCUGUGAGGGACUGGC






CACUCAGACCCACUUAG



 


 56
120/419
TTGTCCAGGTTGAAAAATAATGTGCTGATGCTAGA
UUGUCCAGGUUGAAAAAUAAUGUGCUGA
LSRLKNNVLMLESLSVHTLLLNTYRHT




GTCCCTCTCTGTCCATACTCTACTTCTAAATACATA
UGCUAGAGUCCCUCUCUGUCCAUACUCUA





TAGGCATACATAG
CUUCUAAAUACAUAUAGGCAUACAUAG



 


 57
121/420
CTGGCAGGGCATAAAGGCCCAGGCCACTTCCTCT
CUGGCAGGGCAUAAAGGCCCAGGCCACUU
LAGHKGPGHFLCPFPALHQSCISGDSLQT




GCCCCTTCCCAGCCCTGCACCAAAGCTGCATTTCA
CCUCUGCCCCUUCCCAGCCCUGCACCAAAG
AQ




GGAGACTCTCTCCAGACAGCCCAGTAA
CUGCAUUUCAGGAGACUCUCUCCAGACAG






CCCAGUAA



 


 58
122/421
TTGACCCACTACAAGGGGTCATGGGAATCAGGAA
UUGACCCACUACAAGGGGUCAUGGGAAUC
LTHYKGSWESGMPKHQIKSKT




TGCCAAAGCACCAGATCAAATCCAAAACTTAA
AGGAAUGCCAAAGCACCAGAUCAAAUCCAA






AACUUAA



 


 59
123/422
ATGTTCAGTTTCTTGGAAAAGGAAGTTTCTACCCC
AUGUUCAGUUUCUUGGAAAAGGAAGUUU
MFSFLEKEVSTPDAFVGRSVLTINLFENLL




TGATGCCTTTGTAGGCAGATCTGTTCTCACCATTA
CUACCCCUGAUGCCUUUGUAGGCAGAUCU
KQFLKREMKASHYITKDYIVPAKIPKFIRA




ATCTTTTTGAAAATCTTTTAAAGCAGTTTTTAAAAA
GUUCUCACCAUUAAUCUUUUUGAAAAUCU
GGEQALVPL




GAGAGATGAAAGCATCACATTATATAACCAAAGA
UUUAAAGCAGUUUUUAAAAAGAGAGAUG





TTACATTGTACCTGCTAAGATACCAAAATTCATAA
AAAGCAUCACAUUAUAUAACCAAAGAUUA





GGGCAGGGGGGGAGCAAGCATTAGTGCCTCTTTG
CAUUGUACCUGCUAAGAUACCAAAAUUCA





A
UAAGGGCAGGGGGGGAGCAAGCAUUAGU






GCCUCUUUGA



 


 60
124/423
TTGCTGAGCAAATTGTTGAAGCTCCATCATTGCAT
UUGCUGAGCAAAUUGUUGAAGCUCCAUCA
LLSKLLKLHHCMVGNGAVLSHCVC




GGTTGGAAATGGAGCTGTTCTTAGCCACTGTGTTT
UUGCAUGGUUGGAAAUGGAGCUGUUCUU





GCTAG
AGCCACUGUGUUUGCUAG



 


 61
125/424
TTGAAATACATTGTAAATGAATATTTGTATCCATG
UUGAAAUACAUUGUAAAUGAAUAUUUGU
LKYIVNEYLYPCFKIEIYIYIYIYIYIYI




TTTCAAAATTGAAATATATATATATATATATATATA
AUCCAUGUUUCAAAAUUGAAAUAUAUAUA





TATATATATATATATATAG
UAUAUAUAUAUAUAUAUAUAUAUAUAUA






UAUAG



 


 62
126/425
ATGCAGTTTTGTTTTGGAAGCTCTCTCAGAACAAA
AUGCAGUUUUGUUUUGGAAGCUCUCUCA
MQFCFGSSLRTNKTPGLIS




CAAGACACCTGGATTGATCAGTTAA
GAACAAACAAGACACCUGGAUUGAUCAGU






UAA



 


 63
127/426
TTGACCAGTGGCCCCCTAATGGGACCTGAGCTGTT
UUGACCAGUGGCCCCCUAAUGGGACCUGA
LTSGPLMGPELLEEENCSLVFTILVREGQF




GGAAGAAGAGAACTGTTCCTTGGTCTTCACCATCC
GCUGUUGGAAGAAGAGAACUGUUCCUUG
PALEPGASALSFTQIPSPEIEVLLLLGVCVL




TTGTGAGAGAAGGGCAGTTTCCTGCATTGGAACC
GUCUUCACCAUCCUUGUGAGAGAAGGGCA





TGGAGCAAGCGCTCTATCTTTCACACAAATTCCCT
GUUUCCUGCAUUGGAACCUGGAGCAAGCG





CACCTGAGATTGAGGTGCTCTTGTTACTGGGTGTC
CUCUAUCUUUCACACAAAUUCCCUCACCUG





TGTGTGCTGTAA
AGAUUGAGGUGCUCUUGUUACUGGGUGU






CUGUGUGCUGUAA



 


 64
128/427
TTGACAAATGAAAATGTGTTTTTCTCTGTTAAAACT
UUGACAAAUGAAAAUGUGUUUUUCUCUG
LTNENVFFSVKTCQSTRSCISVGAGPFLPT




TGTCAGAGTACTAGAAGTTGTATCTCTGTAGGTGC
UUAAAACUUGUCAGAGUACUAGAAGUUG
GRVFFFD




AGGTCCATTTCTGCCCACAGGTAGGGTGTTTTTCT
UAUCUCUGUAGGUGCAGGUCCAUUUCUGC





TTGATTAA
CCACAGGUAGGGUGUUUUUCUUUGAUUA






A



 


 65
129/428
ATGAGAAGCCTTAGAATGGGTGGCCCTTGTGACC
AUGAGAAGCCUUAGAAUGGGUGGCCCUUG
MRSLRMGGPCDLKHFPHKLLNKIVMEL




TGAAACACTTCCCACATAAGCTACTTAACAAGATT
UGACCUGAAACACUUCCCACAUAAGCUACU
QIPLPTKD




GTCATGGAGCTGCAGATTCCATTGCCCACCAAAGA
UAACAAGAUUGUCAUGGAGCUGCAGAUUC





CTAG
CAUUGCCCACCAAAGACUAG



 


 66
130/429
ATGCTGTTTCTCTGGTGGTTCCCTCTCTGGCTGCTG
AUGCUGUUUCUCUGGUGGUUCCCUCUCU
MLFLWWFPLWLLPHSMGTCTLQR




CCTCACAGTATGGGAACCTGTACTCTGCAGAGGT
GGCUGCUGCCUCACAGUAUGGGAACCUGU





GA
ACUCUGCAGAGGUGA



 


 67
131/430
CTGTCCTACAGTGAAGTGCCTGGGGGGTTGTCCT
CUGUCCUACAGUGAAGUGCCUGGGGGGU
LSYSEVPGGLSYPISHLDADSSHHQNDPR




ATCCCATAAGCCACTTGGATGCTGACAGCAGCCAC
UGUCCUAUCCCAUAAGCCACUUGGAUGCU
KKKKKKIKKSPHNPVTPFCFPLDWNID




CATCAGAATGACCCACGCAAAAAAAAGAAAAAAA
GACAGCAGCCACCAUCAGAAUGACCCACGC





AAATTAAAAAGTCCCCTCACAACCCAGTGACACCT
AAAAAAAAGAAAAAAAAAAUUAAAAAGUCC





TTCTGCTTTCCTCTAGACTGGAACATTGATTAG
CCUCACAACCCAGUGACACCUUUCUGCUUU






CCUCUAGACUGGAACAUUGAUUAG



 


 68
132/431
ATGGGGCTCATTTCTCACGGTGGCACTTGGCCTCC
AUGGGGCUCAUUUCUCACGGUGGCACUUG
MGLISHGGTWPPLGSRTSSKR




ACTGGGCAGCAGGACCAGCTCCAAGCGCTAG
GCCUCCACUGGGCAGCAGGACCAGCUCCAA






GCGCUAG



 


 69
133/432
ATGGCAGAAACTTGTTTGTTGGACTACATGTGTGA
AUGGCAGAAACUUGUUUGUUGGACUACA
MAETCLLDYMCDFGSVSASAFRNVIHCV




CTTTGGGTCTGTCTCTGCCTCTGCTTTCAGAAATGT
UGUGUGACUUUGGGUCUGUCUCUGCCUC
KYWLTGLPAKTWPHPLLWLQDRVIVNKE




CATCCATTGTGTAAAATATTGGCTTACTGGTCTGC
UGCUUUCAGAAAUGUCAUCCAUUGUGUAA
TQEKLLMSSYHCC




CAGCTAAAACTTGGCCACATCCCCTGTTATGGCTG
AAUAUUGGCUUACUGGUCUGCCAGCUAAA





CAGGATCGAGTTATTGTTAACAAAGAGACCCAAG
ACUUGGCCACAUCCCCUGUUAUGGCUGCA





AAAAGCTGCTAATGTCCTCTTATCATTGTTGTTAA
GGAUCGAGUUAUUGUUAACAAAGAGACCC






AAGAAAAGCUGCUAAUGUCCUCUUAUCAU






UGUUGUUAA



 


 70
134/433
CTGTTTTCCCCCACTCTCTCTCCACCTCCTCCTGCCT
CUGUUUUCCCCCACUCUCUCUCCACCUCCU
LFSPTLSPPPPAFPTPSAEPEIKR




TCCCCACCCCGAGTGCGGAGCCAGAGATCAAAAG
CCUGCCUUCCCCACCCCGAGUGCGGAGCCA





ATGA
GAGAUCAAAAGAUGA



 


 71
135/434
GTGGACACTGAATTTGGAAGGTGGAGGATTTTGT
GUGGACACUGAAUUUGGAAGGUGGAGGA
VDTEFGRWRILFFSFKIWASFESTLQVLR




TTTTTTCTTTTAAGATCTGGGCATCTTTTGAATCTA
UUUUGUUUUUUUCUUUUAAGAUCUGGGC
DRL




CCCTTCAAGTATTAAGAGACAGACTGTGA
AUCUUUUGAAUCUACCCUUCAAGUAUUAA






GAGACAGACUGUGA



 


 72
136/435
ATGGCCCAGTGTCAAGTTGTGCTTGTTTACAGCAC
AUGGCCCAGUGUCAAGUUGUGCUUGUUU
MAQCQVVLVYSTTLCQPHKRLLILCHGKF




TACTCTGTGCCAGCCACACAAACGTTTACTTATCTT
ACAGCACUACUCUGUGCCAGCCACACAAAC
RELRLSGEIKTKTSKQKKKAKTKQKISQKT




ATGCCACGGGAAGTTTAGAGAGCTAAGATTATCT
GUUUACUUAUCUUAUGCCACGGGAAGUU
LLVFFPQK




GGGGAAATCAAAACAAAAACAAGCAAACAAAAA
UAGAGAGCUAAGAUUAUCUGGGGAAAUCA





AAAAAAGCAAAAACAAAACAAAAAATAAGCCAAA
AAACAAAAACAAGCAAACAAAAAAAAAAAG





AAACCTTGCTAGTGTTTTTTCCTCAAAAATAA
CAAAAACAAAACAAAAAAUAAGCCAAAAAA






CCUUGCUAGUGUUUUUUCCUCAAAAAUAA



 


 73
137/436
TTGACTTTCAATAGTTTTTCTAAGACCTTTGAACTG
UUGACUUUCAAUAGUUUUUCUAAGACCU
LTFNSFSKTFELNVLFSQNLATSTEKSDH




AATGTTCTCTTCAGCCAAAACTTGGCGACTTCCAC
UUGAACUGAAUGUUCUCUUCAGCCAAAAC





AGAAAAGTCTGACCACTGA
UUGGCGACUUCCACAGAAAAGUCUGACCA






CUGA



 


 74
138/437
ATGAAGTTTTCTGCCAAACTCCGTGAAGCCACAAG
AUGAAGUUUUCUGCCAAACUCCGUGAAGC
MKFSAKLREATSTLCPPFSVLWA




CACCTTATGTCCTCCCTTCAGTGTTTTGTGGGCCTG
CACAAGCACCUUAUGUCCUCCCUUCAGUG





A
UUUUGUGGGCCUGA



 


 75
139/438
CTGCTGGAGAAAACTAAAGCTGACAGGTTCCCTTT
CUGCUGGAGAAAACUAAAGCUGACAGGUU
LLEKTKADRFPFWGGIDMFWFSLLLHNL




TTGGGGTGGGATAGACATGTTCTGGTTTTCTTTAT
CCCUUUUUGGGGUGGGAUAGACAUGUUC
AHVQDHF




TATTACACAATCTGGCTCATGTACAGGATCACTTTT
UGGUUUUCUUUAUUAUUACACAAUCUGG





AG
CUCAUGUACAGGAUCACUUUUAG



 


 76
140/439
ATGATTTTCATCTTTTGTGATACACAGATTGAATTA
AUGAUUUUCAUCUUUUGUGAUACACAGA
MIFIFCDTQIELYHFHISPCKY




TATCATTTTCATATCTCTCCTTGTAAATACTAG
UUGAAUUAUAUCAUUUUCAUAUCUCUCCU






UGUAAAUACUAG



 


 77
141/440
TTGACAGAAGTCTCATTTTGCATGCGCTCTGCTCT
UUGACAGAAGUCUCAUUUUGCAUGCGCUC
LTEVSFCMRSALQTELVWLVYCTHL




ACAAACAGAGTTGGTATGGTTGGTATACTGTACTC
UGCUCUACAAACAGAGUUGGUAUGGUUG





ACCTGTGA
GUAUACUGUACUCACCUGUGA



 


 78
142/441
GTGAGGAAGAGAAAAAGAAGGAGCACCAGGGA
GUGAGGAAGAGAAAAAGAAGGAGCACCAG
VRKRKRRSTREKAPSVLGSRQLPGSRTL




GAAGGCTCCGTCTGTGCTGGGCAGCAGACAGCTG
GGAGAAGGCUCCGUCUGUGCUGGGCAGCA





CCAGGATCACGAACTCTGTAG
GACAGCUGCCAGGAUCACGAACUCUGUAG



 


 79
143/442
CTGACTGTCTACGAATTATCTTGTGCCAGTTGCCC
CUGACUGUCUACGAAUUAUCUUGUGCCAG
LTVYELSCASCPGERALGQGSGFHV




AGGTGAGAGGGCACTGGGCCAAGGGAGTGGTTT
UUGCCCAGGUGAGAGGGCACUGGGCCAAG





TCATGTTTGA
GGAGUGGUUUUCAUGUUUGA



 


 80
144/443
TTGTGGGTTTTTTTTTCCCTAATAATATACATGTTT
UUGUGGGUUUUUUUUUCCCUAAUAAUAU
LWVFFSLIIYMFRRIENNFGKMGLWVLH




AGAAGAATTGAAAATAATTTCGGGAAAATGGGAT
ACAUGUUUAGAAGAAUUGAAAAUAAUUUC





TATGGGTCCTTCACTAA
GGGAAAAUGGGAUUAUGGGUCCUUCACU






AA



 


 81
145/444
TTGGAAATGGAGCTGTTCTTAGCCACTGTGTTTGC
UUGGAAAUGGAGCUGUUCUUAGCCACUG
LEMELFLATVFASAHVSLSEDVKPLLIREH




TAGTGCCCATGTTAGCTTATCTGAAGATGTGAAAC
UGUUUGCUAGUGCCCAUGUUAGCUUAUC
LKY




CCTTGCTGATAAGGGAGCATTTAAAGTACTAG
UGAAGAUGUGAAACCCUUGCUGAUAAGGG






AGCAUUUAAAGUACUAG



 


 82
146/445
ATGAATATTTGTATCCATGTTTCAAAATTGAAATAT
AUGAAUAUUUGUAUCCAUGUUUCAAAAU
MNICIHVSKLKYIYIYIYIYIYIYSVCVCSDSF




ATATATATATATATATATATATATATATATATATAT
UGAAAUAUAUAUAUAUAUAUAUAUAUAU
NFLCIFIFGSRSHLMPCTCERGCSFVLEAL




AGTGTGTGTGTGTGTTCTGATAGCTTTAACTTTCTC
AUAUAUAUAUAUAUAUAGUGUGUGUGUG
SEQTRHLD




TGCATCTTTATATTTGGTTCCAGATCACACCTGATG
UGUUCUGAUAGCUUUAACUUUCUCUGCA





CCATGTACTTGTGAGAGAGGATGCAGTTTTGTTTT
UCUUUAUAUUUGGUUCCAGAUCACACCUG





GGAAGCTCTCTCAGAACAAACAAGACACCTGGAT
AUGCCAUGUACUUGUGAGAGAGGAUGCAG





TGA
UUUUGUUUUGGAAGCUCUCUCAGAACAAA






CAAGACACCUGGAUUGA



 


 83
147/446
ATGGAACTGACTGAGATTTACCACAGGGAAGGCC
AUGGAACUGACUGAGAUUUACCACAGGGA
MELTEIYHREGPNLGPKAYPSD




CAAACTTGGGGCCAAAAGCCTACCCAAGTGATTG
AGGCCCAAACUUGGGGCCAAAAGCCUACCC





A
AAGUGAUUGA



 


 84
148/447
CTGCATTGGAACCTGGAGCAAGCGCTCTATCTTTC
CUGCAUUGGAACCUGGAGCAAGCGCUCUA
LHWNLEQALYLSHKFPHLRLRCSCYWVS




ACACAAATTCCCTCACCTGAGATTGAGGTGCTCTT
UCUUUCACACAAAUUCCCUCACCUGAGAU
VCCNSGFGYVL




GTTACTGGGTGTCTGTGTGCTGTAATTCTGGTTTT
UGAGGUGCUCUUGUUACUGGGUGUCUGU





GGATATGTTCTGTAA
GUGCUGUAAUUCUGGUUUUGGAUAUGUU






CUGUAA



 


 85
149/448
ATGAAAATGTGTTTTTCTCTGTTAAAACTTGTCAG
AUGAAAAUGUGUUUUUCUCUGUUAAAAC
MKMCFSLLKLVRVLEVVSL




AGTACTAGAAGTTGTATCTCTGTAG
UUGUCAGAGUACUAGAAGUUGUAUCUCU






GUAG



 


 86
150/449
GTGCAGGTCCATTTCTGCCCACAGGTAGGGTGTTT
GUGCAGGUCCAUUUCUGCCCACAGGUAGG
VQVHFCPQVGCFSLIKRLTLLLPRTSQLN




TTCTTTGATTAAGAGATTGACACTTCTGTTGCCTAG
GUGUUUUUCUUUGAUUAAGAGAUUGACA
HF




GACCTCCCAACTCAACCATTTCTAG
CUUCUGUUGCCUAGGACCUCCCAACUCAAC






CAUUUCUAG



 


 87
151/450
TTGTCATGGAGCTGCAGATTCCATTGCCCACCAAA
UUGUCAUGGAGCUGCAGAUUCCAUUGCCC
LSWSCRFHCPPKTRTHTYPYTKGKTILKCC




GACTAGAACACACACATATCCATACACCAAAGGA
ACCAAAGACUAGAACACACACAUAUCCAUA
FSGGSLSGCCLTVWEPVLCRGDRPDLHYL




AAGACAATTCTGAAATGCTGTTTCTCTGGTGGTTC
CACCAAAGGAAAGACAAUUCUGAAAUGCU
TTLALGANCPTVKCLGGCPIP




CCTCTCTGGCTGCTGCCTCACAGTATGGGAACCTG
GUUUCUCUGGUGGUUCCCUCUCUGGCUGC





TACTCTGCAGAGGTGACAGGCCAGATTTGCATTAT
UGCCUCACAGUAUGGGAACCUGUACUCUG





CTCACAACCTTAGCCCTTGGTGCTAACTGTCCTAC
CAGAGGUGACAGGCCAGAUUUGCAUUAUC





AGTGAAGTGCCTGGGGGGTTGTCCTATCCCATAA
UCACAACCUUAGCCCUUGGUGCUAACUGU






CCUACAGUGAAGUGCCUGGGGGGUUGUCC






UAUCCCAUAA



 


 88
152/451
ATGCTGACAGCAGCCACCATCAGAATGACCCACG
AUGCUGACAGCAGCCACCAUCAGAAUGACC
MLTAATIRMTHAKKRKKKLKSPLTTQ




CAAAAAAAAGAAAAAAAAAATTAAAAAGTCCCCT
CACGCAAAAAAAAGAAAAAAAAAAUUAAAA





CACAACCCAGTGA
AGUCCCCUCACAACCCAGUGA



 


 89
153/452
TTGATTAGGGAGTGCCTCAGACATGACATTCTTGT
UUGAUUAGGGAGUGCCUCAGACAUGACAU
LIRECLRHDILVLSLELIWQQEGADYVNR




GCTGTCCTTGGAATTAATCTGGCAGCAGGAGGGA
UCUUGUGCUGUCCUUGGAAUUAAUCUGG
DKN




GCAGACTATGTAAACAGAGATAAAAATTAA
CAGCAGGAGGGAGCAGACUAUGUAAACAG






AGAUAAAAAUUAA



 


 90
154/453
TTGAAGGAAAAAAGAAATAAGAAGAGAGAGAGA
UUGAAGGAAAAAAGAAAUAAGAAGAGAGA
LKEKRNKKRERKKASHKDFLKRNNFA




AAGAAAGCATCACACAAAGATTTTCTTAAAAGAA
GAGAAAGAAAGCAUCACACAAAGAUUUUC





ACAATTTTGCTTGA
UUAAAAGAAACAAUUUUGCUUGA



 


 91
155/454
GTGGCACTTGGCCTCCACTGGGCAGCAGGACCAG
GUGGCACUUGGCCUCCACUGGGCAGCAGG
VALGLHWAAGPAPSASVLFSFCNLGIFCC




CTCCAAGCGCTAGTGTTCTGTTCTCTTTTTGTAATC
ACCAGCUCCAAGCGCUAGUGUUCUGUUCU
SKYN




TTGGAATCTTTTGTTGCTCTAAATACAATTAA
CUUUUUGUAAUCUUGGAAUCUUUUGUUG






CUCUAAAUACAAUUAA



 


 92
156/455
CTGGTCTGCCAGCTAAAACTTGGCCACATCCCCTG
CUGGUCUGCCAGCUAAAACUUGGCCACAU
LVCQLKLGHIPCYGCRIELLLTKRPKKSC




TTATGGCTGCAGGATCGAGTTATTGTTAACAAAGA
CCCCUGUUAUGGCUGCAGGAUCGAGUUAU





GACCCAAGAAAAGCTGCTAA
UGUUAACAAAGAGACCCAAGAAAAGCUGC






UAA



 


 93
157/456
GTGTCACTATGGAGCTCTCACATGTGGAAGCTGC
GUGUCACUAUGGAGCUCUCACAUGUGGAA
VSLWSSHMWKLQGLLQKSR




AAGGTCTTCTTCAAAAGAGCCGCTGA
GCUGCAAGGUCUUCUUCAAAAGAGCCGCU






GA



 


 94
158/457
CTGCCAGGGACCATGTTTTGCCCATTGACTATTAC
CUGCCAGGGACCAUGUUUUGCCCAUUGAC
LPGTMFCPLTITFHPRRPA




TTTCCACCCCAGAAGACCTGCCTGA
UAUUACUUUCCACCCCAGAAGACCUGCCU






GA



 


 95
159/458
GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC
GUGGAGAUGAAGCUUCUGGGUGUCACUA
VEMKLLGVTMELSHVEAARSSSKEPLK




TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA
UGGAGCUCUCACAUGUGGAAGCUGCAAGG





GAGCCGCTGAAG
UCUUCUUCAAAAGAGCCGCUGAAG



 


 96
160/459
TTGGAGACTGCCAGGGACCATGTTTTGCCCATTGA
UUGGAGACUGCCAGGGACCAUGUUUUGCC
LETARDHVLPIDYYFPPQKTCLICGDEASG




CTATTACTTTCCACCCCAGAAGACCTGCCTGATCT
CAUUGACUAUUACUUUCCACCCCAGAAGA
CHYGALTCGSCKVFFKRAAEVWRLPGT




GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC
CCUGCCUGAUCUGUGGAGAUGAAGCUUCU
MFCPLTITFHPRRPA




TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA
GGGUGUCACUAUGGAGCUCUCACAUGUGG





GAGCCGCTGAAGTTTGGAGACTGCCAGGGACCAT
AAGCUGCAAGGUCUUCUUCAAAAGAGCCG





GTTTTGCCCATTGACTATTACTTTCCACCCCAGAAG
CUGAAGUUUGGAGACUGCCAGGGACCAUG





ACCTGCCTGA
UUUUGCCCAUUGACUAUUACUUUCCACCC






CAGAAGACCUGCCUGA



 


 97
161/460
GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC
GUGGAGAUGAAGCUUCUGGGUGUCACUA
VEMKLLGVTMELSHVEAARSSSKEPLKFG




TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA
UGGAGCUCUCACAUGUGGAAGCUGCAAGG
DCQGPCFAH




GAGCCGCTGAAGTTTGGAGACTGCCAGGGACCAT
UCUUCUUCAAAAGAGCCGCUGAAGUUUGG





GTTTTGCCCATTGA
AGACUGCCAGGGACCAUGUUUUGCCCAUU






GA



 


 98 (BSS)
162/461
CTGTGCGCCAGCAGAAATGATTGCACTATTGATAA
CUGUGCGCCAGCAGAAAUGAUUGCACUAU
LCASRNDCTIDKFRRKNCPSCRLRKCYEA




ATTCCGAAGGAAAAATTGTCCATCTTGTCGTCTTC
UGAUAAAUUCCGAAGGAAAAAUUGUCCAU
GMTLGVWRLPGTMFCPLTITFHPRRPA




GGAAATGTTATGAAGCAGGGATGACTCTGGGAGT
CUUGUCGUCUUCGGAAAUGUUAUGAAGCA





TTGGAGACTGCCAGGGACCATGTTTTGCCCATTGA
GGGAUGACUCUGGGAGUUUGGAGACUGC





CTATTACTTTCCACCCCAGAAGACCTGCCTGA
CAGGGACCAUGUUUUGCCCAUUGACUAUU






ACUUUCCACCCCAGAAGACCUGCCUGA



 


 99 (BSS)
163/462
ATGCACAAGTCCCGGATGTACAGCCAGTGTGTCC
AUGCACAAGUCCCGGAUGUACAGCCAGUG
MHKSRMYSQCVRMRHLSQEFGWLQITP




GAATGAGGCACCTCTCTCAAGAGTTTGGATGGCT
UGUCCGAAUGAGGCACCUCUCUCAAGAGU
QEFLCMKALLLFSISFRNLHVDDQMAVIQ




CCAAATCACCCCCCAGGAATTCCTGTGCATGAAAG
UUGGAUGGCUCCAAAUCACCCCCCAGGAA
YSWMGLMVFAMGWRSFTNVNSRMLY




CACTGCTACTCTTCAGCATTAGCTTCCGCAACTTAC
UUCCUGUGCAUGAAAGCACUGCUACUCUU
FAPDLVFN




ACGTGGACGACCAGATGGCTGTCATTCAGTACTCC
CAGCAUUAGCUUCCGCAACUUACACGUGG





TGGATGGGGCTCATGGTGTTTGCCATGGGCTGGC
ACGACCAGAUGGCUGUCAUUCAGUACUCC





GATCCTTCACCAATGTCAACTCCAGGATGCTCTAC
UGGAUGGGGCUCAUGGUGUUUGCCAUGG





TTCGCCCCTGATCTGGTTTTCAAT
GCUGGCGAUCCUUCACCAAUGUCAACUCCA






GGAUGCUCUACUUCGCCCCUGAUCUGGUU






UUCAAU



 


100 (BSS)
164/463
TTGCATGCAAAAGAAAAAATCCCACATCCTGCTCA
UUGCAUGCAAAAGAAAAAAUCCCACAUCCU
LHAKEKIPHPAQDASTSSPSSWTPCSLLP




AGACGCTTCTACCAGCTCACCAAGCTCCTGGACTC
GCUCAAGACGCUUCUACCAGCUCACCAAGC
QLTRGRPDGCHSVLLDGAHGVCHGLAIL




CGTGCAGCCTGCTTCCGCAACTTACACGTGGACGA
UCCUGGACUCCGUGCAGCCUGCUUCCGCA
HQCQLQDALLRP




CCAGATGGCTGTCATTCAGTACTCCTGGATGGGG
ACUUACACGUGGACGACCAGAUGGCUGUC





CTCATGGTGTTTGCCATGGGCTGGCGATCCTTCAC
AUUCAGUACUCCUGGAUGGGGCUCAUGGU





CAATGTCAACTCCAGGATGCTCTACTTCGCCCCTG
GUUUGCCAUGGGCUGGCGAUCCUUCACCA





A
AUGUCAACUCCAGGAUGCUCUACUUCGCC






CCUGA



 


101 (BSS)
165/464
ATGCAAAAGAAAAAATCCCACATCCTGCTCAAGAC
AUGCAAAAGAAAAAAUCCCACAUCCUGCUC
MQKKKSHILLKTLLPAHQAPGLRAACFRN




GCTTCTACCAGCTCACCAAGCTCCTGGACTCCGTG
AAGACGCUUCUACCAGCUCACCAAGCUCCU
LHVDDQMAVIQYSWMGLMVFAMGW




CAGCCTGCTTCCGCAACTTACACGTGGACGACCAG
GGACUCCGUGCAGCCUGCUUCCGCAACUU
RSFTNVNSRMLYFAPDLVFN




ATGGCTGTCATTCAGTACTCCTGGATGGGGCTCAT
ACACGUGGACGACCAGAUGGCUGUCAUUC





GGTGTTTGCCATGGGCTGGCGATCCTTCACCAATG
AGUACUCCUGGAUGGGGCUCAUGGUGUU





TCAACTCCAGGATGCTCTACTTCGCCCCTGATCTG
UGCCAUGGGCUGGCGAUCCUUCACCAAUG





GTTTTCAAT
UCAACUCCAGGAUGCUCUACUUCGCCCCU






GAUCUGGUUUUCAAU



 


102 (BSS)
166/465
GTGGATGGGCTGAAAAATCAAAAATTCTTTGATG
GUGGAUGGGCUGAAAAAUCAAAAAUUCUU
VDGLKNQKFFDELRMNYIKELDRIIACKR




AACTTCGAATGAACTACATCAAGGAACTCGATCGT
UGAUGAACUUCGAAUGAACUACAUCAAGG
KNPTSCSRRFYQLTKLLDSVQPASATYTW




ATCATTGCATGCAAAAGAAAAAATCCCACATCCTG
AACUCGAUCGUAUCAUUGCAUGCAAAAGA
TTRWLSFSTPGWGSWCLPWAGDPSPM




CTCAAGACGCTTCTACCAGCTCACCAAGCTCCTGG
AAAAAUCCCACAUCCUGCUCAAGACGCUUC
STPGCSTSPLIWFSM




ACTCCGTGCAGCCTGCTTCCGCAACTTACACGTGG
UACCAGCUCACCAAGCUCCUGGACUCCGUG





ACGACCAGATGGCTGTCATTCAGTACTCCTGGATG
CAGCCUGCUUCCGCAACUUACACGUGGAC





GGGCTCATGGTGTTTGCCATGGGCTGGCGATCCTT
GACCAGAUGGCUGUCAUUCAGUACUCCUG





CACCAATGTCAACTCCAGGATGCTCTACTTCGCCC
GAUGGGGCUCAUGGUGUUUGCCAUGGGC





CTGATCTGGTTTTCAATG
UGGCGAUCCUUCACCAAUGUCAACUCCAG






GAUGCUCUACUUCGCCCCUGAUCUGGUUU






UCAAUG





FOLH1






neo-






antigen

DNA sequence
RNA sequence
Protein Sequence





  1
167/466
GTGGTATGTCACTCAGAAAGAATCGTAATGGGTA
GUGGUAUGUCACUCAGAAAGAAUCGUAAU
VVCHSERIVMGILINFKIGIFEIKLNIIYSYVS




TATTGATAAATTTTAAAATTGGTATATTTGAAATAA
GGGUAUAUUGAUAAAUUUUAAAAUUGGU
VYICVCLYCLSSPYGLKLNFIIIRGYSEVEKF




AGTTGAATATTATATATAGTTATGTGAGTGTTTAT
AUAUUUGAAAUAAAGUUGAAUAUUAUAU
NSVLNLRRMA




ATATGTGTGTGTTTATATTGTTTATCTTCTCCCTAT
AUAGUUAUGUGAGUGUUUAUAUAUGUGU





GGATTAAAACTGAATTTCATAATTATAAGAGGTTA
GUGUUUAUAUUGUUUAUCUUCUCCCUAU





TTCTGAAGTGGAAAAATTTAACTCAGTATTAAATC
GGAUUAAAACUGAAUUUCAUAAUUAUAAG





TAAGGAGAATGGCCTAA
AGGUUAUUCUGAAGUGGAAAAAUUUAAC






UCAGUAUUAAAUCUAAGGAGAAUGGCCUA






A



 


  2
168/467
ATGTCACTTCACACAGAAGAAAACATCAGTATGTC
AUGUCACUUCACACAGAAGAAAACAUCAG
MSLHTEENISMSESTLGNMHKIIPSQRPH




AGAGAGCACACTGGGGAATATGCACAAGATTATC
UAUGUCAGAGAGCACACUGGGGAAUAUGC
GLPGQPGLRGSLSQHTIWEMDQITLLVN




CCAAGCCAGAGGCCTCACGGCCTACCTGGCCAGC
ACAAGAUUAUCCCAAGCCAGAGGCCUCACG
VITL




CTGGGCTGAGAGGATCACTATCTCAGCACACTATT
GCCUACCUGGCCAGCCUGGGCUGAGAGGA





TGGGAAATGGATCAAATCACACTTTTAGTAAATGT
UCACUAUCUCAGCACACUAUUUGGGAAAU





TATCACTCTATAG
GGAUCAAAUCACACUUUUAGUAAAUGUUA






UCACUCUAUAG



 


  3
169/468
ATGAACACTTGTGAACCTAATAGCCATATGAAGAA
AUGAACACUUGUGAACCUAAUAGCCAUAU
MNTCEPNSHMKKITFLISLDAPCTNDSYA




AATAACATTTCTAATATCTTTGGATGCCCCATGTAC
GAAGAAAAUAACAUUUCUAAUAUCUUUGG
FAFS




TAATGACAGTTATGCTTTTGCATTTTCTTGA
AUGCCCCAUGUACUAAUGACAGUUAUGCU






UUUGCAUUUUCUUGA



 


  4
170/469
CTGTCATTATTTATAATTTTATCACACATGGCTGTA
CUGUCAUUAUUUAUAAUUUUAUCACACAU
LSLFIILSHMAVSFTCFGIMYF




TCCTTTACATGTTTTGGCATTATGTATTTTTGA
GGCUGUAUCCUUUACAUGUUUUGGCAUU






AUGUAUUUUUGA



 


  5
171/470
TTGACACTTCAGAACTCCCCAGAAACTTGTCTTCT
UUGACACUUCAGAACUCCCCAGAAACUUG
LTLQNSPETCLLGQCVKLFMKKCQARGA




GGGCCAATGTGTAAAGCTGTTTATGAAGAAATGT
UCUUCUGGGCCAAUGUGUAAAGCUGUUU
LLQIWQRTISGEALGRWVLLATMNFRK




CAAGCCAGAGGGGCTCTACTACAAATTTGGCAAA
AUGAAGAAAUGUCAAGCCAGAGGGGCUCU
WVP




GGACAATTTCAGGAGAAGCTCTTGGCCGCTGGGT
ACUACAAAUUUGGCAAAGGACAAUUUCAG





TCTCCTGGCCACCATGAACTTCAGGAAGTGGGTG
GAGAAGCUCUUGGCCGCUGGGUUCUCCUG





CCATAG
GCCACCAUGAACUUCAGGAAGUGGGUGCC






AUAG



 


  6
172/471
CTGGGCACTGGTGTAGCTCTGTATGCCCTCCGTGT
CUGGGCACUGGUGUAGCUCUGUAUGCCCU
LGTGVALYALRVRCWRCHLHCQSLPRVH




CAGATGCTGGAGATGTCATTTGCATTGCCAGAGTT
CCGUGUCAGAUGCUGGAGAUGUCAUUUGC
TESRLKSTLLEHLSNAFYSQSLTSLTRDKEE




TGCCAAGGGTGCACACAGAAAGCAGATTGAAAAG
AUUGCCAGAGUUUGCCAAGGGUGCACACA
LFNGPRSIYEDNQVGVWSG




CACCCTCTTGGAACATCTCTCCAATGCCTTCTACTC
GAAAGCAGAUUGAAAAGCACCCUCUUGGA





ACAAAGTTTAACATCATTAACACGTGACAAAGAA
ACAUCUCUCCAAUGCCUUCUACUCACAAAG





GAACTATTTAATGGGCCCAGATCTATTTATGAAGA
UUUAACAUCAUUAACACGUGACAAAGAAG





CAATCAAGTGGGAGTTTGGAGTGGATAA
AACUAUUUAAUGGGCCCAGAUCUAUUUAU






GAAGACAAUCAAGUGGGAGUUUGGAGUG






GAUAA



 


  7
173/472
ATGCCCCATGTACTAATGACAGTTATGCTTTTGCA
AUGCCCCAUGUACUAAUGACAGUUAUGCU
MPHVLMTVMLLHFLEFYVYLSFLCHYL




TTTTCTTGAATTTTATGTTTATTTATCTTTCCTCTGT
UUUGCAUUUUCUUGAAUUUUAUGUUUAU





CATTATTTATAA
UUAUCUUUCCUCUGUCAUUAUUUAUAA



 


  8
174/473
CTGTATCCTTTACATGTTTTGGCATTATGTATTTTT
CUGUAUCCUUUACAUGUUUUGGCAUUAU
LYPLHVLALCIFELFVKTIIPCVIFRDLIFFID




GAACTTTTTGTAAAGACAATCATACCATGTGTAAT
GUAUUUUUGAACUUUUUGUAAAGACAAU
F




TTTCAGGGACTTGATTTTTTTCATTGACTTTTAA
CAUACCAUGUGUAAUUUUCAGGGACUUGA






UUUUUUUCAUUGACUUUUAA



 


  9
175/474
ATGGTGAATTTGGAGCAGCCAATGAAGAGTCCCC
AUGGUGAAUUUGGAGCAGCCAAUGAAGAG
MVNLEQPMKSPLTLWPRSKLRSRCSVAL




TCACATTGTGGCCTCGCTCAAAGTTAAGAAGTCGC
UCCCCUCACAUUGUGGCCUCGCUCAAAGU
EESASN




TGTAGTGTTGCCCTTGAAGAATCTGCTTCAAATTG
UAAGAAGUCGCUGUAGUGUUGCCCUUGAA





A
GAAUCUGCUUCAAAUUGA



 


 10
176/475
ATGCCCTCCGTGTCAGATGCTGGAGATGTCATTTG
AUGCCCUCCGUGUCAGAUGCUGGAGAUGU
MPSVSDAGDVICIARVCQGCTQKAD




CATTGCCAGAGTTTGCCAAGGGTGCACACAGAAA
CAUUUGCAUUGCCAGAGUUUGCCAAGGGU





GCAGATTGA
GCACACAGAAAGCAGAUUGA



 


 11
177/476
GTGACAAAGAAGAACTATTTAATGGGCCCAGATC
GUGACAAAGAAGAACUAUUUAAUGGGCCC
VTKKNYLMGPDLFMKTIKWEFGVDNPN




TATTTATGAAGACAATCAAGTGGGAGTTTGGAGT
AGAUCUAUUUAUGAAGACAAUCAAGUGGG
LDNW




GGATAACCCAAATTTGGATAACTGGTGA
AGUUUGGAGUGGAUAACCCAAAUUUGGA






UAACUGGUGA



 


 12
178/477
TTGAATTTGTGTGGTATGTCACTCAGAAAGAATCG
UUGAAUUUGUGUGGUAUGUCACUCAGAA
LNLCGMSLRKNRNGYIDKF




TAATGGGTATATTGATAAATTTTAA
AGAAUCGUAAUGGGUAUAUUGAUAAAUU






UUAA



 


 13
179/478
ATGTGTGTGTTTATATTGTTTATCTTCTCCCTATGG
AUGUGUGUGUUUAUAUUGUUUAUCUUCU
MCVFILFIFSLWIKTEFHNYKRLF




ATTAAAACTGAATTTCATAATTATAAGAGGTTATT
CCCUAUGGAUUAAAACUGAAUUUCAUAAU





CTGA
UAUAAGAGGUUAUUCUGA



 


 14
180/479
TTGAATTTTATGTTTATTTATCTTTCCTCTGTCATTA
UUGAAUUUUAUGUUUAUUUAUCUUUCCU
LNFMFIYLSSVIIYNFITHGCILYMFWHYV




TTTATAATTTTATCACACATGGCTGTATCCTTTACA
CUGUCAUUAUUUAUAAUUUUAUCACACAU
FLNFL




TGTTTTGGCATTATGTATTTTTGAACTTTTTGTAA
GGCUGUAUCCUUUACAUGUUUUGGCAUU






AUGUAUUUUUGAACUUUUUGUAA



 


 15
181/480
ATGAAATATTGTCTAGTAATATGTAAAGAGAAGTC
AUGAAAUAUUGUCUAGUAAUAUGUAAAG
MKYCLVICKEKSQEYVMSRCKELLLSPW




TCAAGAATATGTGATGAGCAGATGTAAGGAATTG
AGAAGUCUCAAGAAUAUGUGAUGAGCAGA





CTCTTGTCTCCATGGTGA
UGUAAGGAAUUGCUCUUGUCUCCAUGGU






GA



 


 16
182/481
GTGTTGCCCTTGAAGAATCTGCTTCAAATTGACAC
GUGUUGCCCUUGAAGAAUCUGCUUCAAAU
VLPLKNLLQIDTSELPRNLSSGPMCKAVY




TTCAGAACTCCCCAGAAACTTGTCTTCTGGGCCAA
UGACACUUCAGAACUCCCCAGAAACUUGUC
EEMSSQRGSTTNLAKDNFRRSSWPLGSP




TGTGTAAAGCTGTTTATGAAGAAATGTCAAGCCA
UUCUGGGCCAAUGUGUAAAGCUGUUUAU
GHHELQEVGAIAAA




GAGGGGCTCTACTACAAATTTGGCAAAGGACAAT
GAAGAAAUGUCAAGCCAGAGGGGCUCUAC





TTCAGGAGAAGCTCTTGGCCGCTGGGTTCTCCTGG
UACAAAUUUGGCAAAGGACAAUUUCAGGA





CCACCATGAACTTCAGGAAGTGGGTGCCATAGCA
GAAGCUCUUGGCCGCUGGGUUCUCCUGGC





GCAGCCTGA
CACCAUGAACUUCAGGAAGUGGGUGCCAU






AGCAGCAGCCUGA



 


 17
183/482
ATGCTGGAGATGTCATTTGCATTGCCAGAGTTTGC
AUGCUGGAGAUGUCAUUUGCAUUGCCAGA
MLEMSFALPEFAKGAHRKQIEKHPLGTSL




CAAGGGTGCACACAGAAAGCAGATTGAAAAGCAC
GUUUGCCAAGGGUGCACACAGAAAGCAGA
QCLLLTKFNIINT




CCTCTTGGAACATCTCTCCAATGCCTTCTACTCACA
UUGAAAAGCACCCUCUUGGAACAUCUCUC





AAGTTTAACATCATTAACACGTGA
CAAUGCCUUCUACUCACAAAGUUUAACAU






CAUUAACACGUGA



 


 18
184/483
CTGAATGGTGCAGGAGACCCTCTCACACCAGGTT
CUGAAUGGUGCAGGAGACCCUCUCACACC
LNGAGDPLTPGYPANEYAYRRGIAEAVG




ACCCAGCAAATGAATATGCTTATAGGCGTGGAATT
AGGUUACCCAGCAAAUGAAUAUGCUUAUA
LPSIPVHPIGYYDAQKLLEVVYKILQ




GCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCA
GGCGUGGAAUUGCAGAGGCUGUUGGUCU





TCCAATTGGATACTATGATGCACAGAAGCTCCTAG
UCCAAGUAUUCCUGUUCAUCCAAUUGGAU





AGGTGGTTTATAAAATCCTCCAATGA
ACUAUGAUGCACAGAAGCUCCUAGAGGUG






GUUUAUAAAAUCCUCCAAUGA



 


 19 (BSS)
185/484
CTGAGAACATCAAGAAGTTCTTATAGGTGGTTTAT
CUGAGAACAUCAAGAAGUUCUUAUAGGUG
LRTSRSSYRWFIKSSNEATNITPKHNMKA




AAAATCCTCCAATGAAGCTACTAACATTACTCCAA
GUUUAUAAAAUCCUCCAAUGAAGCUACUA
FLDELKAENIKKFL




AGCATAATATGAAAGCATTTTTGGATGAATTGAAA
ACAUUACUCCAAAGCAUAAUAUGAAAGCA





GCTGAGAACATCAAGAAGTTCTTA
UUUUUGGAUGAAUUGAAAGCUGAGAACA






UCAAGAAGUUCUUA



 


 20 (BSS)
186/485
TTGAACCACCTCCTCCAGGATATGAAAATGTTTCG
UUGAACCACCUCCUCCAGGAUAUGAAAAU
LNHLLQDMKMFRILYHLSVLSLLKECQRF




GATATTGTACCACCTTTCAGTGCTTTCTCTCCTCAA
GUUUCGGAUAUUGUACCACCUUUCAGUGC
STHHYLNHLLQDMKMFRILYHLSVLSLLK




GGAATGCCAGAGATTTTCAACACATCATTATTTGA
UUUCUCUCCUCAAGGAAUGCCAGAGAUUU
ECQ




ACCACCTCCTCCAGGATATGAAAATGTTTCGGATA
UCAACACAUCAUUAUUUGAACCACCUCCUC





TTGTACCACCTTTCAGTGCTTTCTCTCCTCAAGGAA
CAGGAUAUGAAAAUGUUUCGGAUAUUGU





TGCCAG
ACCACCUUUCAGUGCUUUCUCUCCUCAAG






GAAUGCCAG





Nkx3.1






neo-






antigen

DNA sequence
RNA sequence
Protein Sequence





  1
187/486
GTGTGCACACCAAAGCTATTGGAGATTTGCGTGG
GUGUGCACACCAAAGCUAUUGGAGAUUUG
VCTPKLLEICVEISDSSLVRQ




AAATCTCAGATTCTTCACTGGTGAGACAATGA
CGUGGAAAUCUCAGAUUCUUCACUGGUGA






GACAAUGA



 


  2
188/487
ATGGTATGCCAACTTAAGTATTTACAGGGTGGCCC
AUGGUAUGCCAACUUAAGUAUUUACAGGG
MVCQLKYLQGGPNRTRCTRCDFKTSCIN




AAATAGAACAAGATGCACTCGCTGTGATTTTAAGA
UGGCCCAAAUAGAACAAGAUGCACUCGCU
RTPLQEGGPGQENLRLSKTGA




CAAGCTGTATAAACAGAACTCCACTGCAAGAGGG
GUGAUUUUAAGACAAGCUGUAUAAACAGA





GGGGCCGGGCCAGGAGAATCTCCGCTTGTCCAAG
ACUCCACUGCAAGAGGGGGGGCCGGGCCA





ACAGGGGCCTAA
GGAGAAUCUCCGCUUGUCCAAGACAGGGG






CCUAA



 


  3
189/488
ATGAGCAGAGAGCAAAGGAGAAATCTGGCTGTCC
AUGAGCAGAGAGCAAAGGAGAAAUCUGGC
MSREQRRNLAVLPFSFCYLR




TTCCATTTTCATTCTGTTATCTCAGGTGA
UGUCCUUCCAUUUUCAUUCUGUUAUCUCA






GGUGA



 


  4
190/489
TTGGGCTCCACATTGCAATGTTCAATGCCACGTGC
UUGGGCUCCACAUUGCAAUGUUCAAUGCC
LGSTLQCSMPRAADTDRSTSQHKRQGSL




TGCTGACACCGACCGGAGTACTAGCCAGCACAAA
ACGUGCUGCUGACACCGACCGGAGUACUA
NCFLLFTFLLK




AGGCAGGGTAGCCTGAATTGCTTTCTGCTCTTTAC
GCCAGCACAAAAGGCAGGGUAGCCUGAAU





ATTTCTTTTAAAATAA
UGCUUUCUGCUCUUUACAUUUCUUUUAA






AAUAA



 


  5
191/490
CTGAGTACTCTTTCTCTCCCCTCCTCTGAATTTAATT
CUGAGUACUCUUUCUCUCCCCUCCUCUGA
LSTLSLPSSEFNSFNLQFARITHFTVMYIVL




CTTTCAACTTGCAATTTGCAAGGATTACACATTTCA
AUUUAAUUCUUUCAACUUGCAAUUUGCAA
QKKKKSVFV




CTGTGATGTATATTGTGTTGCAAAAAAAAAAAAAA
GGAUUACACAUUUCACUGUGAUGUAUAU





AGTGTCTTTGTTTAA
UGUGUUGCAAAAAAAAAAAAAAAGUGUCU






UUGUUUAA



 


  6
192/491
CTGACAGGTGAATTGGATGGTTCTCAGAACCATTT
CUGACAGGUGAAUUGGAUGGUUCUCAGA
LTGELDGSQNHFTQTACFYPV




CACCCAGACAGCCTGTTTCTATCCTGTTTAA
ACCAUUUCACCCAGACAGCCUGUUUCUAU






CCUGUUUAA



 


  7
193/492
CTGAAAACACTTCAGGCGCCCTTCCAAGGCTTCCC
CUGAAAACACUUCAGGCGCCCUUCCAAGGC
LKTLQAPFQGFPKPLSSRRSAPELPSPTLR




CAAACCCCTAAGCAGCCGCAGAAGCGCTCCCGAG
UUCCCCAAACCCCUAAGCAGCCGCAGAAGC





CTGCCTTCTCCCACACTCAGGTGA
GCUCCCGAGCUGCCUUCUCCCACACUCAGG






UGA



 


  8
194/493
CTGCCTTCCCCAGGGTGTCTCTATGAAAAGCACAA
CUGCCUUCCCCAGGGUGUCUCUAUGAAAA
LPSPGCLYEKHKGPRSGSKRCAHQSYWR




GGGGCCAAGGTCAGGGAGCAAGAGGTGTGCACA
GCACAAGGGGCCAAGGUCAGGGAGCAAGA
FAWKSQILHW




CCAAAGCTATTGGAGATTTGCGTGGAAATCTCAG
GGUGUGCACACCAAAGCUAUUGGAGAUUU





ATTCTTCACTGGTGA
GCGUGGAAAUCUCAGAUUCUUCACUGGUG






A



 


  9
195/494
CTGTTTGAAGGGGAGAGAGGGAAAATCAAGTGG
CUGUUUGAAGGGGAGAGAGGGAAAAUCA
LFEGERGKIKWYFPALCMILDELYTQGFC




TATTTTCCAGCACTTTGTATGATTTTGGATGAGTTG
AGUGGUAUUUUCCAGCACUUUGUAUGAU
SATPSSCVTEYQL




TACACCCAAGGATTCTGTTCTGCAACTCCATCCTCC
UUUGGAUGAGUUGUACACCCAAGGAUUCU





TGTGTCACTGAATATCAACTCTGA
GUUCUGCAACUCCAUCCUCCUGUGUCACU






GAAUAUCAACUCUGA



 


 10
196/495
CTGTTGGCCTTGGAATATGGCCAAGGCTCTCTCTG
CUGUUGGCCUUGGAAUAUGGCCAAGGCUC
LLALEYGQGSLCPCKREGQIESLQENALM




TCCCTGTAAAAGAGAGGGGCAAATAGAGAGTCTC
UCUCUGUCCCUGUAAAAGAGAGGGGCAAA
LSTYLHGRGRWVGGDENISFSYSFLFLLK




CAAGAGAACGCCCTCATGCTCAGCACATATTTGCA
UAGAGAGUCUCCAAGAGAACGCCCUCAUG
WYANLSIYRVAQIEQDALAVILRQAV




TGGGAGGGGGAGATGGGTGGGAGGAGATGAAA
CUCAGCACAUAUUUGCAUGGGAGGGGGAG





ATATCAGCTTTTCTTATTCCTTTTTATTCCTTTTAAA
AUGGGUGGGAGGAGAUGAAAAUAUCAGC





ATGGTATGCCAACTTAAGTATTTACAGGGTGGCCC
UUUUCUUAUUCCUUUUUAUUCCUUUUAA





AAATAGAACAAGATGCACTCGCTGTGATTTTAAGA
AAUGGUAUGCCAACUUAAGUAUUUACAGG





CAAGCTGTATAA
GUGGCCCAAAUAGAACAAGAUGCACUCGC






UGUGAUUUUAAGACAAGCUGUAUAA



 


 11
197/496
CTGGAGAATTTAGAATCAGAAGTTTCCTGGAGTTT
CUGGAGAAUUUAGAAUCAGAAGUUUCCUG
LENLESEVSWSFQAIIYTVS




TCAGGCTATCATATATACTGTATCCTGA
GAGUUUUCAGGCUAUCAUAUAUACUGUA






UCCUGA



 


 12
198/497
TTGGGGGCAGATTCTGAATTGGCTAAAAGACATG
UUGGGGGCAGAUUCUGAAUUGGCUAAAA
LGADSELAKRHAFLKLATLISFL




CATTTTTAAAACTAGCAACTCTTATTTCTTTCCTTTA
GACAUGCAUUUUUAAAACUAGCAACUCUU





A
AUUUCUUUCCUUUAA



 


 13
199/498
TTGAGAATCTTTGCATGCAGAGGAGGTAAGAGGT
UUGAGAAUCUUUGCAUGCAGAGGAGGUA
LRIFACRGGKRYWIFTEEEHSAE




ATTGGATTTTCACAGAGGAAGAACACAGCGCAGA
AGAGGUAUUGGAUUUUCACAGAGGAAGA





ATGA
ACACAGCGCAGAAUGA



 


 14
200/499
CTGTCCAGTGGAGGGCTCATGGGTGGGACATGGA
CUGUCCAGUGGAGGGCUCAUGGGUGGGA
LSSGGLMGGTWKRRQPRPWGAQSTEQ




AAAGAAGGCAGCCTAGGCCCTGGGGAGCCCAGTC
CAUGGAAAAGAAGGCAGCCUAGGCCCUGG
ARD




CACTGAGCAAGCAAGGGACTGA
GGAGCCCAGUCCACUGAGCAAGCAAGGGA






CUGA



 


 15
201/500
GTGAGCCTTTTGCAGGAAAAGGCTAAGAAAAAGG
GUGAGCCUUUUGCAGGAAAAGGCUAAGAA
VSLLQEKAKKKENHSKTQQETVQMLWE




AAAACCATTCTAAAACACAACAAGAAACTGTCCAA
AAAGGAAAACCAUUCUAAAACACAACAAGA
LCLLPIMGPQNG




ATGCTTTGGGAACTGTGTTTATTGCCTATAATGGG
AACUGUCCAAAUGCUUUGGGAACUGUGUU





TCCCCAAAATGGGTAA
UAUUGCCUAUAAUGGGUCCCCAAAAUGGG






UAA



 


 16
202/501
TTGGCCAATTTCACCCCATTTTCTGTGGTTTGGGCT
UUGGCCAAUUUCACCCCAUUUUCUGUGGU
LANFTPFSVVWAPHCNVQCHVLLTPTGV




CCACATTGCAATGTTCAATGCCACGTGCTGCTGAC
UUGGGCUCCACAUUGCAAUGUUCAAUGCC
LASTKGRVA




ACCGACCGGAGTACTAGCCAGCACAAAAGGCAGG
ACGUGCUGCUGACACCGACCGGAGUACUA





GTAGCCTGA
GCCAGCACAAAAGGCAGGGUAGCCUGA



 


 17
203/502
TTGTGTTGCAAAAAAAAAAAAAAAGTGTCTTTGTT
UUGUGUUGCAAAAAAAAAAAAAAAGUGUC
LCCKKKKKVSLFKITWFVNPSCFFPIGTSH




TAAAATTACTTGGTTTGTGAATCCATCTTGCTTTTT
UUUGUUUAAAAUUACUUGGUUUGUGAAU





CCCCATTGGAACTAGTCATTAA
CCAUCUUGCUUUUUCCCCAUUGGAACUAG






UCAUUAA



 


 18
204/503
GTGAATTGGATGGTTCTCAGAACCATTTCACCCAG
GUGAAUUGGAUGGUUCUCAGAACCAUUUC
VNWMVLRTISPRQPVSILFNKLVWVLYM




ACAGCCTGTTTCTATCCTGTTTAATAAATTAGTTTG
ACCCAGACAGCCUGUUUCUAUCCUGUUUA
HNKPCSNLSHKSL




GGTTCTCTACATGCATAACAAACCCTGCTCCAATC
AUAAAUUAGUUUGGGUUCUCUACAUGCA





TGTCACATAAAAGTCTGTGA
UAACAAACCCUGCUCCAAUCUGUCACAUAA






AAGUCUGUGA



 


 19
205/504
CTGCGTGGGCAGCTGGAGCCCAGCTTTTTGGTAA
CUGCGUGGGCAGCUGGAGCCCAGCUUUUU
LRGQLEPSFLVMPAQVTTIMIKNCLPQG




TGCCAGCTCAGGTGACAACCATTATGATCAAAAAC
GGUAAUGCCAGCUCAGGUGACAACCAUUA
VSMKSTRGQGQGARGVHTKAIGDLRGN




TGCCTTCCCCAGGGTGTCTCTATGAAAAGCACAAG
UGAUCAAAAACUGCCUUCCCCAGGGUGUC
LRFFTGETMKQQRQ




GGGCCAAGGTCAGGGAGCAAGAGGTGTGCACAC
UCUAUGAAAAGCACAAGGGGCCAAGGUCA





CAAAGCTATTGGAGATTTGCGTGGAAATCTCAGA
GGGAGCAAGAGGUGUGCACACCAAAGCUA





TTCTTCACTGGTGAGACAATGAAACAACAGAGAC
UUGGAGAUUUGCGUGGAAAUCUCAGAUU





AGTGA
CUUCACUGGUGAGACAAUGAAACAACAGA






GACAGUGA



 


 20
206/505
TTGCTTCTGGCTACCTGTTTGAAGGGGAGAGAGG
UUGCUUCUGGCUACCUGUUUGAAGGGGA
LLLATCLKGREGKSSGIFQHFV




GAAAATCAAGTGGTATTTTCCAGCACTTTGTATGA
GAGAGGGAAAAUCAAGUGGUAUUUUCCAG






CACUUUGUAUGA



 


 21
207/506
ATGGGAGGGGGAGATGGGTGGGAGGAGATGAA
AUGGGAGGGGGAGAUGGGUGGGAGGAGA
MGGGDGWEEMKISAFLIPFYSF




AATATCAGCTTTTCTTATTCCTTTTTATTCCTTTTAA
UGAAAAUAUCAGCUUUUCUUAUUCCUUU






UUAUUCCUUUUAA



 


 22
208/507
CTGTATAAACAGAACTCCACTGCAAGAGGGGGGG
CUGUAUAAACAGAACUCCACUGCAAGAGG
LYKQNSTARGGAGPGESPLVQDRGLRRV




CCGGGCCAGGAGAATCTCCGCTTGTCCAAGACAG
GGGGGCCGGGCCAGGAGAAUCUCCGCUUG
STLLLGAVAFFY




GGGCCTAAGGAGGGTCTCCACACTGCTGCTAGGG
UCCAAGACAGGGGCCUAAGGAGGGUCUCC





GCTGTTGCATTTTTTTATTAG
ACACUGCUGCUAGGGGCUGUUGCAUUUU






UUUAUUAG



 


 23
209/508
CTGTATCCTGAAAGGCAACATAATTCTTCCTTCCCT
CUGUAUCCUGAAAGGCAACAUAAUUCUUC
LYPERQHNSSFPPFKILCSFLQQLLTKGLH




CCTTTTAAAATTTTGTGTTCCTTTTTGCAGCAATTA
CUUCCCUCCUUUUAAAAUUUUGUGUUCCU
FSPDF




CTCACTAAAGGGCTTCATTTTAGTCCAGATTTTTAG
UUUUGCAGCAAUUACUCACUAAAGGGCUU






CAUUUUAGUCCAGAUUUUUAG



 


 24
210/509
ATGCCTCGCTTATTTAGCCCGAGATCTGGTCTTTTT
AUGCCUCGCUUAUUUAGCCCGAGAUCUGG
MPRLFSPRSGLFFFFFFFFSVSPKLYLS




TTTTTTTTTTTTTTTTTTTTTTCCGTCTCCCCAAAGCT
UCUUUUUUUUUUUUUUUUUUUUUUUUU





TTATCTGTCTTGA
UUCCGUCUCCCCAAAGCUUUAUCUGUCUU






GA



 


 25
211/510
TTGCATGCAGAGGAGGTAAGAGGTATTGGATTTT
UUGCAUGCAGAGGAGGUAAGAGGUAUUG
LHAEEVRGIGFSQRKNTAQNEGPGLLSCP




CACAGAGGAAGAACACAGCGCAGAATGAAGGGC
GAUUUUCACAGAGGAAGAACACAGCGCAG
VEGSWVGHGKEGSLGPGEPSPLSKQGTE




CAGGCTTACTGAGCTGTCCAGTGGAGGGCTCATG
AAUGAAGGGCCAGGCUUACUGAGCUGUCC





GGTGGGACATGGAAAAGAAGGCAGCCTAGGCCC
AGUGGAGGGCUCAUGGGUGGGACAUGGA





TGGGGAGCCCAGTCCACTGAGCAAGCAAGGGACT
AAAGAAGGCAGCCUAGGCCCUGGGGAGCC





GAGTGA
CAGUCCACUGAGCAAGCAAGGGACUGAGU






GA



 


 26
212/511
ATGGGTAACCTAGACTTCAGAGAGAATGAGCAGA
AUGGGUAACCUAGACUUCAGAGAGAAUGA
MGNLDFRENEQRAKEKSGCPSIFILLSQV




GAGCAAAGGAGAAATCTGGCTGTCCTTCCATTTTC
GCAGAGAGCAAAGGAGAAAUCUGGCUGUC
SW




ATTCTGTTATCTCAGGTGAGCTGGTAG
CUUCCAUUUUCAUUCUGUUAUCUCAGGUG






AGCUGGUAG



 


 27
213/512
TTGAAGTTTAGTCAGCACCCCCACCAAACTTTATTT
UUGAAGUUUAGUCAGCACCCCCACCAAACU
LKFSQHPHQTLFFYVFFATYECFENKVPM




TTCTATGTGTTTTTTGCAACATATGAGTGTTTTGAA
UUAUUUUUCUAUGUGUUUUUUGCAACAU
SLLDL




AATAAAGTACCCATGTCTTTATTAGATTTA
AUGAGUGUUUUGAAAAUAAAGUACCCAUG






UCUUUAUUAGAUUUA



 


 28 (BSS)
214/513
GTGCGGGCCGGGCGGGTGCATTCAGGCCAAGGC
GUGCGGGCCGGGCGGGUGCAUUCAGGCCA
VRAGRVHSGQGGAAGMLRVPEPRPGEA




GGGGCCGCCGGGATGCTCAGGGTTCCGGAGCCG
AGGCGGGGCCGCCGGGAUGCUCAGGGUUC
KAEGAAPPTPSKPLTSFLIQDILRDGAQR




CGGCCCGGGGAGGCGAAAGCGGAGGGGGCCGC
CGGAGCCGCGGCCCGGGGAGGCGAAAGCG
QGGRTSSQRQRDPEPEPEPEPEGGRSRA




GCCGCCGACCCCGTCCAAGCCGCTCACGTCCTTCC
GAGGGGGCCGCGCCGCCGACCCCGUCCAAG
GAQNDQLSTGPRAAPEEAETLAETEPGG




TCATCCAGGACATCCTGCGGGACGGCGCGCAGCG
CCGCUCACGUCCUUCCUCAUCCAGGACAUC
AGRAGAFRPRRGRRDAQGSGAAARGGE




GCAAGGCGGCCGCACGAGCAGCCAGAGACAGCG
CUGCGGGACGGCGCGCAGCGGCAAGGCGG
SGGGRAADPVQAAHVLPHPGHPAGRRA




CGACCCGGAGCCGGAGCCAGAGCCAGAGCCAGA
CCGCACGAGCAGCCAGAGACAGCGCGACCC
AARRPHEQPETARPGAGARARARGRTQ




GGGAGGACGCAGCCGCGCCGGGGCGCAGAACGA
GGAGCCGGAGCCAGAGCCAGAGCCAGAGG
PRRGAERPAEHRAPRRAGGGRDAGRDR




CCAGCTGAGCACCGGGCCCCGCGCCGCGCCGGAG
GAGGACGCAGCCGCGCCGGGGCGCAGAAC
A




GAGGCCGAGACGCTGGCAGAGACCGAGCCAGGC
GACCAGCUGAGCACCGGGCCCCGCGCCGCG





GGTGCGGGCCGGGCGGGTGCATTCAGGCCAAGG
CCGGAGGAGGCCGAGACGCUGGCAGAGAC





CGGGGCCGCCGGGATGCTCAGGGTTCCGGAGCC
CGAGCCAGGCGGUGCGGGCCGGGCGGGUG





GCGGCCCGGGGAGGCGAAAGCGGAGGGGGCCG
CAUUCAGGCCAAGGCGGGGCCGCCGGGAU





CGCCGCCGACCCCGTCCAAGCCGCTCACGTCCTTC
GCUCAGGGUUCCGGAGCCGCGGCCCGGGG





CTCATCCAGGACATCCTGCGGGACGGCGCGCAGC
AGGCGAAAGCGGAGGGGGCCGCGCCGCCG





GGCAAGGCGGCCGCACGAGCAGCCAGAGACAGC
ACCCCGUCCAAGCCGCUCACGUCCUUCCUC





GCGACCCGGAGCCGGAGCCAGAGCCAGAGCCAG
AUCCAGGACAUCCUGCGGGACGGCGCGCA





AGGGAGGACGCAGCCGCGCCGGGGCGCAGAACG
GCGGCAAGGCGGCCGCACGAGCAGCCAGA





ACCAGCTGAGCACCGGGCCCCGCGCCGCGCCGGA
GACAGCGCGACCCGGAGCCGGAGCCAGAGC





GGAGGCCGAGACGCTGGCAGAGACCGAGCC
CAGAGCCAGAGGGAGGACGCAGCCGCGCC






GGGGCGCAGAACGACCAGCUGAGCACCGG






GCCCCGCGCCGCGCCGGAGGAGGCCGAGAC






GCUGGCAGAGACCGAGCC





NPY neo-






antigen

DNA sequence
RNA sequence
Protein sequence





  1
215/514
CTGGCTCTCACCCCTCGGAGACGCTCGCCCGACAG
CUGGCUCUCACCCCUCGGAGACGCUCGCCC
LALTPRRRSPDSIVLAAQPRPRASHHAR




CATAGTACTTGCCGCCCAGCCACGCCCGCGCGCCA
GACAGCAUAGUACUUGCCGCCCAGCCACGC





GCCACCATGCTAGGTAA
CCGCGCGCCAGCCACCAUGCUAGGUAA



 


  2
216/515
GTGCCTGGGTGCGCTGGCCGAGGCGTACCCCTCC
GUGCCUGGGUGCGCUGGCCGAGGCGUACC
VPGCAGRGVPLQAGQPGRGRTSGGHG




AAGCCGGACAACCCGGGCGAGGACGCACCAGCG
CCUCCAAGCCGGACAACCCGGGCGAGGACG
QILLGAATLHQPHHQAEIWKTIQPRDTD




GAGGACATGGCCAGATACTACTCGGCGCTGCGAC
CACCAGCGGAGGACAUGGCCAGAUACUAC
FRPLDERKHRKCSQNSA




ACTACATCAACCTCATCACCAGGCAGAGATATGGA
UCGGCGCUGCGACACUACAUCAACCUCAUC





AAACGATCCAGCCCAGAGACACTGATTTCAGACCT
ACCAGGCAGAGAUAUGGAAAACGAUCCAG





CTTGATGAGAGAAAGCACAGAAAATGTTCCCAGA
CCCAGAGACACUGAUUUCAGACCUCUUGA





ACTCGGCTTGA
UGAGAGAAAGCACAGAAAAUGUUCCCAGA






ACUCGGCUUGA



 


  3
217/516
GTGGTGATGGGAAATGAGACTTGCTCTCTGGCCT
GUGGUGAUGGGAAAUGAGACUUGCUCUC
VVMGNETCSLAFSYFQPIFHRVKRESTHP




TTTCCTATTTTCAGCCCATATTTCATCGTGTAAAAC
UGGCCUUUUCCUAUUUUCAGCCCAUAUUU
TNACSHCAEFCNVFLCHHCIYVCLNKVSC




GAGAATCCACCCATCCTACCAATGCATGCAGCCAC
CAUCGUGUAAAACGAGAAUCCACCCAUCCU
IQK




TGTGCTGAATTCTGCAATGTTTTCCTTTGTCATCAT
ACCAAUGCAUGCAGCCACUGUGCUGAAUU





TGTATATATGTGTGTTTAAATAAAGTATCATGCAT
CUGCAAUGUUUUCCUUUGUCAUCAUUGU





TCAAAAGTGA
AUAUAUGUGUGUUUAAAUAAAGUAUCAU






GCAUUCAAAAGUGA



 


  4
218/517
ATGCATGCAGCCACTGTGCTGAATTCTGCAATGTT
AUGCAUGCAGCCACUGUGCUGAAUUCUGC
MHAATVLNSAMFSFVIIVYMCV




TTCCTTTGTCATCATTGTATATATGTGTGTTTAA
AAUGUUUUCCUUUGUCAUCAUUGUAUAU






AUGUGUGUUUAA



 


  5
219/518
GTGCGCTGGCCGAGGCGTACCCCTCCAAGCCGGA
GUGCGCUGGCCGAGGCGUACCCCUCCAAG
VRWPRRTPPSRTTRARTHQRRTWPDTT




CAACCCGGGCGAGGACGCACCAGCGGAGGACAT
CCGGACAACCCGGGCGAGGACGCACCAGCG
RRCDTTSTSSPGRDMENDPAQRH




GGCCAGATACTACTCGGCGCTGCGACACTACATCA
GAGGACAUGGCCAGAUACUACUCGGCGCU





ACCTCATCACCAGGCAGAGATATGGAAAACGATC
GCGACACUACAUCAACCUCAUCACCAGGCA





CAGCCCAGAGACACTGA
GAGAUAUGGAAAACGAUCCAGCCCAGAGA






CACUGA



 


  6
220/519
TTGCTCTCTGGCCTTTTCCTATTTTCAGCCCATATTT
UUGCUCUCUGGCCUUUUCCUAUUUUCAGC
LLSGLFLFSAHISSCKTRIHPSYQCMQPLC




CATCGTGTAAAACGAGAATCCACCCATCCTACCAA
CCAUAUUUCAUCGUGUAAAACGAGAAUCC





TGCATGCAGCCACTGTGCTGA
ACCCAUCCUACCAAUGCAUGCAGCCACUGU






GCUGA



 


  7 (BSS)
221/520
CTGATTTCAGACCTCTTGATGAGAGAAAGCACAG
CUGAUUUCAGACCUCUUGAUGAGAGAAAG
LISDLLMRESTENVPRTRYGKRSSPETLIS




AAAATGTTCCCAGAACTCGATATGGAAAACGATCC
CACAGAAAAUGUUCCCAGAACUCGAUAUG
DLLMRESTENVPRT




AGCCCAGAGACACTGATTTCAGACCTCTTGATGAG
GAAAACGAUCCAGCCCAGAGACACUGAUU





AGAAAGCACAGAAAATGTTCCCAGAACT
UCAGACCUCUUGAUGAGAGAAAGCACAGA






AAAUGUUCCCAGAACU



 


  8 (BSS)
222/521
GTGCCTGGGTGCGCTGGCCGAGGCGTACCCCTCC
GUGCCUGGGUGCGCUGGCCGAGGCGUACC
VPGCAGRGVPLQAGQPGRGRTSGGHG




AAGCCGGACAACCCGGGCGAGGACGCACCAGCG
CCUCCAAGCCGGACAACCCGGGCGAGGACG
QILLGAATLHQPHHQAEMLGNKRLGLSG




GAGGACATGGCCAGATACTACTCGGCGCTGCGAC
CACCAGCGGAGGACAUGGCCAGAUACUAC
LTLALSLLVCLGAEAYPSKPDNPGEDAPA




ACTACATCAACCTCATCACCAGGCAGAGATGCTAG
UCGGCGCUGCGACACUACAUCAACCUCAUC
EDMARYYSALRHYINLITRQ




GTAACAAGCGACTGGGGCTGTCCGGACTGACCCT
ACCAGGCAGAGAUGCUAGGUAACAAGCGA





CGCCCTGTCCCTGCTCGTGTGCCTGGGTGCGCTGG
CUGGGGCUGUCCGGACUGACCCUCGCCCU





CCGAGGCGTACCCCTCCAAGCCGGACAACCCGGG
GUCCCUGCUCGUGUGCCUGGGUGCGCUGG





CGAGGACGCACCAGCGGAGGACATGGCCAGATA
CCGAGGCGUACCCCUCCAAGCCGGACAACC





CTACTCGGCGCTGCGACACTACATCAACCTCATCA
CGGGCGAGGACGCACCAGCGGAGGACAUG





CCAGGCAG
GCCAGAUACUACUCGGCGCUGCGACACUAC






AUCAACCUCAUCACCAGGCAG





SPDEF neo-






antigen

DNA sequence
RNA sequence
Protein sequence





  1
223/522
CTGACTTCCTCCCAGCACATTCCTGCACTCTGCCGT
CUGACUUCCUCCCAGCACAUUCCUGCACUC
LTSSQHIPALCRVHTAPQTQSSKPAASSL




GTCCACACTGCCCCACAGACCCAGTCCTCCAAGCC
UGCCGUGUCCACACUGCCCCACAGACCCAG
QAPQVGPCHGASRQPWAGGRGLPTGT




TGCTGCCAGCTCCCTGCAAGCCCCTCAGGTTGGGC
UCCUCCAAGCCUGCUGCCAGCUCCCUGCAA
QP




CTTGCCACGGTGCCAGCAGGCAGCCCTGGGCTGG
GCCCCUCAGGUUGGGCCUUGCCACGGUGC





GGGTAGGGGACTCCCTACAGGCACGCAGCCCTGA
CAGCAGGCAGCCCUGGGCUGGGGGUAGGG






GACUCCCUACAGGCACGCAGCCCUGA



 


  2
224/523
GTGGCCTCAGCTGCCCACACCTCTTCCCGGCCCCT
GUGGCCUCAGCUGCCCACACCUCUUCCCGG
VASAAHTSSRPLKLALQQTAPWAPGS




GAAGTTGGCACTGCAGCAGACAGCTCCCTGGGCA
CCCCUGAAGUUGGCACUGCAGCAGACAGC





CCAGGCAGCTAA
UCCCUGGGCACCAGGCAGCUAA



 


  3
225/524
TTGACATGCTGTACCCTGAGGACAGCAGCTGGGC
UUGACAUGCUGUACCCUGAGGACAGCAGC
LTCCTLRTAAGQPRPLGPAVGRSHLRSLS




AGCCAAGGCCCCTGGGGCCAGCAGTCGGGAGGA
UGGGCAGCCAAGGCCCCUGGGGCCAGCAG
SARSLTAKPQRAAWTWCPAG




GCCACCTGAGGAGCCTGAGCAGTGCCCGGTCATT
UCGGGAGGAGCCACCUGAGGAGCCUGAGC





GACAGCCAAGCCCCAGCGGGCAGCCTGGACTTGG
AGUGCCCGGUCAUUGACAGCCAAGCCCCAG





TGCCCGGCGGGCTGA
CGGGCAGCCUGGACUUGGUGCCCGGCGGG






CUGA



 


  4
226/525
ATGTGCAGAAGTGGCTCCTGTGGACAGAGCACCA
AUGUGCAGAAGUGGCUCCUGUGGACAGAG
MCRSGSCGQSTNTGCPPWARPSRSWR




ATACCGGCTGCCCCCCATGGGCAAGGCCTTCCAG
CACCAAUACCGGCUGCCCCCCAUGGGCAAG
ARSCAPCRRSSSASARPWVGMCCTPTW




GAGCTGGCGGGCAAGGAGCTGTGCGCCATGTCG
GCCUUCCAGGAGCUGGCGGGCAAGGAGCU
TSGSQRPG




GAGGAGCAGTTCCGCCAGCGCTCGCCCCTGGGTG
GUGCGCCAUGUCGGAGGAGCAGUUCCGCC





GGGATGTGCTGCACGCCCACCTGGACATCTGGAA
AGCGCUCGCCCCUGGGUGGGGAUGUGCUG





GTCAGCGGCCTGGATGA
CACGCCCACCUGGACAUCUGGAAGUCAGCG






GCCUGGAUGA



 


  5
227/526
CTGGGGCGATTCACTACTGTGCCTCGACCAGTGA
CUGGGGCGAUUCACUACUGUGCCUCGACC
LGRFTTVPRPVRRAGPTARWTHHAPGSP




GGAGAGCTGGACCGACAGCGAGGTGGACTCATC
AGUGAGGAGAGCUGGACCGACAGCGAGGU
STCGSSSRSCYSSPTAMAASLGGSTRRRA




ATGCTCCGGGCAGCCCATCCACCTGTGGCAGTTCC
GGACUCAUCAUGCUCCGGGCAGCCCAUCCA
SSKLRTQPRWPGCGASARTVPP




TCAAGGAGTTGCTACTCAAGCCCCACAGCTATGGC
CCUGUGGCAGUUCCUCAAGGAGUUGCUAC





CGCTTCATTAGGTGGCTCAACAAGGAGAAGGGCA
UCAAGCCCCACAGCUAUGGCCGCUUCAUUA





TCTTCAAAATTGAGGACTCAGCCCAGGTGGCCCG
GGUGGCUCAACAAGGAGAAGGGCAUCUUC





GCTGTGGGGCATCCGCAAGAACCGTCCCGCCATG
AAAAUUGAGGACUCAGCCCAGGUGGCCCG





A
GCUGUGGGGCAUCCGCAAGAACCGUCCCG






CCAUGA



 


  6
228/527
CTGGCCCAGGGCCTGAAACCCGCCCTCAGGGGCC
CUGGCCCAGGGCCUGAAACCCGCCCUCAGG
LAQGLKPALRGLSPACPASARP




TCTCTCCTGCCTGCCCTGCCTCAGCCAGGCCCTGA
GGCCUCUCUCCUGCCUGCCCUGCCUCAGCC






AGGCCCUGA



 


  7
229/528
CTGACCTTCCAGAGCCCAAGGTCAGGGAGGGGCA
CUGACCUUCCAGAGCCCAAGGUCAGGGAG
LTFQSPRSGRGNQLPQGDMGPLGPSGP




ACCAACTGCCCCAGGGGGATATGGGTCCTCTGGG
GGGCAACCAACUGCCCCAGGGGGAUAUGG
WGRGASSSGPAAPLEDRGRQGCSPTPA




GCCTTCGGGACCCTGGGGCAGGGGTGCTTCCTCC
GUCCUCUGGGGCCUUCGGGACCCUGGGGC
SDPSISRAEPTEGQ




TCAGGCCCAGCTGCTCCCCTGGAGGACAGAGGGA
AGGGGUGCUUCCUCCUCAGGCCCAGCUGC





GACAGGGCTGCTCCCCAACACCTGCCTCTGACCCC
UCCCCUGGAGGACAGAGGGAGACAGGGCU





AGCATTTCCAGAGCAGAGCCTACAGAAGGGCAGT
GCUCCCCAACACCUGCCUCUGACCCCAGCA





GA
UUUCCAGAGCAGAGCCUACAGAAGGGCAG






UGA



 


  8
230/529
ATGGTGCAGGGAGACATCTGCACCCCTGAGTTGG
AUGGUGCAGGGAGACAUCUGCACCCCUGA
MVQGDICTPELGSQECPREWIIKILEN




GCAGCCAGGAGTGCCCCCGGGAATGGATAATAAA
GUUGGGCAGCCAGGAGUGCCCCCGGGAAU





GATACTAGAGAACTGA
GGAUAAUAAAGAUACUAGAGAACUGA



 


  9
231/530
CTGCACTCTGCCGTGTCCACACTGCCCCACAGACC
CUGCACUCUGCCGUGUCCACACUGCCCCAC
LHSAVSTLPHRPSPPSLLPAPCKPLRLGLA




CAGTCCTCCAAGCCTGCTGCCAGCTCCCTGCAAGC
AGACCCAGUCCUCCAAGCCUGCUGCCAGCU
TVPAGSPGLGVGDSLQARSPETSEGHPL




CCCTCAGGTTGGGCCTTGCCACGGTGCCAGCAGG
CCCUGCAAGCCCCUCAGGUUGGGCCUUGC
RVARPPVANLSAASATSPAGPWFRWPP




CAGCCCTGGGCTGGGGGTAGGGGACTCCCTACAG
CACGGUGCCAGCAGGCAGCCCUGGGCUGG
RCLAETRQWPQLPTPLPGP




GCACGCAGCCCTGAGACCTCAGAGGGCCACCCCT
GGGUAGGGGACUCCCUACAGGCACGCAGC





TGAGGGTGGCCAGGCCCCCAGTGGCCAACCTGAG
CCUGAGACCUCAGAGGGCCACCCCUUGAG





TGCTGCCTCTGCCACCAGCCCTGCTGGCCCCTGGT
GGUGGCCAGGCCCCCAGUGGCCAACCUGA





TCCGCTGGCCCCCCAGATGCCTGGCTGAGACACG
GUGCUGCCUCUGCCACCAGCCCUGCUGGCC





CCAGTGGCCTCAGCTGCCCACACCTCTTCCCGGCC
CCUGGUUCCGCUGGCCCCCCAGAUGCCUG





CCTGA
GCUGAGACACGCCAGUGGCCUCAGCUGCCC






ACACCUCUUCCCGGCCCCUGA



 


 10
232/531
CTGGAGTCCCAGTCCACCCGCCACGCCCGAGCAG
CUGGAGUCCCAGUCCACCCGCCACGCCCGA
LESQSTRHARAGPVRLLPLLL




GGCCTGTCCGCCTTCTACCTCTCCTACTTTGA
GCAGGGCCUGUCCGCCUUCUACCUCUCCU






ACUUUGA



 


 11
233/532
CTGCAAGCTGCTCAACATCACCGCAGATCCCATGG
CUGCAAGCUGCUCAACAUCACCGCAGAUCC
LQAAQHHRRSHGLEPQQCAEVAPVDRA




ACTGGAGCCCCAGCAATGTGCAGAAGTGGCTCCT
CAUGGACUGGAGCCCCAGCAAUGUGCAGA
PIPAAPHGQGLPGAGGQGAVRHVGGAV




GTGGACAGAGCACCAATACCGGCTGCCCCCCATG
AGUGGCUCCUGUGGACAGAGCACCAAUAC
PPALAPGWGCAARPPGHLEVSGLDERA




GGCAAGGCCTTCCAGGAGCTGGCGGGCAAGGAG
CGGCUGCCCCCCAUGGGCAAGGCCUUCCAG
DFTWGDSLLCLDQ




CTGTGCGCCATGTCGGAGGAGCAGTTCCGCCAGC
GAGCUGGCGGGCAAGGAGCUGUGCGCCAU





GCTCGCCCCTGGGTGGGGATGTGCTGCACGCCCA
GUCGGAGGAGCAGUUCCGCCAGCGCUCGC





CCTGGACATCTGGAAGTCAGCGGCCTGGATGAAA
CCCUGGGUGGGGAUGUGCUGCACGCCCAC





GAGCGGACTTCACCTGGGGCGATTCACTACTGTG
CUGGACAUCUGGAAGUCAGCGGCCUGGAU





CCTCGACCAGTGA
GAAAGAGCGGACUUCACCUGGGGCGAUUC






ACUACUGUGCCUCGACCAGUGA



 


 12
234/533
CTGGACCGACAGCGAGGTGGACTCATCATGCTCC
CUGGACCGACAGCGAGGUGGACUCAUCAU
LDRQRGGLIMLRAAHPPVAVPQGVATQ




GGGCAGCCCATCCACCTGTGGCAGTTCCTCAAGG
GCUCCGGGCAGCCCAUCCACCUGUGGCAG
APQLWPLH




AGTTGCTACTCAAGCCCCACAGCTATGGCCGCTTC
UUCCUCAAGGAGUUGCUACUCAAGCCCCAC





ATTAG
AGCUAUGGCCGCUUCAUUAG



 


 13
235/534
GTGGGGCATCCGCAAGAACCGTCCCGCCATGAAC
GUGGGGCAUCCGCAAGAACCGUCCCGCCA
VGHPQEPSRHELRQAEPLHPPVLQEGHH




TACGACAAGCTGAGCCGCTCCATCCGCCAGTATTA
UGAACUACGACAAGCUGAGCCGCUCCAUCC
PEARHLPAPRLPVRAPHLSAWPRA




CAAGAAGGGCATCATCCGGAAGCCAGACATCTCC
GCCAGUAUUACAAGAAGGGCAUCAUCCGG





CAGCGCCTCGTCTACCAGTTCGTGCACCCCATCTG
AAGCCAGACAUCUCCCAGCGCCUCGUCUAC





AGTGCCTGGCCCAGGGCCTGA
CAGUUCGUGCACCCCAUCUGAGUGCCUGG






CCCAGGGCCUGA



 


 14
236/535
CTGCCTGCCCTGCCTCAGCCAGGCCCTGAGATGG
CUGCCUGCCCUGCCUCAGCCAGGCCCUGAG
LPALPQPGPEMGENGQSALLL




GGGAAAACGGGCAGTCTGCTCTGCTGCTCTGA
AUGGGGGAAAACGGGCAGUCUGCUCUGCU






GCUCUGA



 


 15
237/536
GTGCTTCCTCCTCAGGCCCAGCTGCTCCCCTGGAG
GUGCUUCCUCCUCAGGCCCAGCUGCUCCCC
VLPPQAQLLPWRTEGDRAAPQHLPLTPA




GACAGAGGGAGACAGGGCTGCTCCCCAACACCTG
UGGAGGACAGAGGGAGACAGGGCUGCUCC
FPEQSLQKGSDSTKATGSPGLSLLHPPAS




CCTCTGACCCCAGCATTTCCAGAGCAGAGCCTACA
CCAACACCUGCCUCUGACCCCAGCAUUUCC
HSAPHLAWCRETSAPLSWAARSAPGNG




GAAGGGCAGTGACTCGACAAAGGCCACAGGCAG
AGAGCAGAGCCUACAGAAGGGCAGUGACU





TCCAGGCCTCTCTCTGCTCCATCCCCCTGCCTCCCA
CGACAAAGGCCACAGGCAGUCCAGGCCUCU





TTCTGCACCACACCTGGCATGGTGCAGGGAGACA
CUCUGCUCCAUCCCCCUGCCUCCCAUUCUG





TCTGCACCCCTGAGTTGGGCAGCCAGGAGTGCCC
CACCACACCUGGCAUGGUGCAGGGAGACA





CCGGGAATGGATAA
UCUGCACCCCUGAGUUGGGCAGCCAGGAG






UGCCCCCGGGAAUGGAUAA



 


 16
238/537
CTGTCTGACTTCCTCCCAGCACATTCCTGCACTCTG
CUGUCUGACUUCCUCCCAGCACAUUCCUGC
LSDFLPAHSCTLPCPHCPTDPVLQACCQL




CCGTGTCCACACTGCCCCACAGACCCAGTCCTCCA
ACUCUGCCGUGUCCACACUGCCCCACAGAC
PASPSGWALPRCQQAALGWG




AGCCTGCTGCCAGCTCCCTGCAAGCCCCTCAGGTT
CCAGUCCUCCAAGCCUGCUGCCAGCUCCCU





GGGCCTTGCCACGGTGCCAGCAGGCAGCCCTGGG
GCAAGCCCCUCAGGUUGGGCCUUGCCACG





CTGGGGGTAG
GUGCCAGCAGGCAGCCCUGGGCUGGGGGU






AG



 


 17
239/538
GTGCCTGGCCCAGGGCCTGAAACCCGCCCTCAGG
GUGCCUGGCCCAGGGCCUGAAACCCGCCCU
VPGPGPETRPQGPLSCLPCLSQALRWGK




GGCCTCTCTCCTGCCTGCCCTGCCTCAGCCAGGCC
CAGGGGCCUCUCUCCUGCCUGCCCUGCCUC
TGSLLCCSDLPEPKVREGQPTAPGGYGSS




CTGAGATGGGGGAAAACGGGCAGTCTGCTCTGCT
AGCCAGGCCCUGAGAUGGGGGAAAACGGG
GAFGTLGQGCFLLRPSCSPGGQRETGLLP




GCTCTGACCTTCCAGAGCCCAAGGTCAGGGAGGG
CAGUCUGCUCUGCUGCUCUGACCUUCCAG
NTCL




GCAACCAACTGCCCCAGGGGGATATGGGTCCTCT
AGCCCAAGGUCAGGGAGGGGCAACCAACU





GGGGCCTTCGGGACCCTGGGGCAGGGGTGCTTCC
GCCCCAGGGGGAUAUGGGUCCUCUGGGGC





TCCTCAGGCCCAGCTGCTCCCCTGGAGGACAGAG
CUUCGGGACCCUGGGGCAGGGGUGCUUCC





GGAGACAGGGCTGCTCCCCAACACCTGCCTCTGA
UCCUCAGGCCCAGCUGCUCCCCUGGAGGAC






AGAGGGAGACAGGGCUGCUCCCCAACACC






UGCCUCUGA



 


 18
240/539
GTGACTCGACAAAGGCCACAGGCAGTCCAGGCCT
GUGACUCGACAAAGGCCACAGGCAGUCCA
VTRQRPQAVQASLCSIPLPPILHHTWHG




CTCTCTGCTCCATCCCCCTGCCTCCCATTCTGCACC
GGCCUCUCUCUGCUCCAUCCCCCUGCCUCC
AGRHLHP




ACACCTGGCATGGTGCAGGGAGACATCTGCACCC
CAUUCUGCACCACACCUGGCAUGGUGCAG





CTGA
GGAGACAUCUGCACCCCUGA





TP53 neo-






antigen

DNA sequence
RNA sequence
Protein sequence





  1
241/540
CTGACATTCTCCACTTCTTGTTCCCCACTGACAGCC
CUGACAUUCUCCACUUCUUGUUCCCCACU
LTFSTSCSPLTASHPHLSLPCHFGFWVFEP




TCCCACCCCCATCTCTCCCTCCCCTGCCATTTTGGG
GACAGCCUCCCACCCCCAUCUCUCCCUCCCC
LLAIGVRQKHPGLPFALSRGSTEQVGLH




TTTTGGGTCTTTGAACCCTTGCTTGCAATAGGTGT
UGCCAUUUUGGGUUUUGGGUCUUUGAAC
WCFVVGRRMGSRTYQLRF




GCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGT
CCUUGCUUGCAAUAGGUGUGCGUCAGAAG





CCCGGGGCTCCACTGAACAAGTTGGCCTGCACTG
CACCCAGGACUUCCAUUUGCUUUGUCCCG





GTGTTTTGTTGTGGGGAGGAGGATGGGGAGTAG
GGGCUCCACUGAACAAGUUGGCCUGCACU





GACATACCAGCTTAGATTTTAA
GGUGUUUUGUUGUGGGGAGGAGGAUGG






GGAGUAGGACAUACCAGCUUAGAUUUUAA



 


  2
242/541
TTGGGCAGCTGGTTAGGTAGAGGGAGTTGTCAAG
UUGGGCAGCUGGUUAGGUAGAGGGAGUU
LGSWLGRGSCQVSAGPAKPCLTTSW




TCTCTGCTGGCCCAGCCAAACCCTGTCTGACAACC
GUCAAGUCUCUGCUGGCCCAGCCAAACCCU





TCTTGGTGA
GUCUGACAACCUCUUGGUGA



 


  3
243/542
ATGGGATTGGGGTTTTCCCCTCCCATGTGCTCAAG
AUGGGAUUGGGGUUUUCCCCUCCCAUGU
MGLGFSPPMCSRLALKVLSFSKV




ACTGGCGCTAAAAGTTTTGAGCTTCTCAAAAGTCT
GCUCAAGACUGGCGCUAAAAGUUUUGAGC





AG
UUCUCAAAAGUCUAG



 


  4
244/543
TTGTTCCCTCTCCCTGTTGGTCGGTGGGTTGGTAG
UUGUUCCCUCUCCCUGUUGGUCGGUGGG
LFPLPVGRWVGSFYSWAAG




TTTCTACAGTTGGGCAGCTGGTTAG
UUGGUAGUUUCUACAGUUGGGCAGCUGG






UUAG



 


  5
245/544
CTGACTCAGACTGACATTCTCCACTTCTTGTTCCCC
CUGACUCAGACUGACAUUCUCCACUUCUU
LTQTDILHFLFPTDSLPPPSLPPLPFWVLG




ACTGACAGCCTCCCACCCCCATCTCTCCCTCCCCTG
GUUCCCCACUGACAGCCUCCCACCCCCAUC
L




CCATTTTGGGTTTTGGGTCTTTGA
UCUCCCUCCCCUGCCAUUUUGGGUUUUGG






GUCUUUGA



 


  6
246/545
CTGTCCCTCACTGTTGAATTTTCTCTAACTTCAAGG
CUGUCCCUCACUGUUGAAUUUUCUCUAAC
LSLTVEFSLTSRPISVKCWHLHLPHRVHCE




CCCATATCTGTGAAATGCTGGCATTTGCACCTACC
UUCAAGGCCCAUAUCUGUGAAAUGCUGGC
G




TCACAGAGTGCATTGTGAGGGTTAA
AUUUGCACCUACCUCACAGAGUGCAUUGU






GAGGGUUAA



 


  7
247/546
CTGGCCTTGAAACCACCTTTTATTACATGGGGTCT
CUGGCCUUGAAACCACCUUUUAUUACAUG
LALKPPFITWGLELDPLEGACSLSLLVGGL




AGAACTTGACCCCCTTGAGGGTGCTTGTTCCCTCT
GGGUCUAGAACUUGACCCCCUUGAGGGUG
VVSTVGQLVR




CCCTGTTGGTCGGTGGGTTGGTAGTTTCTACAGTT
CUUGUUCCCUCUCCCUGUUGGUCGGUGGG





GGGCAGCTGGTTAGGTAG
UUGGUAGUUUCUACAGUUGGGCAGCUGG






UUAGGUAG



 


  8
248/547
TTGTCAAGTCTCTGCTGGCCCAGCCAAACCCTGTC
UUGUCAAGUCUCUGCUGGCCCAGCCAAAC
LSSLCWPSQTLSDNLLVNLST




TGACAACCTCTTGGTGAACCTTAGTACCTAA
CCUGUCUGACAACCUCUUGGUGAACCUUA






GUACCUAA



 


  9
249/548
CTGGATCCACCAAGACTTGTTTTATGCTCAGGGTC
CUGGAUCCACCAAGACUUGUUUUAUGCUC
LDPPRLVLCSGSISFFFFFFFFLFL




AATTTCTTTTTTCTTTTTTTTTTTTTTTTTTCTTTTTCT
AGGGUCAAUUUCUUUUUUCUUUUUUUUU





TTGA
UUUUUUUUUCUUUUUCUUUGA



 


 10
250/549
GTGTTGCCCAGGCTGGTCTCAAACTCCTGGGCTCA
GUGUUGCCCAGGCUGGUCUCAAACUCCU
GVLPRLVSNSWAQAIHLSQPPRVLGLQL




GGCGATCCACCTGTCTCAGCCTCCCAGAGTGCTGG
GGCUCAGGCGAUCCACCUGUCUCAGCCUCC





GATTACAATTGTGA
CAGAGUGCUGGGAUUACAAUUGUGA





ERG neo-






antigen

DNA sequences
RNA sequences
Protein sequences





  1
251/550
CTGGACCGGTCACGGCCACCCCACGCCCCAGTCG
CUGGACCGGUCACGGCCACCCCACGCCCCA
LDRSRPPHAPVESCSTISFHSAQN




AAAGCTGCTCAACCATCTCCTTCCACAGTGCCCAA
GUCGAAAGCUGCUCAACCAUCUCCUUCCAC





AACTGA
AGUGCCCAAAACUGA



 


  2
252/551
TTGGCAGTTCCTCCTGGAGCTCCTGTCGGACAGCT
UUGGCAGUUCCUCCUGGAGCUCCUGUCGG
LAVPPGAPVGQLQLQLHHLGRHQRGVQ




CCAACTCCAGCTGCATCACCTGGGAAGGCACCAA
ACAGCUCCAACUCCAGCUGCAUCACCUGGG
DDGSRRGGPALGRAEEQTQHELR




CGGGGAGTTCAAGATGACGGATCCCGACGAGGT
AAGGCACCAACGGGGAGUUCAAGAUGACG





GGCCCGGCGCTGGGGAGAGCGGAAGAGCAAACC
GAUCCCGACGAGGUGGCCCGGCGCUGGGG





CAACATGAACTACGATAA
AGAGCGGAAGAGCAAACCCAACAUGAACUA






CGAUAA



 


  3
253/552
GTGGCCCATCAACAGACGTTGATATGCAACTGCAT
GUGGCCCAUCAACAGACGUUGAUAUGCAA
VAHQQTLICNCMACAVLVEIKYIPFDGQL




GGCATGTGCTGTTTTGGTTGAAATCAAATACATTC
CUGCAUGGCAUGUGCUGUUUUGGUUGAA
SAFSNCEDDPKFPTPLQYYRDYELKGGTE




CGTTTGATGGACAGCTGTCAGCTTTCTCAAACTGT
AUCAAAUACAUUCCGUUUGAUGGACAGCU
DVYRVSV




GAAGATGACCCAAAGTTTCCAACTCCTTTACAGTA
GUCAGCUUUCUCAAACUGUGAAGAUGACC





TTACCGGGACTATGAACTAAAAGGTGGGACTGAG
CAAAGUUUCCAACUCCUUUACAGUAUUAC





GATGTGTATAGAGTGAGCGTGTGA
CGGGACUAUGAACUAAAAGGUGGGACUGA






GGAUGUGUAUAGAGUGAGCGUGUGA



 


  4
254/553
CTGGACTCAGGACATTTGGGGACTGTGTACAATG
CUGGACUCAGGACAUUUGGGGACUGUGU
LDSGHLGTVYNELWRLEGSCSQCYTKPS




AGTTATGGAGACTCGAGGGTTCATGCAGTCAGTG
ACAAUGAGUUAUGGAGACUCGAGGGUUCA
VRRKDTA




TTATACCAAACCCAGTGTTAGGAGAAAGGACACA
UGCAGUCAGUGUUAUACCAAACCCAGUGU





GCGTAA
UAGGAGAAAGGACACAGCGUAA



 


  5
255/554
ATGGCCTTCTTGGCTGCCACAATCAGAAATCACGC
AUGGCCUUCUUGGCUGCCACAAUCAGAAA
MAFLAATIRNHAGILGRRPPVFL




AGGCATTTTGGGTAGGCGGCCTCCAGTTTTCCTTT
UCACGCAGGCAUUUUGGGUAGGCGGCCUC





GA
CAGUUUUCCUUUGA



 


  6
256/555
ATGCTTAATGTTTACAATATGAAGTTATTAGTTCTT
AUGCUUAAUGUUUACAAUAUGAAGUUAU
MLNVYNMKLLVLRMQNVCNKISLA




AGAATGCAGAATGTATGTAATAAAATAAGCTTGG
UAGUUCUUAGAAUGCAGAAUGUAUGUAA





CCTAG
UAAAAUAAGCUUGGCCUAG



 


  7
257/556
TTGGGATTCACTAGCCCTGAGCCTGATGTTGCTGG
UUGGGAUUCACUAGCCCUGAGCCUGAUGU
LGFTSPEPDVAGYPLKTMFISII




CTATCCCTTGAAGACAATGTTTATTTCCATAATCTA
UGCUGGCUAUCCCUUGAAGACAAUGUUUA





G
UUUCCAUAAUCUAG



 


  8
258/557
ATGTTTTCCATTAGATCCCTCAACCCTCCACCCCCA
AUGUUUUCCAUUAGAUCCCUCAACCCUCC
MFSIRSLNPPPPVQVISKSYEQLG




GTCCAGGTTATTAGCAAGTCTTATGAGCAACTGG
ACCCCCAGUCCAGGUUAUUAGCAAGUCUU





GATAA
AUGAGCAACUGGGAUAA



 


  9
259/558
GTGGCACCTGCAACCCAGGAGCAGGAGCCGGAG
GUGGCACCUGCAACCCAGGAGCAGGAGCC
VAPATQEQEPEELPSDSRCSRDGYSSGA




GAGCTGCCCTCTGACAGCAGGTGCAGCAGAGATG
GGAGGAGCUGCCCUCUGACAGCAGGUGCA
GKVMGHRESTDVLQRPKVTHCLEKEKKI




GCTACAGCTCAGGAGCTGGGAAGGTGATGGGGC
GCAGAGAUGGCUACAGCUCAGGAGCUGGG
FFKKLVYLASH




ACAGGGAAAGCACAGATGTTCTGCAGCGCCCCAA
AAGGUGAUGGGGCACAGGGAAAGCACAGA





AGTGACCCATTGCCTGGAGAAAGAGAAGAAAATA
UGUUCUGCAGCGCCCCAAAGUGACCCAUU





TTTTTTAAAAAGCTAGTTTATTTAGCTTCTCATTAA
GCCUGGAGAAAGAGAAGAAAAUAUUUUUU






AAAAAGCUAGUUUAUUUAGCUUCUCAUUA






A



 


 10
260/559
ATGAATCAAAAGTGCCTCAAGAGGAATGAAAAAA
AUGAAUCAAAAGUGCCUCAAGAGGAAUGA
MNQKCLKRNEKSFTGAGEGSRGRDPKTL




GCTTTACTGGGGCTGGGGAAGGAAGCCGGGGAA
AAAAAGCUUUACUGGGGCUGGGGAAGGAA
GRELLKSYYRNEEDAKNVTNMDISSVD




GAGATCCAAAGACTCTTGGGAGGGAGTTACTGAA
GCCGGGGAAGAGAUCCAAAGACUCUUGGG





GTCTTACTACAGAAATGAGGAGGATGCTAAAAAT
AGGGAGUUACUGAAGUCUUACUACAGAAA





GTCACGAATATGGACATATCATCTGTGGACTGA
UGAGGAGGAUGCUAAAAAUGUCACGAAUA






UGGACAUAUCAUCUGUGGACUGA



 


 11
261/560
GTGCTGTTTTGGTTGAAATCAAATACATTCCGTTT
GUGCUGUUUUGGUUGAAAUCAAAUACAU
VLFWLKSNTFRLMDSCQLSQTVKMTQSF




GATGGACAGCTGTCAGCTTTCTCAAACTGTGAAG
UCCGUUUGAUGGACAGCUGUCAGCUUUCU
QLLYSITGTMN




ATGACCCAAAGTTTCCAACTCCTTTACAGTATTACC
CAAACUGUGAAGAUGACCCAAAGUUUCCA





GGGACTATGAACTAA
ACUCCUUUACAGUAUUACCGGGACUAUGA






ACUAA



 


 12
262/561
CTGTGTACAATGAGTTATGGAGACTCGAGGGTTC
CUGUGUACAAUGAGUUAUGGAGACUCGA
LCTMSYGDSRVHAVSVIPNPVLGERTQR




ATGCAGTCAGTGTTATACCAAACCCAGTGTTAGGA
GGGUUCAUGCAGUCAGUGUUAUACCAAAC
NGERGSSRIQKQKCASLSLFVK




GAAAGGACACAGCGTAATGGAGAAAGGGGAAGT
CCAGUGUUAGGAGAAAGGACACAGCGUAA





AGTAGAATTCAGAAACAAAAATGCGCATCTCTTTC
UGGAGAAAGGGGAAGUAGUAGAAUUCAG





TTTGTTTGTCAAATGA
AAACAAAAAUGCGCAUCUCUUUCUUUGUU






UGUCAAAUGA



 


 13
263/562
GTGGGGGCTTTGTTCTCCACAGGGTCAGGTAAGA
GUGGGGGCUUUGUUCUCCACAGGGUCAG
VGALFSTGSGKRWPSWLPQSEITQAFW




GATGGCCTTCTTGGCTGCCACAATCAGAAATCACG
GUAAGAGAUGGCCUUCUUGGCUGCCACAA
VGGLQFSFESRTLCVCQNEVYKSMFFPLF




CAGGCATTTTGGGTAGGCGGCCTCCAGTTTTCCTT
UCAGAAAUCACGCAGGCAUUUUGGGUAGG
I




TGAGTCGCGAACGCTGTGCGTTTGTCAGAATGAA
CGGCCUCCAGUUUUCCUUUGAGUCGCGAA





GTATACAAGTCAATGTTTTTCCCCCTTTTTATATAA
CGCUGUGCGUUUGUCAGAAUGAAGUAUAC






AAGUCAAUGUUUUUCCCCCUUUUUAUAUA






A



 


 14
264/563
ATGAAAACATGTGCTGAATGTTGTGGATTTTGTGT
AUGAAAACAUGUGCUGAAUGUUGUGGAU
MKTCAECCGFCVIIYFVQELVQGRAKEIG




TATAATTTACTTTGTCCAGGAACTTGTGCAAGGGA
UUUGUGUUAUAAUUUACUUUGUCCAGGA
CLAPKWRQPLQVLLASPPVFYF




GAGCCAAGGAAATAGGATGTTTGGCACCCAAATG
ACUUGUGCAAGGGAGAGCCAAGGAAAUAG





GCGTCAGCCTCTCCAGGTCCTTCTTGCCTCCCCTCC
GAUGUUUGGCACCCAAAUGGCGUCAGCCU





TGTCTTTTATTTCTAG
CUCCAGGUCCUUCUUGCCUCCCCUCCUGUC






UUUUAUUUCUAG



 


 15
265/564
TTGGAACAGAAGGACCCCGGGTTTCACATTGGAG
UUGGAACAGAAGGACCCCGGGUUUCACAU
LEQKDPGFHIGASIFMPGMERGL




CCTCCATATTTATGCCTGGAATGGAAAGAGGCCTA
UGGAGCCUCCAUAUUUAUGCCUGGAAUGG





TGA
AAAGAGGCCUAUGA



 


 16
266/565
GTGAACAAGCTACCACTCGTAAGGCAAACTGTATT
GUGAACAAGCUACCACUCGUAAGGCAAAC
VNKLPLVRQTVLLLANKASWIAAISHFTET




ATTACTGGCAAATAAAGCGTCATGGATAGCTGCA
UGUAUUAUUACUGGCAAAUAAAGCGUCAU
RDNV




ATTTCTCACTTTACAGAAACAAGGGATAACGTCTA
GGAUAGCUGCAAUUUCUCACUUUACAGAA





G
ACAAGGGAUAACGUCUAG



 


 17
267/566
CTGCTACATCAGAGTTACCTGGGCACTGTGGCTTG
CUGCUACAUCAGAGUUACCUGGGCACUGU
LLHQSYLGTVAWDSLALSLMLLAIP




GGATTCACTAGCCCTGAGCCTGATGTTGCTGGCTA
GGCUUGGGAUUCACUAGCCCUGAGCCUGA





TCCCTTGA
UGUUGCUGGCUAUCCCUUGA



 


 18
268/567
ATGCTGCCAACCTTGGTCCAGGTGAAGGCAACTC
AUGCUGCCAACCUUGGUCCAGGUGAAGGC
MLPTLVQVKATQKVKIQGDRAKALAETS




AAAAGGTGAAAATACAAGGTGACCGTGCGAAGG
AACUCAAAAGGUGAAAAUACAAGGUGACC





CGCTAGCCGAAACATCTTAG
GUGCGAAGGCGCUAGCCGAAACAUCUUAG



 


 19
269/568
GTGCTGTGGATGTTTTGGCAGTGGGCTTTGAAGT
GUGCUGUGGAUGUUUUGGCAGUGGGCUU
VLWMFWQWALKSAGHDYQCS




CGGCAGGACACGATTACCAATGCTCCTGA
UGAAGUCGGCAGGACACGAUUACCAAUGC






UCCUGA



 


 20
270/569
GTGTCATTTGGATTAGACGGAGCCCAACCATCCAT
GUGUCAUUUGGAUUAGACGGAGCCCAACC
VSFGLDGAQPSIILQQPGKAHKVPVSP




CATTTTGCAGCAGCCTGGGAAGGCCCACAAAGTG
AUCCAUCAUUUUGCAGCAGCCUGGGAAGG





CCCGTATCTCCTTAG
CCCACAAAGUGCCCGUAUCUCCUUAG



 


 21
271/570
ATGATTATCATATTCAATTTTAACAGATGTTTTCCA
AUGAUUAUCAUAUUCAAUUUUAACAGAUG
MIIIFNFNRCFPLDPSTLHPQSRLLASLMS




TTAGATCCCTCAACCCTCCACCCCCAGTCCAGGTT
UUUUCCAUUAGAUCCCUCAACCCUCCACCC
NWDNFG




ATTAGCAAGTCTTATGAGCAACTGGGATAATTTTG
CCAGUCCAGGUUAUUAGCAAGUCUUAUGA





GATAA
GCAACUGGGAUAAUUUUGGAUAA



 


 22
272/571
CTGTACAATCTTACTCCTGCTGGCAAGAGATTTGT
CUGUACAAUCUUACUCCUGCUGGCAAGAG
LYNLTPAGKRFVFFSCLQLAFGPCMW




CTTCTTTTCTTGTCTTCAATTGGCTTTCGGGCCTTG
AUUUGUCUUCUUUUCUUGUCUUCAAUUG





TATGTGGTAA
GCUUUCGGGCCUUGUAUGUGGUAA



 


 23
273/572
ATGTGGCACCTGCAACCCAGGAGCAGGAGCCGGA
AUGUGGCACCUGCAACCCAGGAGCAGGAG
MWHLQPRSRSRRSCPLTAGAAEMATAQ




GGAGCTGCCCTCTGACAGCAGGTGCAGCAGAGAT
CCGGAGGAGCUGCCCUCUGACAGCAGGUG
ELGR




GGCTACAGCTCAGGAGCTGGGAAGGTGA
CAGCAGAGAUGGCUACAGCUCAGGAGCUG






GGAAGGUGA



 


 24
274/573
GTGAGGACCAGTCGTTGTTTGAGTGTGCCTACGG
GUGAGGACCAGUCGUUGUUUGAGUGUGC
VRTSRCLSVPTERHTWLRQR




AACGCCACACCTGGCTAAGACAGAGATGA
CUACGGAACGCCACACCUGGCUAAGACAGA






GAUGA



 


 25
275/574
ATGGCTCAAGGAACTCTCCTGATGAATGCAGTGT
AUGGCUCAAGGAACUCUCCUGAUGAAUGC
MAQGTLLMNAVWPKAGRWWAAQTPL




GGCCAAAGGCGGGAAGATGGTGGGCAGCCCAGA
AGUGUGGCCAAAGGCGGGAAGAUGGUGG
G




CACCGTTGGGATGA
GCAGCCCAGACACCGUUGGGAUGA



 


 26
276/575
ATGGCCTTCCAGACGTCAACATCTTGTTATTCCAG
AUGGCCUUCCAGACGUCAACAUCUUGUUA
MAFQTSTSCYSRTSMGRNCAR




AACATCGATGGGAAGGAACTGTGCAAGATGA
UUCCAGAACAUCGAUGGGAAGGAACUGUG






CAAGAUGA



 


 27
277/576
ATGCTAGAAACACAGGGGGTGCAGCTTTTATTTTC
AUGCUAGAAACACAGGGGGUGCAGCUUUU
MLETQGVQLLFSQ1LQYILKLRKELQLGQI




CCAAATACTTCAGTATATCCTGAAGCTACGCAAAG
AUUUUCCCAAAUACUUCAGUAUAUCCUGA
YHMSPPGDQPGPVTATPRPSRKLLNHLL




AATTACAACTAGGCCAGATTTACCATATGAGCCCC
AGCUACGCAAAGAAUUACAACUAGGCCAG
PQCPKLKTSVLS




CCAGGAGATCAGCCTGGACCGGTCACGGCCACCC
AUUUACCAUAUGAGCCCCCCAGGAGAUCA





CACGCCCCAGTCGAAAGCTGCTCAACCATCTCCTT
GCCUGGACCGGUCACGGCCACCCCACGCCC





CCACAGTGCCCAAAACTGAAGACCAGCGTCCTCA
CAGUCGAAAGCUGCUCAACCAUCUCCUUCC





GTTAG
ACAGUGCCCAAAACUGAAGACCAGCGUCCU






CAGUUAG



 


 28
278/577
TTGGACCAACAAGTAGCCGCCTTGCAAATCCAGG
UUGGACCAACAAGUAGCCGCCUUGCAAAU
LDQQVAALQIQAVARSSFGSSSWSSCRT




CAGTGGCCAGATCCAGCTTTGGCAGTTCCTCCTGG
CCAGGCAGUGGCCAGAUCCAGCUUUGGCA
APTPAASPGKAPTGSSR




AGCTCCTGTCGGACAGCTCCAACTCCAGCTGCATC
GUUCCUCCUGGAGCUCCUGUCGGACAGCU





ACCTGGGAAGGCACCAACGGGGAGTTCAAGATG
CCAACUCCAGCUGCAUCACCUGGGAAGGCA





A
CCAACGGGGAGUUCAAGAUGA



 


 29
279/578
ATGGGAAGCGCTACGCCTACAAGTTCGACTTCCAC
AUGGGAAGCGCUACGCCUACAAGUUCGAC
MGSATPTSSTSTGSPRPSSPTPRSHLCTST




GGGATCGCCCAGGCCCTCCAGCCCCACCCCCCGG
UUCCACGGGAUCGCCCAGGCCCUCCAGCCC
PQTSRTWAPITPTHRR




AGTCATCTCTGTACAAGTACCCCTCAGACCTCCCG
CACCCCCCGGAGUCAUCUCUGUACAAGUAC





TACATGGGCTCCTATCACGCCCACCCACAGAAGAT
CCCUCAGACCUCCCGUACAUGGGCUCCUAU





GA
CACGCCCACCCACAGAAGAUGA



 


 30
280/579
TTGCTGCCCCAAACCCATACTGGAATTCACCAACT
UUGCUGCCCCAAACCCAUACUGGAAUUCAC
LLPQTHTGIHQLGVYTPTLGSPPAICLLIW




GGGGGTATATACCCCAACACTAGGCTCCCCACCA
CAACUGGGGGUAUAUACCCCAACACUAGG
ALTTKDLAEAFPISVHSPAHRHKLYRRT




GCCATATGCCTTCTCATCTGGGCACTTACTACTAA
CUCCCCACCAGCCAUAUGCCUUCUCAUCUG





AGACCTGGCGGAGGCTTTTCCCATCAGCGTGCATT
GGCACUUACUACUAAAGACCUGGCGGAGG





CACCAGCCCATCGCCACAAACTCTATCGGAGAACA
CUUUUCCCAUCAGCGUGCAUUCACCAGCCC





TGA
AUCGCCACAAACUCUAUCGGAGAACAUGA



 


 31
281/580
ATGAAAAAAGCTTTACTGGGGCTGGGGAAGGAA
AUGAAAAAAGCUUUACUGGGGCUGGGGAA
MKKALLGLGKEAGEEIQRLLGGSY




GCCGGGGAAGAGATCCAAAGACTCTTGGGAGGG
GGAAGCCGGGGAAGAGAUCCAAAGACUCU





AGTTACTGA
UGGGAGGGAGUUACUGA



 


 32
282/581
ATGAGGAGGATGCTAAAAATGTCACGAATATGGA
AUGAGGAGGAUGCUAAAAAUGUCACGAAU
MRRMLKMSRIWTYHLWTDLVKDSVCRS




CATATCATCTGTGGACTGACCTTGTAAAAGACAGT
AUGGACAUAUCAUCUGUGGACUGACCUUG
MKS




GTATGTAGAAGCATGAAGTCTTAA
UAAAAGACAGUGUAUGUAGAAGCAUGAAG






UCUUAA



 


 33
283/582
CTGTATTTAAAAATAGAAACATATCAAAAACAAGA
CUGUAUUUAAAAAUAGAAACAUAUCAAAA
LYLKIETYQKQEKRHERDCGPSTDVDMQ




GAAAAGACACGAGAGAGACTGTGGCCCATCAACA
ACAAGAGAAAAGACACGAGAGAGACUGUG
LHGMCCFG




GACGTTGATATGCAACTGCATGGCATGTGCTGTTT
GCCCAUCAACAGACGUUGAUAUGCAACUG





TGGTTGA
CAUGGCAUGUGCUGUUUUGGUUGA



 


 34
284/583
GTGATTGTAGACAGAGGGGTGAAGAAGGAGGAG
GUGAUUGUAGACAGAGGGGUGAAGAAGG
VIVDRGVKKEEEEAEKEETRAGKETSQA




GAAGAGGCAGAGAAGGAGGAGACCAGGGCTGG
AGGAGGAAGAGGCAGAGAAGGAGGAGACC
MKTGLRTFGDCVQ




GAAAGAAACTTCTCAAGCAATGAAGACTGGACTC
AGGGCUGGGAAAGAAACUUCUCAAGCAAU





AGGACATTTGGGGACTGTGTACAATGA
GAAGACUGGACUCAGGACAUUUGGGGACU






GUGUACAAUGA



 


 35
285/584
ATGGAGAAAGGGGAAGTAGTAGAATTCAGAAAC
AUGGAGAAAGGGGAAGUAGUAGAAUUCA
MEKGEVVEFRNKNAHLFLCLSNENFNW




AAAAATGCGCATCTCTTTCTTTGTTTGTCAAATGAA
GAAACAAAAAUGCGCAUCUCUUUCUUUGU
NCLIFKRNIQDLIIMWGLCSPQGQVRDG




AATTTTAACTGGAATTGTCTGATATTTAAGAGAAA
UUGUCAAAUGAAAAUUUUAACUGGAAUU
LLGCHNQKSRRHFG




CATTCAGGACCTCATCATTATGTGGGGGCTTTGTT
GUCUGAUAUUUAAGAGAAACAUUCAGGAC





CTCCACAGGGTCAGGTAAGAGATGGCCTTCTTGG
CUCAUCAUUAUGUGGGGGCUUUGUUCUC





CTGCCACAATCAGAAATCACGCAGGCATTTTGGGT
CACAGGGUCAGGUAAGAGAUGGCCUUCUU





AG
GGCUGCCACAAUCAGAAAUCACGCAGGCA






UUUUGGGUAG



 


 36
286/585
TTGAGTCGCGAACGCTGTGCGTTTGTCAGAATGA
UUGAGUCGCGAACGCUGUGCGUUUGUCA
LSRERCAFVRMKYTSQCFSPFLYNNYITY




AGTATACAAGTCAATGTTTTTCCCCCTTTTTATATA
GAAUGAAGUAUACAAGUCAAUGUUUUUCC
AFIHYELISASQRHTTKETIDIMWP




ATAATTATATAACTTATGCATTTATACACTACGAGT
CCCUUUUUAUAUAAUAAUUAUAUAACUUA





TGATCTCGGCCAGCCAAAGACACACGACAAAAGA
UGCAUUUAUACACUACGAGUUGAUCUCGG





GACAATCGATATAATGTGGCCTTGA
CCAGCCAAAGACACACGACAAAAGAGACAA






UCGAUAUAAUGUGGCCUUGA



 


 37
287/586
TTGCCTCCCCTCCTGTCTTTTATTTCTAGCCCCTTTT
UUGCCUCCCCUCCUGUCUUUUAUUUCUAG
LPPLLSFISSPFWNRRTPGFTLEPPYLCLE




GGAACAGAAGGACCCCGGGTTTCACATTGGAGCC
CCCCUUUUGGAACAGAAGGACCCCGGGUU
WKEAYEAGVVIEKF




TCCATATTTATGCCTGGAATGGAAAGAGGCCTATG
UCACAUUGGAGCCUCCAUAUUUAUGCCUG





AAGCTGGGGTTGTCATTGAGAAATTCTAG
GAAUGGAAAGAGGCCUAUGAAGCUGGGG






UUGUCAUUGAGAAAUUCUAG



 


 38
288/587
CTGCAATTTCTCACTTTACAGAAACAAGGGATAAC
CUGCAAUUUCUCACUUUACAGAAACAAGG
LQFLTLQKQGITSRFAAGFLFQELSLGRQL




GTCTAGATTTGCTGCGGGGTTTCTCTTTCAGGAGC
GAUAACGUCUAGAUUUGCUGCGGGGUUU





TCTCACTAGGTAGACAGCTTTAG
CUCUUUCAGGAGCUCUCACUAGGUAGACA






GCUUUAG



 


 39
289/588
CTGGCAGTTAGGCTGACCCAAACTGTGCTAATGG
CUGGCAGUUAGGCUGACCCAAACUGUGCU
LAVRLTQTVLMEKISHFYFGMQSQDTPT




AAAAGATCAGTCATTTTTATTTTGGAATGCAAAGT
AAUGGAAAAGAUCAGUCAUUUUUAUUUU
FFIEIHIYLDNHSVLSSRLSHEQDHKNKT




CAAGACACACCTACATTCTTCATAGAAATACACAT
GGAAUGCAAAGUCAAGACACACCUACAUU





TTACTTGGATAATCACTCAGTTCTCTCTTCAAGACT
CUUCAUAGAAAUACACAUUUACUUGGAUA





GTCTCATGAGCAAGATCATAAAAACAAGACATGA
AUCACUCAGUUCUCUCUUCAAGACUGUCU






CAUGAGCAAGAUCAUAAAAACAAGACAUG






A



 


 40
290/589
TTGGATAACATGATAATACTGAGTTCCTTCAAATA
UUGGAUAACAUGAUAAUACUGAGUUCCUU
LDNMIILSSFKYIILKLFQNGINSLLLL




CATAATTCTTAAATTGTTTCAAAATGGCATTAACTC
CAAAUACAUAAUUCUUAAAUUGUUUCAAA





TCTGTTACTGTTGTAA
AUGGCAUUAACUCUCUGUUACUGUUGUA






A



 


 41
291/590
TTGCATGAACCTTTTCTCTCTGTTTGTCCCTGTCTCT
UUGCAUGAACCUUUUCUCUCUGUUUGUCC
LHEPFLSVCPCLLACPDVYSDSCTILLLLAR




TGGCTTGCCCTGATGTATACTCAGACTCCTGTACA
CUGUCUCUUGGCUUGCCCUGAUGUAUACU
DLSSFLVFNWLSGLVCGKITKSQSRLCFCS




ATCTTACTCCTGCTGGCAAGAGATTTGTCTTCTTTT
CAGACUCCUGUACAAUCUUACUCCUGCUG





CTTGTCTTCAATTGGCTTTCGGGCCTTGTATGTGGT
GCAAGAGAUUUGUCUUCUUUUCUUGUCU





AAAATCACCAAATCACAGTCAAGACTGTGTTTTTG
UCAAUUGGCUUUCGGGCCUUGUAUGUGG





TTCCTAG
UAAAAUCACCAAAUCACAGUCAAGACUGU






GUUUUUGUUCCUAG



 


 42
292/591
ATGTCCCGGAGGGGTTCACAAAGTGCTTTGTCAG
AUGUCCCGGAGGGGUUCACAAAGUGCUUU
MSRRGSQSALSGLLQLEGSLLLLSLLHRC




GACTGCTGCAGTTAGAAGGCTCACTGCTTCTCCTA
GUCAGGACUGCUGCAGUUAGAAGGCUCAC
GTCNPGAGAGGAAL




AGCCTTCTGCACAGATGTGGCACCTGCAACCCAG
UGCUUCUCCUAAGCCUUCUGCACAGAUGU





GAGCAGGAGCCGGAGGAGCTGCCCTCTGA
GGCACCUGCAACCCAGGAGCAGGAGCCGGA






GGAGCUGCCCUCUGA



 


 43
293/592
GTGCAGCAGAGATGGCTACAGCTCAGGAGCTGG
GUGCAGCAGAGAUGGCUACAGCUCAGGAG
VQQRWLQLRSWEGDGAQGKHRCSAAP




GAAGGTGATGGGGCACAGGGAAAGCACAGATGT
CUGGGAAGGUGAUGGGGCACAGGGAAAGC
QSDPLPGEREENIF




TCTGCAGCGCCCCAAAGTGACCCATTGCCTGGAG
ACAGAUGUUCUGCAGCGCCCCAAAGUGAC





AAAGAGAAGAAAATATTTTTTAA
CCAUUGCCUGGAGAAAGAGAAGAAAAUAU






UUUUUAA



 


 44 (BSS)
294/593
ATGCAGTGTGGCCAAAGGCGGGAAGATGGTGGG
AUGCAGUGUGGCCAAAGGCGGGAAGAUGG
MQCGQRREDGGQPRHRWDELRQLHG




CAGCCCAGACACCGTTGGGATGAACTACGGCAGC
UGGGCAGCCCAGACACCGUUGGGAUGAAC
GEAHATPKHDHERAQSYRASRNSPDECS




TACATGGAGGAGAAGCACATGCCACCCCCAAACA
UACGGCAGCUACAUGGAGGAGAAGCACAU
VAKGGKMVGSPDTVGMNYGSYMEEKH




TGACCACGAACGAGCGCAGAGTTATCGTGCCAGC
GCCACCCCCAAACAUGACCACGAACGAGCG
MPPPNMTTNERRVIVPA




AGGAACTCTCCTGATGAATGCAGTGTGGCCAAAG
CAGAGUUAUCGUGCCAGCAGGAACUCUCC





GCGGGAAGATGGTGGGCAGCCCAGACACCGTTG
UGAUGAAUGCAGUGUGGCCAAAGGCGGGA





GGATGAACTACGGCAGCTACATGGAGGAGAAGC
AGAUGGUGGGCAGCCCAGACACCGUUGGG





ACATGCCACCCCCAAACATGACCACGAACGAGCG
AUGAACUACGGCAGCUACAUGGAGGAGAA





CAGAGTTATCGTGCCAGCA
GCACAUGCCACCCCCAAACAUGACCACGAA






CGAGCGCAGAGUUAUCGUGCCAGCA



 


 45 (BSS)
295/594
GTGGCCAAAGGCGGGAAGATGGTGGGCAGCCCA
GUGGCCAAAGGCGGGAAGAUGGUGGGCA
VAKGGKMVGSPDTVGMNYGSYMEEKH




GACACCGTTGGGATGAACTACGGCAGCTACATGG
GCCCAGACACCGUUGGGAUGAACUACGGC
MPPPNMTTNERRVIVPAGTLLMNAVW




AGGAGAAGCACATGCCACCCCCAAACATGACCAC
AGCUACAUGGAGGAGAAGCACAUGCCACCC
PKAGRWWAAQTPLG




GAACGAGCGCAGAGTTATCGTGCCAGCAGGAACT
CCAAACAUGACCACGAACGAGCGCAGAGUU





CTCCTGATGAATGCAGTGTGGCCAAAGGCGGGAA
AUCGUGCCAGCAGGAACUCUCCUGAUGAA





GATGGTGGGCAGCCCAGACACCGTTGGGATGA
UGCAGUGUGGCCAAAGGCGGGAAGAUGG






UGGGCAGCCCAGACACCGUUGGGAUGA



 


 46
296/595
ATGGAGTACAGACCATGTGCGGCAGTGGCTGGA
AUGGAGUACAGACCAUGUGCGGCAGUGGC
MEYRPCAAVAGVGGERIWPSRRQHLVIP


(BSS + RCA)

GTGGGCGGTGAAAGAATATGGCCTTCCAGACGTC
UGGAGUGGGCGGUGAAAGAAUAUGGCCU
EHRWEGTVQDDQGRLPEAHPQLQRRH




AACATCTTGTTATTCCAGAACATCGATGGGAAGGA
UCCAGACGUCAACAUCUUGUUAUUCCAGA
PSLTSPLPQRESYAMEYRPCAAVAGVGG




ACTGTGCAAGATGACCAAGGACGACTTCCAGAGG
ACAUCGAUGGGAAGGAACUGUGCAAGAUG
ERIWPSRRQHLVIPEHRWEGTVQDDQG




CTCACCCCCAGCTACAACGCCGACATCCTTCTCTCA
ACCAAGGACGACUUCCAGAGGCUCACCCCC
RLPEAHPQLQRRHPSLTSPLPQR




CATCTCCACTACCTCAGAGAGAATCCTACGCTATG
AGCUACAACGCCGACAUCCUUCUCUCACAU





GAGTACAGACCATGTGCGGCAGTGGCTGGAGTG
CUCCACUACCUCAGAGAGAAUCCUACGCUA





GGCGGTGAAAGAATATGGCCTTCCAGACGTCAAC
UGGAGUACAGACCAUGUGCGGCAGUGGCU





ATCTTGTTATTCCAGAACATCGATGGGAAGGAACT
GGAGUGGGCGGUGAAAGAAUAUGGCCUU





GTGCAAGATGACCAAGGACGACTTCCAGAGGCTC
CCAGACGUCAACAUCUUGUUAUUCCAGAA





ACCCCCAGCTACAACGCCGACATCCTTCTCTCACAT
CAUCGAUGGGAAGGAACUGUGCAAGAUGA





CTCCACTACCTCAGAGA
CCAAGGACGACUUCCAGAGGCUCACCCCCA






GCUACAACGCCGACAUCCUUCUCUCACAUC






UCCACUACCUCAGAGA



 


 47
297/596
GTGCGGCAGTGGCTGGAGTGGGCGGTGAAAGAA
GUGCGGCAGUGGCUGGAGUGGGCGGUGA
VRQWLEWAVKEYGLPDVNILLFQNIDGK


(BSS + RCA)

TATGGCCTTCCAGACGTCAACATCTTGTTATTCCA
AAGAAUAUGGCCUUCCAGACGUCAACAUC
ELCKMTKDDFQRLTPSYNADILLSHLHYL




GAACATCGATGGGAAGGAACTGTGCAAGATGACC
UUGUUAUUCCAGAACAUCGAUGGGAAGGA
RENPTLWSTDHVRQWLEWAVKEYGLPD




AAGGACGACTTCCAGAGGCTCACCCCCAGCTACA
ACUGUGCAAGAUGACCAAGGACGACUUCC
VNILLFQNIDGKELCKMTKDDFQRLTPSY




ACGCCGACATCCTTCTCTCACATCTCCACTACCTCA
AGAGGCUCACCCCCAGCUACAACGCCGACA
NADILLSHLHYLRE




GAGAGAATCCTACGCTATGGAGTACAGACCATGT
UCCUUCUCUCACAUCUCCACUACCUCAGAG





GCGGCAGTGGCTGGAGTGGGCGGTGAAAGAATA
AGAAUCCUACGCUAUGGAGUACAGACCAU





TGGCCTTCCAGACGTCAACATCTTGTTATTCCAGA
GUGCGGCAGUGGCUGGAGUGGGCGGUGA





ACATCGATGGGAAGGAACTGTGCAAGATGACCAA
AAGAAUAUGGCCUUCCAGACGUCAACAUC





GGACGACTTCCAGAGGCTCACCCCCAGCTACAAC
UUGUUAUUCCAGAACAUCGAUGGGAAGGA





GCCGACATCCTTCTCTCACATCTCCACTACCTCAGA
ACUGUGCAAGAUGACCAAGGACGACUUCC





GAG
AGAGGCUCACCCCCAGCUACAACGCCGACA






UCCUUCUCUCACAUCUCCACUACCUCAGAG






AG



 


 48
298/597
TTGACTTCAGATGATGTTGATAAAGCCTTACAAAA
UUGACUUCAGAUGAUGUUGAUAAAGCCU
LTSDDVDKALQNSPRLMHARNTAPLPHL


(BSS + RCA)

CTCTCCACGGTTAATGCATGCTAGAAACACAGCTC
UACAAAACUCUCCACGGUUAAUGCAUGCU
TSDDVDKALQNSPRLMHARNT




CTCTTCCACATTTGACTTCAGATGATGTTGATAAA
AGAAACACAGCUCCUCUUCCACAUUUGAC





GCCTTACAAAACTCTCCACGGTTAATGCATGCTAG
UUCAGAUGAUGUUGAUAAAGCCUUACAAA





AAACACA
ACUCUCCACGGUUAAUGCAUGCUAGAAAC






ACA



 


 49
299/598
GTGCAGCTTTTATTTTCCCAAATACTTCAGTATATC
GUGCAGCUUUUAUUUUCCCAAAUACUUCA
VQLLFSQILQYILKLRKELQLGQGVQLLFS


(BSS + RCA)

CTGAAGCTACGCAAAGAATTACAACTAGGCCAGG
GUAUAUCCUGAAGCUACGCAAAGAAUUAC
QILQYILKLRKELQLGQ




GGGTGCAGCTTTTATTTTCCCAAATACTTCAGTATA
AACUAGGCCAGGGGGUGCAGCUUUUAUU





TCCTGAAGCTACGCAAAGAATTACAACTAGGCCA
UUCCCAAAUACUUCAGUAUAUCCUGAAGC





G
UACGCAAAGAAUUACAACUAGGCCAG









REFERENCES


    
    
        1. http://www.who.int/cancer/en/
        2. Ott P A, et al., An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017; 547(7662):217-221.
        3. Sahin U, et al., Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547(7662):222-226.
        4. Guarnerio J, et al., Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated
    
    


Chromosomal Translocations. Cell 2016; 165(2):289-302.

    
    
        5. Capel B, et al., Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell 1993; 73(5):1019-1030.
        6. Salzman J, et al., Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012; 7(2):e30733.
        7. Abe N, et al., Rolling Circle Translation of Circular RNA in Living Human Cells. Sci Rep 2015; 5:16435.
        8. Legnini I, et al., Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol Cell 2017; 66(1):22-37 e29.
        9. Rowe R C et al., Handbook of Pharmaceutical Excipients. Pharmaceutical Press, 2012
        10. Wen E P et al., Vaccine Development and Manufacturing, John Wiley & Sons, 17 Nov. 2014
        11. http://en.wikipedia.org/wiki/Peptide_synthesis
        12. http://en.wikipedia.org/wiki/Expression_vector
        13. Creighton T E, Proteins—Structures and Molecular properties—Second edition. WH Freeman and Company.